0001104659-20-091503.txt : 20200806 0001104659-20-091503.hdr.sgml : 20200806 20200806170112 ACCESSION NUMBER: 0001104659-20-091503 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 201082592 BUSINESS ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE STREET 2: SUITE 270 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 10-Q 1 tm2020466-1_10q.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-12584

SYNTHETIC BIOLOGICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Nevada	13-3808303
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

9605 Medical Center Drive, Suite 270
Rockville, MD	20850
(Address of Principal Executive Offices)	(Zip Code)

(301) 417-4364

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	SYN	NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of August 3, 2020, the registrant had 19,440,346 shares of common stock, $0.001 par value per share, outstanding.

SYNTHETIC BIOLOGICS, INC.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In particular, statements contained in this Quarterly Report on Form 10-Q, including but not limited to, statements regarding the timing of our clinical trials, the development and commercialization of our pipeline products, the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities and the timing of any such financing, our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future research, development or operations, are forward-looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “seeks,” “goals,” “estimates,” “predicts,” “potential” and “continue” or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part II, Item 1A. “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q, and those identified under Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 (the “2019 Form 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on February 20, 2020. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.

NOTE REGARDING COMPANY REFERENCES

Throughout this Quarterly Report on Form 10-Q, “Synthetic Biologics,” the “Company,” “we,” “us” and “our” refer to Synthetic Biologics, Inc.

NOTE REGARDING TRADEMARKS

All trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

SYNTHETIC BIOLOGICS, INC.

FORM 10-Q

TABLE OF CONTENTS

		Page
	PART I. FINANCIAL INFORMATION	3

Item 1.	Financial Statements (Unaudited)	3

	Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019	3
	Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2020 and 2019	4
	Condensed Consolidated Statements of Stockholders’ Equity (Deficit) for the Six Months ended June 30, 2020 and 2019	5
	Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2020 and 2019	6
	Notes to Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	35
Item 4.	Controls and Procedures	35

	PART II. OTHER INFORMATION	35

Item 1.	Legal Proceedings	35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	38
Item 3.	Defaults Upon Senior Securities	39
Item 4.	Mine Safety Disclosures	39
Item 5.	Other Information	39
Item 6.	Exhibits	39

SIGNATURES		40

PART I–FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

Synthetic Biologics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands except share and par value amounts)

	June 30, 2020			December 31, 2019
Assets

Current Assets
Cash and cash equivalents	$	8,059		$	15,045
Prepaid expenses and other current assets		897			1,381
Total Current Assets		8,956			16,426

Property and equipment, net		251			367

Right of use asset		352			419

Deposits and other assets		23			23

Total Assets	$	9,582		$	17,235

Liabilities and Stockholders' Deficit

Current Liabilities:
Accounts payable	$	1,025		$	2,315
Accrued expenses		1,209			1,776
Accrued employee benefits		927			935
Lease liability		268			249
Total Current Liabilities		3,429			5,275

Lease liability - Long term		334			473

Total Liabilities		3,763			5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding		12,669			12,544
Stockholders' Deficit:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 5,525 issued and outstanding and 7,638 issued and outstanding		3,444			4,761
Common Stock, $0.001 par value; 200,000,000 shares authorized, 18,646,152 and 16,808,758 issued and 18,643,824 and 16,806,430 outstanding		19			17
Additional paid-in capital		234,860			232,580
Accumulated deficit		(242,289	)		(235,537	)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit		(3,966	)		1,821
Non-controlling interest		(2,884	)		(2,878	)
Total Stockholders' Deficit		(6,850	)		(1,057	)

Total Liabilities and Stockholders' Deficit	$	9,582		$	17,235

See accompanying notes to unaudited condensed consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

	For the three months ended June,						For the six months ended June 30,
	2020			2019			2020			2019
Operating Costs and Expenses:
General and administrative	$	1,286		$	1,044		$	2,679		$	2,199
Research and development		1,603			2,594			3,238			5,012
Total Operating Costs and Expenses		2,889			3,638			5,917			7,211

Loss from Operations		(2,889	)		(3,638	)		(5,917	)		(7,211	)

Other Income:
Interest income		6			80			44			125
Total Other Income		6			80			44			125

Net Loss		(2,883	)		(3,558	)		(5,873	)		(7,086	)

Net Loss Attributable to Non-controlling Interest		(16	)		(27	)		(42	)		(43	)

Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$	(2,867	)	$	(3,531	)	$	(5,831	)	$	(7,043	)
Series A Preferred Stock Dividends		(63	)		(61	)		(125	)		(122	)
Series B Preferred Stock Dividends		(392	)		(117	)		(796	)		(515	)

Net Loss Attributable to Common Stockholders	$	(3,322	)	$	(3,709	)	$	(6,752	)	$	(7,680	)

Net Loss Per Share - Basic and Dilutive	$	(0.18	)	$	(0.23	)	$	(0.38	)	$	(0.48	)

Weighted average number of shares outstanding during the period - Basic and Dilutive		18,405,884			16,465,314			17,748,688			16,063,283

See accompanying notes to unaudited condensed consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders Equity (Deficit)

(In thousands, except share and par value amounts)

	Common Stock $0.001 Par Value				Series B Preferred
	Shares		Amount		Shares			Amount			APIC		Accumulated Deficit			Non- Controlling Interest			Total Stockholders' Equity
Balance at December 31, 2019		16,806,430	$	17		7,638		$	4,761		$	232,580	$	(235,537	)	$	(2,878	)	$	(1,057	)

Stock-based compensation		-		-		-			-			83		-			-			83
Series A Preferred Stock Dividends ($0.01 per share)		-		-		-			-			-		(62	)		-			(62	)
Issuance of SYN Biomics Stock		-		-		-			-					-			26			26
Conversion of Series B Preferred Stock to Common ($0.03 per share)		933,045		1		(1,073	)		(669	)		1,072		(404	)		-			-
Net loss		-		-		-			-			-		(2,964	)		-			(2,964	)
Non-controlling interest		-		-		-			-			-		-			(26	)		(26	)

Balance at March 31, 2020		17,739,475	$	18		6,565		$	4,092		$	233,735	$	(238,967	)	$	(2,878	)	$	(4,000	)

Stock-based compensation		-		-		-			-			86		-			-			86
Series A Preferred Stock Dividends ($0.01 per share)		-		-		-			-			-		(63	)		-			(63	)
Issuance of SYN Biomics Stock		-		-		-			-			-		-			10			10
Conversion of Series B Preferred Stock to Common ($0.03 per share)		904,349		1		(1,040	)		(648	)		1,039		(392	)		-			-
Net loss		-		-		-			-			-		(2,867	)		-			(2,867	)
Non-controlling interest		-		-		-			-			-		-			(16	)		(16	)

Balance at June 30, 2020		18,643,824	$	19		5,525		$	3,444		$	234,860	$	(242,289	)	$	(2,884	)	$	(6,850	)

	Common Stock $0.001 Par Value				Series B Preferred
	Shares		Amount		Shares			Amount			APIC			Accumulated Deficit			Non- Controlling Interest			Total Stockholders' Equity
Balance at December 31, 2018		15,482,083	$	15		9,161		$	5,760		$	230,754		$	(219,461	)	$	(2,909	)	$	14,159

Stock-based compensation		-		-		-			-			64			-			-			64
Series A Preferred Stock Dividends ($0.01 per share)		-		-		-			-			-			(61	)		-			(61	)
Issuance of SYN Biomics Stock		-		-		-			-			(36	)		-			53			17
Conversion of Series B Preferred Stock to Common ($0.03 per share)		900,869		1		(1,036	)		(638	)		1,035			(398	)		-			-
Net loss		-		-		-			-			-			(3,512	)		-			(3,512	)
Non-controlling interest		-		-		-			-			-			-			(16	)		(16	)

Balance at March 31, 2019		16,382,952	$	16		8,125		$	5,122		$	231,817		$	(223,432	)	$	(2,872	)	$	10,651

Stock-based compensation		-		-		-			-			91			-			-			91
Series A Preferred Stock Dividends ($0.01 per share)		-		-		-			-			-			(61	)		-			(61	)
Issuance of SYN Biomics Stock		-		-		-			-			-			-			45			45
Conversion of Series B Preferred Stock to Common ($0.03 per share)		262,608		1		(302	)		(187	)		303			(117	)		-			-
Net loss		-		-		-			-			-			(3,531	)		-			(3,531	)
Non-controlling interest		-		-		-			-			-			-			(27	)		(27	)

Balance at June 30, 2019		16,645,560	$	17		7,823		$	4,935		$	232,211		$	(227,141	)	$	(2,854	)	$	7,168

See accompanying notes to unaudited condensed consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	For the Six Months Ended June 30,
	2020			2019
Cash Flows From Operating Activities:
Net loss	$	(5,873	)	$	(7,086	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		169			155
Subsidiary stock issued to vendor		36			62
Depreciation		116			122
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		484			(706	)
Right of use asset		67			56
Accounts payable		(1,290	)		490
Accrued expenses		(567	)		627
Accrued employee benefits		(8	)		(821	)
Lease liability		(120	)		(105	)
Net Cash Used In Operating Activities		(6,986	)		(7,206	)

Net Cash From Investing Activities		-			-

Net Cash From Financing Activities		-			-

Net decrease in cash and cash equivalents		(6,986	)		(7,206	)

Cash and cash equivalents at beginning of period		15,045			28,918

Cash and cash equivalents at end of period	$	8,059		$	21,712

Noncash Financing Activities:
Conversion of Series B Preferred Stock	$	1,317		$	825
Deemed dividends for accretion of Series B Preferred Stock discount	$	796		$	515
In-kind dividends paid in preferred stock	$	125		$	122
Right or use asset from operating lease	$	-		$	538

See accompanying notes to unaudited condensed consolidated financial statements.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Organization, Nature of Operations and Basis of Presentation

Description of Business

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2019 Form 10-K. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results for the full year.

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.

Recent Accounting Pronouncements and Developments

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was enacted. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States’ economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company has assessed the impact of the CARES Act and based upon our initial assessment, we do not believe that it will have a significant effect on our financial position, results of operations or cash flows. The Company continues to evaluate its impact as new information becomes available.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Impairment of Long-Lived Assets

Long-lived assets include property, equipment and right-of-use assets. In accordance with Accounting Standards Codification (“ASC”) 360 - Property, Plant and Equipment (“ASC 360”), management reviews the Company’s recorded long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between fair value and the carrying value of the asset. The Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2020.

2. Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company continues to incur losses and, as of June 30, 2020, the Company had an accumulated deficit of approximately $242.3 million. Since inception, the Company has financed its activities principally from the proceeds from the issuance of equity securities.

The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

The Company does not have sufficient capital to fund its operations for the next twelve months following the issuance date of its Quarterly Report on Form 10-Q. In order to address its capital needs, including its planned clinical trials, the Company is actively pursuing additional equity or debt financing in the form of either a private placement or a public offering. The Company has been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. Such additional financing opportunities might not be available to the Company when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances, the Company’s operating results and prospects will be adversely affected.

In January 2020, the World Health Organization declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple countries, including throughout the United States. As the COVID-19 coronavirus continues to spread around the globe, the Company has experienced disruptions that impact our business and clinical trials, including temporarily halting the enrollment of new patients in its SYN-010 Phase 2b clinical study and the postponement of clinical site initiation for its SYN-004 Phase 1b/2a clinical study. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, results of operations and growth prospects could be materially adversely affected. With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, initiation of the Company’s Phase 1b/2a clinical study of SYN-004 to be conducted by Washington University in Allogeneic HCT Recipients has been postponed until Q1 2021, subject to COVID-19 global pandemic. Enrollment of new patients in the Company’s Phase 2b clinical study of SYN-010 was temporarily halted during the first and second quarter of 2020 due to the COVID-19 pandemic and has since recommenced. However, the ability to continue to recruit new patients into this clinical trial remains at the discretion of CSMC and contingent upon the COVID-19 global pandemic.

At June 30, 2020, the Company had cash and cash equivalents of approximately $8.1 million. As a result of the global COVID-19 pandemic, management has been able to extend its cash runway since its clinical development partners (Cedars-Sinai Medical Center (CSMC) and Washington University) continued to limit non-essential activities during the second quarter, which included the halting of enrollment in the ongoing Phase 2b clinical trial of SYN-010 and postponement of the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase). The Company anticipates its current cash will allow it to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts, including completing its funding requirements for its ongoing Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

2. Going Concern – (continued)

The Company does not anticipate any additional expense related to the Phase 1b/2a SYN-004 (ribaxamase) clinical trial until the trial is cleared for commencement by Washington University. Commencement of planned future Phase 3 clinical trials of SYN-004 and SYN-010 are subject to the Company’s successful pursuit of opportunities that will allow it to establish the clinical infrastructure and financial resources necessary to successfully initiate and complete its plan. The Company will be required to obtain additional funding in order to continue the development of its current product candidates beyond its Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients within the anticipated time periods, if at all, and to continue to fund operations at the current cash expenditure levels. Currently, the Company does not have commitments from any third parties to provide it with capital. If the Company fails to obtain additional funding for its clinical trials, whether through the sale of securities or a partner or collaborator, and otherwise when needed, it will not be able to fully execute its business plan as planned and will be forced to cease certain development activities until funding is received and its business will suffer, which would have a material adverse effect on its financial position, results of operations and cash flows. Potential sources of financing include strategic relationships, public or private sales of equity (including through the “at-the-market” Issuance Sales Agreement (the “FBR Sales Agreement”) that the Company entered into with FBR Capital Markets & Co. in August 2016) or debt and other sources. The Company cannot assure that it will meet the requirements for use of the FBR Sales Agreement or that additional funding will be available on favorable terms, or at all. Current cash is expected to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond its control. These factors include the following:

the progress of its research activities;

	·	the number and scope of its research programs;

	·	the ability to recruit patients for clinical studies in a timely manner;

the progress of its preclinical and clinical development activities;

the progress of the development efforts of parties with whom the Company has entered into research and development agreements and amount of funding received from partners and collaborators;

its ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;

its ability to achieve our milestones under licensing arrangements;

the costs associated with manufacturing-related services to produce material for use in our clinical trials;

the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;

the costs and timing of regulatory approvals; and

the ability to commence or complete clinical trials due to the ongoing impact of the COVID-19 global pandemic.

The Company has based its estimates of funding requirements on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates.

If the Company raises funds by selling additional shares of Common Stock or other securities convertible into Common Stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out its business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

3. Fair Value of Financial Instruments

ASC 820, Fair Value Measurement, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.

The carrying amounts of the Company’s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.

Cash and cash equivalents include money market accounts of $114,000 as of June 30, 2020 and $98,000 as of December 31, 2019 that are measured using Level 1 inputs.

The Company uses Monte Carlo simulations to estimate the fair value of its stock warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company’s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price.

4. Selected Balance Sheet Information

Prepaid expenses and other current assets (in thousands)

	June 30, 2020		December 31, 2019
Prepaid clinical research organizations	$	471	$	48
Prepaid insurances		241		549
Prepaid manufacturing expenses		94		622
Prepaid consulting, subscriptions and other expenses		91		134
Prepaid conferences, travel		-		25
Other receivables		-		3

Total	$	897	$	1,381

Amounts prepaid to clinical research organizations (CROs) are classified as current assets. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

4. Selected Balance Sheet Information – (continued)

Property and equipment, net (in thousands)

	June 30, 2020			December 31, 2019
Computers and office equipment	$	804		$	804
Leasehold improvements		439			439
Software		11			11
		1,254			1,254
Less: accumulated depreciation and amortization		(1,003	)		(887	)

Total	$	251		$	367

Accrued expenses (in thousands)

	June 30, 2020		December 31, 2019
Accrued clinical consulting services	$	704	$	684
Accrued vendor payments		376		456
Accrued manufacturing costs		129		635
Other accrued expenses		-		1

Total	$	1,209	$	1,776

Accrued employee benefits (in thousands)

	June 30, 2020		December 31, 2019
Accrued severance expense	$	399	$	-
Accrued bonus expense		396		858
Accrued vacation expense		132		77

	$	927	$	935

5. Stock-Based Compensation

Stock Incentive Plans

On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 71,429 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2020, there were 7,052 options issued and outstanding under the 2007 Stock Plan.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

5. Stock-Based Compensation – (continued)

On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 85,714 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 85,714 to 171,429.

On May 15, 2015, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 171,429 to 228,572. On August 25, 2016, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 228,572 to 400,000. On September 7, 2017, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 400,000 to 500,000. On September 24, 2018, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 500,000 to 1,000,000. On September 5, 2019, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Common Stock reserved for issuance under the 2010 Stock Plan from 1,000,000 to 4,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and expire between five and ten years after the grant date. As of June 30, 2020, there were 2,465,310 options issued and outstanding under the 2010 Stock Plan.

In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized as compensation expense over the stated vesting period.

The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three and six months ended June 30, 2020 and 2019. The assumptions used for the awards during the year ended December 31, 2019 were as follows:

Exercise price	$	0.42
Expected dividends		0	%
Expected volatility		84	%
Risk free interest rate		1.61	%
Expected life of option		4.5 years

Expected dividends —The Company has never declared or paid dividends on its Common Stock and has no plans to do so in the foreseeable future.

Expected volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.

Risk-free interest rate—The assumed risk free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.

Expected life of the option—The period of time that the options granted are expected to remain unexercised. Options granted during 2019 have a maximum term of seven years. The Company estimates the expected life of the option based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

5. Stock-Based Compensation – (continued)

The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:

immediate vesting;

half vesting immediately and remaining over three years;

in full on one-year anniversary of grant date;

quarterly over three years;

annually over three years;

one-third immediate vesting and remaining annually over two years;

one half immediate vesting and remaining over nine months;

one quarter immediate vesting and remaining over three years;

one quarter immediate vesting and remaining over 33 months; and

monthly over three years.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

5. Stock-Based Compensation – (continued)

A summary of stock option activity for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:

	Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
Balance - December 31, 2018		938,982		$	15.18		6.19 years	$	-

Granted		1,725,000			0.42
Exercised		-			-
Expired		(94,738	)		58.25
Forfeited		(67,232	)		5.95
Balance - December 31, 2019		2,502,012		$	3.62		6.51 years	$	153,353

Granted		-			-
Exercised		-			-
Expired		-			-
Forfeited		(29,650	)		0.55

Balance – June 30, 2020 - outstanding		2,472,362		$	3.65		5.98 years	$	158,270

Balance – June 30, 2020 - exercisable		628,408		$	12.89		5.16 years	$	15,129

Grant date fair value of options granted – six months ended June 30, 2020				$	-

Weighted average grant date fair value – six months ended June 30, 2020				$	-

Grant date fair value of options granted – year ended December 31, 2019				$	470,000

Weighted average grant date fair value – year ended December 31, 2019				$	0.27

Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $40,000 and $79,000, respectively, and $50,000 and $106,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in research and development expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $15,000 and $31,000, respectively, and $32,000 and $110,000 for the three and six months ended June 30, 2019, respectively.

Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2020 was $27,000 and $53,000, respectively, and $9,000 and $19,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and six months ended June 30, 2020 was $4,000 and $6,000, respectively, and $1,000 for the three and six months ended June 30, 2019.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

5. Stock-Based Compensation – (continued)

As of June 30, 2020, total unrecognized stock-based compensation expense related to stock options was $498,000, which is expected to be expensed through July 2022.

The FASB’s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June 30, 2020 and 2019.

6. Stock Warrants

On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of Common Stock, and one five-year warrant to purchase one share of Common Stock at an exercise price of $1.38 per share (each a “Warrant” and collectively, the “Warrants”), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the “Class B Units”, and together with the Class A Units, the “Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the “Underwriters”), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.

The Warrants are immediately exercisable at a price of $1.38 per share of Common Stock (which is 120% of the public offering price of the Class A Units) and expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations.

On November 18, 2016, the Company completed a public offering of 714,286 shares of Common Stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of Common Stock. The stock and warrants were sold in combination, with two warrants for each share of Common Stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of Common Stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of Common Stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $50.05 and the per share exercise price of the Series B warrants is $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants may be exercised at any time on or after the date of issuance. The Series A warrants are exercisable until the four-year anniversary of the issuance date. The Series B warrants expired on December 31, 2017 and none were exercised prior to expiration. The warrants include a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Condensed Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and June 30, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

6. Stock Warrants – (continued)

On October 10, 2014, the Company raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company’s Common Stock and a warrant to purchase 0.50 shares of Common Stock. The warrants, exercisable for an aggregate of 200,852 shares of Common Stock, had an exercise price of $61.25 per share and a life of five years. The warrants vested immediately and expired on October 10, 2019.

The warrants issued in conjunction with the registered direct offering in October 2014 included a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date, which was $7.4 million, and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and 2019, the fair value of the warrant liability was zero. The warrants were valued on the date of grant using the Black-Scholes option pricing model which approximates the value derived using Monte Carlo simulations. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price.

A summary of all warrant activity for the Company for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:

	Number of Warrants			Weighted Average Exercise Price
Balance at December 31, 2018		18,915,851		$	3.85
Granted		-			-
Exercised		-			-
Forfeited		(200,852	)		61.25
Balance at December 31, 2019		18,714,999			3.24
Granted		-			-
Exercised		-			-
Forfeited		-			-
Balance at June 30, 2020		18,714,999		$	3.24

On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, was paid a monthly fee, and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company’s Common Stock on the date of issuance. The warrant is equity classified and the fair value of the warrant approximated $9,000 on the date of grant and was measured using the Black-Scholes option pricing model. This entire expense was recorded in the quarter ended March 31, 2018.

A summary of all outstanding and exercisable warrants as of June 30, 2020 is as follows:

Exercise Price		Warrants Outstanding		Warrants Exercisable		Weighted Average Remaining Contractual Life
$	1.38		17,999,999		17,999,999		3.28 years
	18.20		714		714		2.49 years
	50.05		714,286		714,286		0.39 years
$	3.24		18,714,999		18,714,999		3.17 years

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

7. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the three and six months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.1 million and $0.5 million, respectively, on converted shares and $0.1 million of Series A accrued dividends. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020 and 2019 were 4,804,348 and 6,802,608, respectively. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively, and for the six months ended June 30, 2019 were 843,119 and 18,915,851, respectively, because their effect is anti-dilutive.

8. Non-controlling Interest

The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”), and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Synthetic Biomics, Inc. (“SYN Biomics”). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN-010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company’s equity interest in SYN Biomics is 83% and the non-controlling stockholder’s interest is 17%. As of June 30, 2020, the accumulated net loss attributable to the non-controlling interest is $2.9 million.

In consideration of the support provided by CSMC for the Study, the Company will pay $441,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB): (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (“Synbiomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. During the three and six months ended June 30, 2019, research and development expense recorded related to this transaction approximated $119,000 and $174,000, respectively.

The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

9. Common and Preferred Stock

Series B Preferred Stock

In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October 10, 2018, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.

The Units were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018.

The conversion price of the Series B Preferred Stock and exercise price of the October 2018 Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.

During the three and six months ended June 30, 2020, 1,040 and 2,113 Series B shares, respectively, have been converted into common stock resulting in the recognition of $392,000 and $796,000, respectively, of unamortized discount from the conversion. During the three and six months ended June 30, 2019, 302 and 1,338 Series B shares, respectively, have been converted into common stock resulting in the recognition of $117,000 and $515,000, respectively, of unamortized discount from the conversion. As of June 30, 2020, 10,198 shares have been converted resulting in the recognition of $3.8 million of unamortized discount. This is recorded as a deemed dividend in accumulated deficit.

The October 2018 Warrants are immediately exercisable at a price of $1.38 per share of common stock (which is 120% of the public offering price of the Class A Units) and will expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October 2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October 2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.

The Company may not effect, and the holder will not be entitled to, exercise any Warrants or conversion of the Series B Preferred Stock, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the exercise or conversion, as such percentage ownership is determined in accordance with the terms of the October 2018 Warrants or Series B Preferred Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to the Company. The holders of the Series B Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Upon a defined Fundamental Transaction, the holders of the Series B Preferred Stock are entitled to the same consideration as are holders of Common Stock. The Series B Preferred Stock ranks junior to existing Series A Preferred Stock but on parity with common stock. Liquidation preference is equal to an amount pari passu with the common stock on an as converted basis (i.e., there is no preference to common stock).

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

9. Common and Preferred Stock – (continued)

Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2018, the Company recorded a discount of $9.1 million and immediately amortized the discount to record the deemed dividend.

Series A Preferred Stock

On September 11, 2017, the Company entered into a share purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) for an aggregate purchase price of $12 million, or $100 per share.

The Series A Preferred Stock ranks senior to the shares of the Company’s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets upon any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $18.90 per share, subject to certain customary anti-dilution adjustments.

Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.

On or at any time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock of $7,875, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred Stock, or (ii) the five year anniversary of the issuance date, the Company has the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value (as defined in the Certificate of Designations).

The Series A Preferred Stock is classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company’s control. Since the effective conversion price of the Series A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively. During the three and six months ended June 30, 2019, the Company accrued dividends of $61,000 and $122,000, respectively. Once the dividend is declared, the Company will reclassify the declared amount from temporary equity to a dividends payable liability. When the redemption of the Series A Preferred Stock becomes probable, the temporary equity will be accreted to redemption value as a deemed dividend.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

9. Common and Preferred Stock – (continued)

B. Riley FBR Sales Agreement

On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.), which enables the Company to offer and sell shares of the Company’s common stock with an aggregate sales price of up to $40.0 million from time to time through B. Riley FBR, Inc. as the Company’s sales agent. Sales of common stock under the B. Riley FBR Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley FBR, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Company’s common stock sold on the Company’s behalf. The Company has not sold any shares during 2020 and 2019 through the B. Riley FBR Sales Agreement.

10. Related Party Transactions

On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN-010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) to: (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary Synthetic Biomics, Inc. (“SYN Biomics”) owned by the Company, such that after such issuance CSMC will own an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock.

In December 2013, through the Company’s subsidiary, Synthetic Biomics, Inc., the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2020 and 2019, the Company did not owe and did not pay CSMC for milestone payments related this license agreement.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

11. Commitments and Contingencies

Leases

All of the Company’s existing leases as of June 30, 2020 are classified as operating leases. As of June 30, 2020, the Company has one material operating lease for facilities with a remaining term expiring in 2022. The existing lease has fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the lease liability was 9.9%. The rates implicit within the Company's leases are generally not determinable, therefore, the Company's incremental borrowing rate is used to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. Because the Company currently has no outstanding debt, the incremental borrowing rate for each lease is primarily based on publicly-available information for companies within the same industry and with similar credit profiles. The rate is then adjusted for the impact of collateralization, the lease term and other specific terms included in the Company’s lease arrangements. The incremental borrowing rate is determined at lease commencement, or as of January 1, 2019 for operating leases in existence upon adoption of ASC 842. The incremental borrowing rate is subsequently reassessed upon a modification to the lease arrangement. ROU assets are subsequently assessed for impairment in accordance with the Company’s accounting policy for long-lived assets. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statement of operations, and for the three and six months ended June 30, 2020 approximated $50,000 and $101,000, respectively, and for three and six months ended June 30, 2019 approximated $50,000 and $101,000, respectively. For the three and six months ended June 30, 2020, operating cash flows used for operating leases approximated $77,000 and $154,000, respectively, and for three and six months ended June 30, 2019 approximated $75,000 and $149,000, respectively. The right of use assets exchanged for operating lease obligations was $0. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.

A maturity analysis of our operating leases as of June 30, 2020 is as follows (amounts in thousands of dollars):

Future undiscounted cash flow for the years ending December 31:
2020	$	156
2021		321
2022		192
Total	$	669

Discount factor	$	(67	)
Lease liability	$	602
Amount due within 12 months	$	(268	)
Lease liability – long term	$	334

Risks and Uncertainties

As the COVID-19 coronavirus continues to spread around the globe, the Company experienced disruptions that impact its business and clinical trials, including halting the enrollment of new patients in the ongoing Phase 2b investigator-sponsored clinical trial of SYN-010 and postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company’s business, the clinical development of SYN-010, SYN-004 (ribaxamase) and SYN-020, the business of the Company’s suppliers and other commercial partners, the Company’s corporate development objectives and the value of and market for the Company’s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.

Synthetic Biologics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

12. Subsequent Events

On June 30, 2020 the Company submitted an Investigational New Drug (IND) application with the FDA for SYN-020, an oral formulation of recombinant intestinal alkaline phosphatase (IAP). On July 30, 2020 the Company announced that it received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 single ascending dose study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. The Phase 1 clinical program is intended to support the clinical development of SYN-020 in multiple indications, including the treatment of radiation enteropathy secondary to pelvic cancer therapy.

On January 7, 2020 the Company held a Type-C meeting with the FDA to discuss the clinical program requirements needed to evaluate safety, tolerability and potential absorption into the systemic circulation (if any) of SYN-004 (ribaxamase) in adult allogeneic HCT recipients. On July 30, 2020 the Company received written notification from the FDA informing it that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients is safe to proceed per the submitted clinical program protocol.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q, and our audited consolidated financial statements and notes thereto for the year ended December 31, 2019 included in our 2019 Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Our actual results and the timing of events could differ materially from those expressed or implied by the forward-looking statements due to important factors and risks including, but not limited to, those set forth below under “Risk Factors” and elsewhere herein, and those identified under Part I, Item 1A of our 2019 Form 10-K. All share and per share numbers set forth in this Management’s Discussion and Analysis of Financial Conditions and Results of Operations reflect the one-for-thirty five reverse stock split effected August 10, 2018.

Overview

We are a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the GI tract to prevent microbiome damage, Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). We are also advancing SYN-020, an early-stage oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

We are in close contact with our clinical sites and are assessing the impact of COVID-19 on our studies and current timelines and costs. With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, initiation of our Phase 1b/2a clinical study of SYN-004 to be conducted by Washington University in Allogeneic HCT Recipients has been postponed until Q1 2021, subject to the COVID-19 global pandemic. Enrollment of new patients in our Phase 2b clinical study of SYN-010 was temporarily halted during the first and second quarter of 2020 due to the COVID-19 pandemic and has since recommenced. However, the ability to continue to recruit new patients into the Phase 2b clinical trial of SYN-010 remains at the discretion of CSMC and contingent upon the COVID-19 pandemic. If the COVID-19 pandemic continues and persists for an extended period of time, we could experience significant disruptions to our clinical development timeline, which would adversely affect our business, financial condition, results of operations and growth prospects.

In response to the spread of COVID-19 as well as public health directives and orders, we have implemented a number of measures designed to ensure employee safety and business continuity. We have limited access to our offices and are allowing our administrative employees to continue their work outside of our offices in order to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state and local government and health authorities. The effects of the governmental orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.

Our Product Pipeline:

AAD antibiotic associated diarrhea; aGVHD acute graft-vs-host disease; AMR antimicrobial resistance; CDI Clostridioides difficile infection; CIC chronic idiopathic constipation; CPI checkpoint inhibitor autoimmune enteropathy; CRE carbapenem resistant enterococci; DR delayed release; Est. estimated; HCT hematopoietic cell transplant patients; IAP intestinal alkaline phosphatase; IBS-C irritable bowel syndrome with constipation; VRE vancomycin resistant enterococci.

¹Additional products with preclinical proof-of-concept include SYN-006 (carbapenemase) being designed to prevent aGVHD and infection by carbapenem resistant Enterobacteriaceae and SYN-007 (ribaxamase) DR being designed to prevent antibiotic associated diarrhea with oral β-lactam antibiotics. ²Dependent on funding/partnership.

*Based on management’s current beliefs and expectations.

Summary of Clinical and Preclinical Programs

Therapeutic Area	Product Candidate	Current Status

Prevention of microbiome damage, CDI, overgrowth of pathogenic organisms, AMR, and aGVHD in allogeneic HCT recipients (Degrade IV beta-lactam antibiotics)	SYN-004 (ribaxamase) (oral enzyme)	· Announced outcomes from End of Phase 2 meeting, including FDA-proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval on the basis of a single Phase 3 clinical trial (Q4 2018) · Anticipate initiation of the Phase 3 clinical program proposed by the FDA for the prevention of CDI only after securing additional potential funding via a strategic partnership · Clarified market/potential partner needs and identified potential additional indications in specialty patient populations such as allogeneic hematopoietic cell transplant patients · Announced clinical trial agreement (CTA) with Washington University School of Medicine to conduct a Phase 1b/2a clinical trial to evaluate safety, tolerability and pharmacokinetics in up to 36 evaluable adult allogeneic HCT recipients (Q3 2019) · Received official meeting minutes from FDA Type-C meeting held on December 2, 2019 to discuss development in allogeneic HCT recipients who are administered IV beta-lactam antibiotics in response to fever (Q1 2020) · Received written notification from the FDA informing the Company that the FDA determined the Phase 1b/2a clinical program in adult allogeneic hematopoietic cell transplant (HCT) recipients may proceed per the submitted clinical program protocol (Q3 2020) · Initiation of proposed Phase 1b/2a clinical trial to be conducted by Washington University in adult allogeneic HCT recipients temporarily postponed until Q1 2021, subject to COVID-19 global pandemic

Treatment of IBS-C	SYN-010 (oral modified-release lovastatin lactone)	· Confirmed key elements of Pivotal Phase 2b/3 clinical trial design pursuant to consultations with FDA (Q1 2017) · Entered into agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to evaluate SYN-010 dose response and inform Phase 3 clinical development (Q3 2018) · Enrollment in the Phase 2b investigator-sponsored clinical study of SYN-010 conducted by CSMC was temporarily halted in Q1 and Q2 2020 due to the COVID-19 global pandemic · Patient recruitment has recommenced and remains contingent upon CSMC’s ability to enroll new patients during the COVID-19 global pandemic (Q3 2020)

Preserve gut barrier, treat local GI inflammation, and restore gut microbiome

SYN-020
(oral IAP enzyme)

· Generated high expressing manufacturing cell lines for intestinal alkaline phosphatase (IAP) (1H 2017)

· Identified basic drug supply manufacturing process and potential tablet and capsule formulations (2H 2017)

· Identified potential clinical indications with unmet medical need including enterocolitis associated with radiation therapy for cancer (Q1 2019)

· Completed pre-IND (Investigational New Drug) meeting with the FDA to clarify requirements for IND-enabling toxicology studies and manufacturing requirements (Q2 2019)

· Entered into an agreement with Massachusetts General Hospital (“MGH”) granting the Company an option for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases (Q2 2020)

· Submitted IND application with U.S. FDA supporting an initial indication for the treatment of radiation enteropathy secondary to pelvic cancer therapy (Q2 2020)

· Received study-may-proceed letter from U.S. FDA to conduct a Phase 1 single ascending dose study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters (Q3 2020)

Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade IV carbapenem antibiotics)

SYN-006

(oral enzyme)

· Identified P2A as a potent carbapenemase that is stable in the GI tract

· Manufactured a formulated research lot for oral delivery (2017)

· Demonstrated microbiome protection in a pig model of ertapenem administration (Q1 2018)

· Reported supporting data demonstrating SYN-006 attenuated emergence of antibiotic resistance genes in a pig model, including those encoding beta-lactamases and genes conferring resistance to a broad range of antibiotics such as aminoglycosides and macrolides (Q1 2019)

Prevention of CDI, overgrowth of pathogenic organisms and AMR (Degrade oral beta-lactam antibiotics)

SYN-007
(oral enzyme)

· Preclinical work ongoing to expand the utility of SYN-004 (ribaxamase) for use with oral beta-lactam antibiotics

· Reported supportive data from a second canine animal model demonstrating that when co-administered with oral amoxicillin and oral Augmentin, oral SYN-007 did not interfere with systemic absorption of antibiotics but did diminish microbiome damage associated with these antibiotics (Q2 2018)

· Reported supportive data demonstrating SYN-007 mitigated antibiotic-mediated gut microbiome alterations and maintained gut microbiome integrity when co-administered with oral amoxicillin in a dose-response canine study (Q2 2019)

· Reported supportive data demonstrating SYN-007 protected the gut microbiome of dogs from amoxicillin and the beta-lactam/beta-lactamase inhibitor combination amoxicillin/clavulanate and also reduced the emergence of antibiotic resistance in a canine study (Q1 2020)

Prevention and treatment of pertussis

SYN-005
(monoclonal antibody
therapies)

· Reported supportive preclinical data demonstrating that an extended half-life version of hu1B7, a component of SYN-005, provided protection from pertussis for five weeks in a neonatal non-human primate study (Q4 2017)

· Collaboration with UT Austin

Our Microbiome-Focused Pipeline

Our SYN-004 (ribaxamase) and SYN-010 clinical programs are focused on the gut microbiome, which is home to billions of microbial species and composed of a natural balance of both “good” beneficial species and potentially “bad” pathogenic species. When the natural balance or normal function of these microbial species is disrupted, a person’s health can be compromised. All of our programs are supported by our growing intellectual property portfolio. We are maintaining and building our patent portfolio through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent applications.

Recent Developments

Clinical and Pre-Clinical Update

SYN-004 (ribaxamase) — Prevention of antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients

Phase 1b/2a Clinical Study in Allogeneic HCT Recipients

In August 2019, we entered into a Clinical Trial Agreement (CTA) with the Washington University School of Medicine (Washington University) to conduct a Phase 1b/2a clinical trial of SYN-004 (ribaxamase). Under the terms of this agreement, we will serve as the sponsor of the study and supply SYN-004 (ribaxamase). Dr. Erik R. Dubberke, Professor of Medicine and Clinical Director, Transplant Infectious Diseases at Washington University and a member of the SYN-004 (ribaxamase) steering committee will serve as the principal investigator of the clinical trial in collaboration with his Washington University colleague Dr. Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation and Leukemia.

On January 7, 2020, we announced the receipt of official meeting minutes from the FDA following a Type-C meeting held on December 2, 2019 at our request to discuss the development of SYN-004 (ribaxamase) for treatment of allogeneic HCT recipients who are administered IV beta-lactam antibiotics in response to fever. Based on the final meeting minutes, the Phase 1b/2a clinical trial will comprise a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients. The goal of this study is to evaluate the safety, tolerability and potential absorption into the systemic circulation (if any) of 150 mg oral SYN-004 (ribaxamase) administered to allogeneic HCT recipients four times per day who receive an IV beta-lactam antibiotic to treat fever. Study participants will be enrolled into three sequential cohorts administered a different study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 (ribaxamase) and four will receive placebo. On July 30, 2020 we received written notification from the FDA informing us that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients may proceed per the submitted clinical program protocol.

Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring Committee (DSMC), which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic. The clinical trial will also evaluate potential protective effects of SYN-004 (ribaxamase) on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 (ribaxamase) in allogeneic HCT recipients. Initiation of this clinical trial remains contingent upon approval of the clinical study protocol by the Washington University School of Medicine’s Institutional Review Board (IRB).

Due to the unique challenges posed by the global COVID-19 pandemic, Washington University continues to evaluate non-essential activities, which may have a direct impact on planned and ongoing clinical trials. We have been notified by Washington University that they could consider initiating planned clinical trials, including the SYN-004 (ribaxamase) Phase 1b/2a clinical program as early as September 2020. However, this remains largely at their discretion and is contingent upon Washington University’s ability to conduct this clinical program free from the impact of COVID-19, and approval from their IRB and the FDA. At this time, we have determined that postponing the initiation of the planned Phase 1b/2a clinical trial in allogeneic HCT recipients until at least the first quarter of 2021 remains the appropriate course of action in the current operating environment. We remain in close contact with Washington University and are actively monitoring the crisis caused by the spread of COVID-19 and its impact to the clinical development plans for our SYN-004 (ribaxamase) program.

SYN-010 — Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

On September 5, 2018, we entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by us and CSMC. The Phase 2b study is being conducted out of the Medically Associated Science and Technology (MAST) Program at CSMC and is a 12-week, placebo-controlled, double-blind, randomized clinical trial to evaluate two dose strengths of oral SYN-010 21 mg and 42 mg in as many as 150 patients diagnosed with IBS-C using a breath methane screening level as a criterion for patient enrollment.

The primary objective for the study is to determine the efficacy of SYN-010, measured as an improvement from baseline in the weekly average number of complete spontaneous bowel movements (CSBMs) during the 12-week treatment period for SYN-010 21 mg and 42 mg daily doses relative to placebo. Secondary efficacy endpoints for both dose strengths of SYN-010 will measure changes from baseline in abdominal pain, bloating, stool frequency as well as the use of rescue medication relative to placebo. Exploratory outcomes include Adequate Relief and quality of life measures using the well-validated EQ-5D-5L and PAC-SYM patient questionnaires.

Importantly, this study will aim to generate a comprehensive and meaningful data set to provide additional insights and address specific queries into potential SYN-010 clinical efficacy, including dose response, length of treatment and microbiome effects, intended to be evaluated in the FDA-agreed Phase 2b/3 adaptive design clinical program. We believe outcomes from this clinical trial are important to solidifying existing clinical outcomes data, and potentially simplifying and reducing costs for future Phase 3 clinical development. Generating such a data set requires rigorous screening criteria in order to obtain reliable baseline parameters that includes foregoing current constipation interventions for a period of time prior to breath methane screening. This has proven challenging for a portion of prospective participants leading to higher than anticipated and inadvertent patient-related screen-fail rates for IBS-C patients who presented at screening with breath-methane levels below the protocol-required ten parts-per-million. During the first quarter of 2020, we met with the study investigators at CSMC and, following some discussion, we collectively determined that generating a meaningful data set may be possible with a smaller patient population than previously anticipated. We believe the successful completion of this study will allow us to re-engage with prospective partners, both domestically and abroad, who found the results from our previously completed Phase 2 studies compelling and have indicated their interest in reviewing a more robust and meaningful clinical data set.

Enrollment in this study commenced in January 2019 and was temporarily halted during the first and second quarter of 2020 due to the unique challenges posed by the global COVID-19 pandemic which required CSMC to temporarily limit all non-essential activities, directly impacting their ability to actively recruit and screen new patients. During this time, active study participants who did not complete the study prior to the decision to halt all non-essential activities were given the opportunity to complete the study as CSMC took steps to ensure data from this group was collected in accordance with the clinical trial protocol. The recruitment of new patients into this trial has since recommenced, however, the ability to continue to recruit new patients into this clinical trial remains at the discretion of CSMC and contingent upon the COVID-19 global pandemic. A data readout in the form of an interim futility analysis is anticipated during the third quarter of 2020 and topline data is anticipated during the first quarter of 2021, subject to COVID-19.

SYN-020 — Oral Intestinal Alkaline Phosphatase

SYN-020 is a quality-controlled, recombinant version of bovine Intestinal Alkaline Phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery. The published literature indicates that IAP functions to diminish GI inflammation, tighten the gut barrier to diminish “leaky gut,” promote a healthy microbiome, and diminish GI and systemic inflammation. Based on these known mechanisms as well as our own supporting animal model data, we are initially developing SYN-020 to mitigate the intestinal damage caused by radiation therapy that is routinely used to treat pelvic cancers, including the treatment and prevention of radiation enteropathy secondary to cancer therapy. Despite its broad therapeutic potential, a key hurdle to commercialization has been the high cost of IAP manufacture which is commercially available for as much as $10,000 per gram. We believe we have developed technologies to traverse this hurdle and now have the ability to produce more than 3 grams per liter of SYN-020 for roughly a few hundred dollars per gram at commercial scale.

On June 30, 2020 we submitted an Investigational New Drug (IND) application to the FDA in support of an initial indication for the treatment of radiation enteropathy secondary to pelvic cancer therapy. On July 30, 2020 we announced that we received a study-may-proceed letter from the FDA to conduct a Phase 1 single ascending dose study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. The Phase 1 clinical program is intended to support the clinical development of SYN-020 for multiple indications.

During the second quarter of 2020, we also announced that we entered into an agreement with Massachusetts General Hospital (“MGH”) granting us an option for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. Research published by a team of investigators led by Richard Hodin, MD, Chief of the Massachusetts General Hospital Division of General and Gastrointestinal Surgery and Professor of Surgery, Harvard Medical School, evaluated long-term oral supplementation of IAP, including SYN-020, in mice. Dr. Hodin’s research demonstrated that IAP administration, starting at 10 months of age, slowed the microbiome changes, gut-barrier dysfunction, and gastrointestinal and systemic inflammation that normally accompany aging. Additionally, the IAP administration resulted in improved metabolic profiles in the aged mice, diminished frailty, and extended lifespan. Under the terms of the agreement, we are granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging. If executed, we plan to use this license in the advancement of an expanded clinical development program for SYN-020. In addition, we continue to explore and evaluate potential future indications for use of SYN-020 in chronic inflammatory diseases such as inflammatory bowel disease (IBD), Celiac disease, Crohn’s disease and metabolic syndrome, where decreased IAP expression and impairment of the intestinal barrier has been linked as a causative factor.

Intellectual Property

All of our programs are supported by growing patent estates that we either own or exclusively license. Each potential product has issued patents that provide protection. In total, we have over 110 U.S. and foreign patents and over 100 U.S. and foreign patents pending. The SYN-004 (ribaxamase) program is supported by IP that is assigned to Synthetic Biologics, namely U.S. patents and foreign patents (in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others) and U.S. and foreign patents pending in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others). For instance, U.S. Patent Nos. 8,894,994 and 9,587,234, which include claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004 (ribaxamase), have patent terms to at least 2031. Further, U.S. Patent 9,301,995 and 9,301,996, both of which will expire in 2031, cover various uses of beta-lactamases, including SYN-004 (ribaxamase), in protecting the microbiome, and U.S. Patent Nos. 9,290,754, 9,376,673, 9,404,103, 9,464,280, and 9,695,409 which will expire in at least 2035, covers further beta-lactamase compositions of matter related to SYN-004 (ribaxamase). The SYN-010 program is supported by IP that is exclusively licensed to (and, in some cases co-owned by) Synthetic Biologics, namely U.S. patents and foreign patents (in most major markets, e.g. Europe (including Germany, Great Britain and France), and Canada, among others) and U.S. and foreign patents pending in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others). For instance, U.S. Patent No. 9,192,618, which expires in at least 2023, includes claims that cover use of statins, including SYN-010, for the treatment of IBS-C. U.S. Patent No. 9,289,418, which expires in at least 2033, includes claims that cover the use of a variety of compounds, including the active agent of SYN-010, to treat constipation in certain screened patients. U.S. Patent No. 9,744,208 covers methods of use of the active agent of SYN-010 for the treatment of constipation until at least 2034. U.S. Patent No. 9,956,292 includes claims related to composition of matter of anti-methanogenic compositions that find use in treating IBS-C and will expire in at least 2035. Further, U.S. Patent No. 10,328,151, covers the composition of matter of the SYN-010 clinical agent and U.S. Patent 10,519,515 covers methods of treating IBS-C with a statin, inclusive of SYN-010, in a selected patient population.

Our goal is to (i) obtain, maintain, and enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, (ii) preserve our trade secrets, and (iii) operate without infringing on the proprietary rights of other parties worldwide. We seek, where appropriate, the broadest intellectual property protection for product candidates, proprietary information, and proprietary technology through a combination of contractual arrangements and patents.

Critical Accounting Policies

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the condensed consolidated financial statements and the judgments and assumptions used are consistent with those described under Part II, Item 7 of our 2019 Form 10-K.

Results of Operations

Three Months Ended June 30, 2020 and 2019

General and Administrative Expenses

General and administrative expenses increased by 23% to $1.3 million for the three months ended June 30, 2020, from $1.0 million for the three months ended June 30, 2019. This increase is primarily due to increased legal costs related to business development, patent execution and employee contract matters, vacation expense, and insurance costs. The charge related to stock-based compensation expense was $67,000 for the three months ended June 30, 2020, compared to $59,000 the three months ended June 30, 2019.

Research and Development Expenses

Research and development expenses decreased by 38% to $1.6 million for the three months ended June 30, 2020, from $2.6 million for the three months ended June 30, 2019. This decrease is primarily the result of the response to the global COVID-19 pandemic by our clinical development partners which has led to the postponement of the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients and a temporary halt in new enrollment in the Phase 2b investigator sponsored clinical trial of SYN-010. The charge related to stock-based compensation expense was $19,000 for the three months ended June 30, 2020, compared to $31,000 for the three months ended June 30, 2019.

The following table sets forth our research and development expenses directly related to our therapeutic areas for the three months ended June 30, 2020 and 2019. These direct expenses were external costs associated with preclinical studies and clinical trials. Indirect research and development expenses related to employee costs, facilities, stock-based compensation and research and development support services that are not directly allocated to specific drug candidates.

Therapeutic Areas	June 30, 2020		June 30, 2019
SYN-010	$	94	$	159
Ribaxamase		40		46
SYN-005		4		13

Total direct costs		138		218
Total indirect costs		1,465		2,376

Total Research and Development	$	1,603	$	2,594

Other Income/Expense

Other income was $6,000 for the three months ended June 30, 2020, compared to other income of $80,000 for the three months ended June 30, 2019. Other income for the three months ended June 30, 2020 and 2019 is primarily comprised of interest income.

Net Loss Attributable to Common Stockholders

Our net loss attributable to common stockholders was $3.3 million, or $0.18 per basic and dilutive common share for the three months ended June 30, 2020, compared to a net loss of $3.7 million, or $0.23 per basic common share and dilutive common share for the three months ended June 30, 2019. Net loss attributable to common stockholders for the three months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $16,000 and includes the accretion of Series B preferred discount of $392,000 on converted shares and Series A Preferred Stock accrued dividends of $63,000. Net loss attributable to common stockholders for the three months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $27,000 and includes the accretion of Series B preferred discount of $117,000 on converted shares and $61,000 of Series A accrued dividends.

Six Months Ended June 30, 2020 and 2019

General and Administrative Expenses

General and administrative expenses increased by 22% to $2.7 million for the six months ended June 30, 2020, from $2.2 million for the six months ended June 30, 2019. This increase is primarily due to increased legal costs related to business development, patent execution and employee contract matters, vacation expense, insurance costs and registration fees. The charge related to stock-based compensation expense was $132,000 for the six months ended June 30, 2020, compared to $125,000 for the six months ended June 30, 2019.

Research and Development Expenses

Research and development expenses decreased by 35% to $3.2 million for the six months ended June 30, 2020, from $5.0 million for the six months ended June 30, 2019. This decrease is primarily the result of the response to the global COVID-19 pandemic by our clinical development partners which has led to the postponement of the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients and a temporary halt in new enrollment in the Phase 2b investigator sponsored clinical trial of SYN-010. Research and development expenses also include a charge relating to stock-based compensation expense of $37,000 for the six months ended June 30, 2020, compared to $30,000 for the six months ended June 30, 2019.

The following table sets forth our research and development expenses directly related to our therapeutic areas for the six months ended June 30, 2020 and 2019. These direct expenses were external costs associated with preclinical studies and clinical trials. Indirect research and development expenses related to employee costs, facilities, stock-based compensation and research and development support services that are not directly allocated to specific drug candidates.

Therapeutic Areas	June 30, 2020		June 30, 2019
SYN-010	$	248	$	253
SYN-004 (ribaxamase)		105		112
Other therapeutic areas		28		16
Total direct costs		381		381
Total indirect costs		2,857		4,631

Total Research and Development Expenses	$	3,238	$	5,012

Other Income

Other income was $44,000 for the six months ended June 30, 2020, compared to other income of $125,000 for the six months ended June 30, 2019. Other income for the six months ended June 30, 2020 and 2019 is primarily comprised of interest income.

Net Loss Attributable to Common Stockholders

Our net loss attributable to common stockholders was $6.8 million, or $0.38 per basic and dilutive common share for the six months ended June 30, 2020, compared to a net loss of $7.7 million, or $0.48 per basic common share and dilutive common share for the six months ended June 30, 2019. Net loss attributable to common stockholders for the six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $42,000 and includes the accretion of Series B preferred discount of $796,000 on converted shares and Series A Preferred Stock accrued dividends of $125,000. Net loss attributable to common stockholders for the six months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $43,000 and includes the accretion of Series B preferred discount of $515,000 on converted shares and $122,000 of Series A accrued dividends.

Liquidity and Capital Resources

With the exception of the three months ended June 30, 2010 and the three months ended December 31, 2017, we have experienced significant losses since inception, incurred negative cash flows from operations, and have a significant accumulated deficit. We have incurred an accumulated deficit of $242.3 million as of June 30, 2020 and expect to continue to incur losses in the foreseeable future. Our ability to continue as a going concern is dependent upon our ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us. These factors raise substantial doubt about our ability to continue as a going concern.

We do not have sufficient capital to fund our operations beyond the next twelve months. In order to address our capital needs, including our planned clinical trials, we are actively pursuing additional equity or debt financing in the form of either a private placement or a public offering. We have been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. Such additional financing opportunities might not be available to us when and if needed, on acceptable terms or at all. If we are unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances, our operating results and prospects will be adversely affected.

Our cash and cash equivalents totaled $8.1 million as of June 30, 2020, a decrease of $7.0 million from December 31, 2019. During the three months ended June 30, 2020, the primary use of cash was for working capital requirements and operating activities which resulted in a net loss of $2.9 million for the three months ended June 30, 2020. With the cash available in early August 2020, we believe these resources will be sufficient to fund our operations through at least the end of the first quarter of 2021.

As a result of the global COVID-19 pandemic, management has the ability to further extend its cash runway since its clinical development partners (Cedars-Sinai Medical Center (CSMC) and Washington University) reduced their operating capacity during the second quarter of 2020 to include only essential activities, which excluded all planned and ongoing clinical trials of SYN-004 and SYN-010. However, our planned clinical trial timelines will be adversely impacted. We anticipate reduced research and development costs through the end of the year, since we anticipate that our proposed Phase 1b/2a clinical trial to be conducted by Washington University will be postponed until 2021, subject to further COVID-19 developments and we anticipate slower enrollment than anticipated in our Phase 2b investigator-sponsored clinical study of SYN-010 conducted by CSMC due to the pandemic. We anticipate our current cash will allow us to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts, including completing our funding requirements for our ongoing Phase 2b investigator-sponsored clinical study of SYN-010, and the initiation of the Phase 1b/2a SYN-004 (ribaxamase) clinical trial. Due to the unique challenges posed by the global COVID-19 pandemic, we have determined that postponing the commencement of the planned Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients until the first quarter of 2021 remains the appropriate response to the novel coronavirus pandemic. We do not anticipate any additional expense related to the Phase 1b/2a SYN-004 (ribaxamase) clinical trial until the trial is cleared for commencement by Washington University. Commencement of planned future Phase 3 clinical trials of SYN-004 and SYN-010 are subject to our successful pursuit of opportunities that will allow us to establish the clinical infrastructure and financial resources necessary to successfully initiate and complete our plan. We will be required to obtain additional funding in order to continue the development of our current product candidates beyond our Phase 2b investigator-sponsored clinical study of SYN-010 and our planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients within the anticipated time periods, if at all, and to continue to fund operations at the current cash expenditure levels. Currently, we do not have commitments from any third parties to provide us with capital. If we fail to obtain additional funding for our clinical trials, whether through the sale of securities or a partner or collaborator, and otherwise when needed, we will not be able to fully execute our business plan as planned and we will be forced to cease certain development activities until funding is received and our business will suffer, which would have a material adverse effect on our financial position, results of operations and cash flows.

While we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the COVID-19 pandemic, our business, financial condition, results of operations and growth prospects could be materially adversely affected.

Historically, we have financed our operations primarily through public and private sales of our securities, and we expect to continue to seek to obtain our required capital in a similar manner. During the year ended December 31, 2019 and the six months ended June 30, 2020, we did not engage in any financing activity as our financings conducted during the year ended December 31, 2018 were sufficient to satisfy our cash needs during 2019 and the six months ended June 30, 2020. During the year ended December 31, 2018, our only sources of funding were from our underwritten public offering (the “Offering”) described below pursuant to which we received net proceeds of approximately $16.7 million and sales of 3.5 million shares of our Common Stock in our at-the-market offering program through the FBR Sales Agreement pursuant to which we received net proceeds of approximately $12.2 million. The FBR Sales Agreement enables us to offer and sell shares of our Common Stock from time to time through FBR Capital Markets & Co. as our sales agent, provided that we meet certain conditions. Sales of Common Stock under the FBR Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. FBR Capital Markets & Co. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of our Common Stock sold on our behalf.

On October 15, 2018, we closed the Offering pursuant to which we received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by us and sold an aggregate of (i) 2,520,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of Common Stock, and one five-year warrant to purchase one share of Common Stock at an exercise price of $1.38 per share (the “October 2018 Warrants”), with each Class A Unit offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the “Class B Units), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of our Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October 2018 Warrants. A.G.P./Alliance Global Partners (the “Underwriters”) acted as sole book-running manager for the Offering. In addition, pursuant to the Underwriting Agreement that we entered into with the Underwriters on October 10, 2018, we granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional October 2018 Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from us additional October 2018 Warrants to purchase 1,807,826 shares of Common Stock. The Units were offered by us pursuant to a registration statement on Form S-1 (File No. 333-227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018. As of December 31, 2019, 8,085 shares of Series B Preferred Stock have been converted to Common Stock and 7,638 shares of Series B Preferred Stock remain outstanding.

We have spent, and expect to continue to spend, a substantial amount of funds in connection with implementing our business strategy, including our planned product development efforts, preparation for our planned clinical trials, performance of clinical trials and our research and discovery efforts. Based on our current plans, our cash and cash equivalents will not be sufficient to enable us to meet our long-term expected plans as it is anticipated that we will not have enough cash to continue our operations beyond the next twelve months. We will be required to obtain additional funding in order to continue the development of certain product candidates within the anticipated time periods, if at all, and to continue to fund operations at the current cash expenditure levels.

Our ability to continue as a going concern is dependent upon our ability to raise additional capital. Our cash and cash equivalents will not be sufficient to enable us to meet our long-term expected plans, including initiation or completion of future registrational studies for SYN-010, potential Phase 3 clinical programs of SYN-004 (ribaxamase) for prevention of CDI and/or the prevention of aGVHD in allogeneic HCT recipients, or later-stage clinical trials of SYN-020. Therefore, we do not intend to commence future registrational studies of SYN-010, Phase 3 clinical programs of SYN-004 (ribaxamase) for prevention of CDI and/or the prevention of aGVHD in allogeneic HCT recipients, or later-stage clinical trials of SYN-020 until we are confident that we have funding necessary to complete such trials. We are actively pursuing additional equity or debt financing, in the form of either a private placement or a public offering and have been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. However, we do not currently have commitments from any third parties to provide us with capital. Potential sources of financing that we are pursuing include strategic relationships, public or private sales of our equity (including through the FBR Sales Agreement) or debt and other sources. Such additional financing opportunities might not be available to the Company when and if needed, on acceptable terms or at all. We cannot assure that we will meet the requirements for use of the FBR Sales Agreement especially in light of the fact that we are currently limited by rules of the SEC as to the number of shares of Common Stock that we can sell pursuant to the FBR Sales Agreement due to the market value of our Common Stock held by non-affiliates. Even if we meet the requirements for use of the FBR Sales Agreement, there can be no assurance that we will be able to continue to raise funds through the sale of shares of Common Stock through the FBR Sales Agreement. Additionally, we may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. If we are unable to obtain additional capital (which is not assured at this time), our long-term business plan may not be accomplished and we may be forced to cease certain development activities. More specifically, the completion of future Phase 3 and/or registrational clinical studies will require significant financing or a significant partnership. If we raise funds by selling additional shares of Common Stock or other securities convertible into Common Stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain funding for future clinical trials when needed, we will be unable to carry out our business plan and we will be forced to delay the initiation of future clinical trials until such time as we obtain adequate financing and our operating results and prospects will be adversely affected.

Following the completion of our ongoing Phase 2b clinical study of SYN-010, our planned Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients and planned IND filing of SYN-020, we will need to obtain additional funds for future clinical trials. We anticipate that our future clinical trials will be much larger in size and require larger cash expenditures than the current investigator sponsored Phase 2b study of SYN-010 or the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase) to be conducted by Washington University. We do not have any committed sources of financing for future clinical trials at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.

On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. As the COVID-19 coronavirus continues to spread around the globe, we have experienced disruptions that impact our business and clinical trials, including halting the enrollment of new patients in our ongoing Phase 2b investigator-sponsored clinical trial of SYN-010 clinical study and postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. We are actively monitoring the global situation and its potential impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the future effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity.

Off-Balance Sheet Arrangements

During the three and six months ended June 30, 2020, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Contractual Obligations

Leases

At the inception of a contract we determine if the arrangement is, or contains, a lease. Right-of-use (“ROU”) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.

We have made certain accounting policy elections whereby we (i) do not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii) combine lease and non-lease elements of our operating leases. ROU assets are included in other noncurrent assets and lease liabilities are included in other current and non-current liabilities in our condensed consolidated balance sheets. As of June 30, 2020, we did not have any material finance leases.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. Our exposure to market risk is confined to our cash and cash equivalents. As of June 30, 2020, our cash and cash equivalents consisted primarily of investments in treasury securities. We do not engage in any hedging activities against changes in interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio. We may, however, require additional financing to fund future obligations and no assurance can be given that the terms of future sources of financing will not expose us to material market risk.

ITEM 4. CONTROLS AND PROCEDURES.

(a) Evaluation of Disclosure Controls and Procedures

The Company has adopted and maintains disclosure controls and procedures (as defined Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form 10-Q, is collected, recorded, processed, summarized and reported within the time periods specified in the rules of the SEC. The Company’s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule 13a-15, the Company’s management, including the Chief Executive Officer, who also serves as the Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures as of June 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that based on such evaluation, the Company’s disclosure controls and procedures are effective as of June 30, 2020 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control over Financial Reporting

There have not been any changes in our internal controls over financial reporting during the three months ended June 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II–OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

ITEM 1A. RISK FACTORS.

The following information updates, and should be read in conjunction with, the information disclosed in Part I, Item 1A, “Risk Factors,” contained in our 2019 Form 10-K. Except as disclosed below, there have been no material changes from the risk factors disclosed in our 2019 Form 10-K.

RISKS RELATING TO OUR BUSINESS

Our auditor’s report on our consolidated financial statements for the years ended December 31, 2019 and 2018 contains an explanatory paragraph regarding our ability to continue as a going concern and the notes to our financial statements for the quarter ended June 30, 2020 mention there being substantial doubt about our ability to continue as a going concern.

Our consolidated financial statements as of December 31, 2019 have been prepared under the assumption that we will continue as a going concern for the next twelve months. In addition, our independent registered public accounting firm has issued a report that includes an explanatory paragraph referring to our recurring losses from operations (anticipated continued losses in the future) and net capital deficiency that raise substantial doubt about our ability to continue as a going concern without additional capital becoming available. Our consolidated financial statements as of December 31, 2019 did not include any adjustments that might result from the outcome of this uncertainty.

The consolidated financial statements for the quarter ended June 30, 2020 have been prepared assuming we will continue as a going concern. We continue to incur losses and, as of June 30, 2020, we had an accumulated deficit of approximately $242.3 million. Our consolidated financial statements as of June 30, 2020 do not include any adjustments that might result from the outcome of this uncertainty.

Our ability to continue as a going concern is dependent upon our ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us. These factors raise substantial doubt about our ability to continue as a going concern.

We will need to raise additional capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate our development programs or commercialization efforts.

During the six months ended June 30, 2020, our operating activities used net cash of approximately $7.0 million and our cash and cash equivalents were $8.1 million as of June 30, 2020. With the exception of the three months ended June 30, 2010 and the three months ended December 31, 2017, we have experienced significant losses since inception and have a significant accumulated deficit. As of June 30, 2020, our accumulated deficit totaled approximately $242.3 million on a consolidated basis. We do not have sufficient capital to fund our operations beyond twelve months following the issuance date of this Quarterly Report on Form 10-Q. We expect to incur additional operating losses in the future and therefore expect our cumulative losses to increase. With the exception of the quarter ended September 30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March 2012, we have generated very minimal revenues. We do not expect to derive revenue from any source in the near future until we or our potential partners successfully commercialize our products. We expect our expenses to increase in connection with our anticipated activities, particularly as we continue research and development, initiate and conduct clinical trials, recommence clinical trials that have been on hold or postponed and seek marketing approval for our product candidates. Until such time as we receive approval from the FDA and other regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore we will not have product revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing and collaboration fees and grants, if any.

We will need to raise additional capital to fund our operations and meet our current timelines and we cannot be certain that funding will be available on acceptable terms on a timely basis, or at all. Based on our current plans, our cash and cash equivalents will not be sufficient to complete our planned Phase 3 clinical trial for SYN-004 or our planned Phase 3 clinical trial for SYN-010, which are expected to require significant cash expenditures. In addition, based on the anticipated significant cost of a Phase 3 clinical program in a broad indication for SYN-004, we expect it will not be feasible for us to initiate and complete this trial at this time without a partner given the capital constraints tied to our current market cap and share price. In addition, based on the anticipated cost of our planned Phase 3 clinical trial for SYN-010, we expect that we may also reach the same determination regarding the feasibility of initiating and completing the trial without a partner given the capital constraints tied to our current market cap and share price at such time. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business and also have a dilutive effect on our stockholders. A failure otherwise to secure additional funds when needed in the future whether through an equity or debt financing or a sufficient amount of capital without a strategic partnership could result in us being unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Our ability to raise capital through the sale of securities is currently limited by the rules of the SEC and NYSE American that place limits on the number and dollar amount of securities that may be sold. There can be no assurances that we will be able to raise the funds needed, especially in light of the fact that our ability to sell securities registered on registration statement Form S-3 will be limited until such time the market value of our voting securities held by non-affiliates is $75 million or more. We also may be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available.

The COVID-19 global health crisis has impacted our planned operations, including our clinical studies

In January 2020, the World Health Organization declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple countries, including throughout the United States. We have experienced disruptions that have impacted our business and clinical trials and expect to experience additional disruptions as the pandemic continues, including:

•

halting enrollment of new patients into our SYN-010 clinical study during the first and second quarter of 2020;

•

unwillingness of potential study participants to enroll in new clinical trials and/or visit healthcare facilities;

•

postponement in clinical site initiation for our SYN-004 clinical study;

•

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

•

interruption of key clinical trial activities, such as clinical site visits by study participants and clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;

•

limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;

•

delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;

•

delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;

•

interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;

•

changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;

•

delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees;

•

delay in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention to approval of other therapeutics or other activities related to COVID-19.

Our business and the business of the suppliers of our clinical product candidates has been and is expected to continue to be materially and adversely affected by the pandemic. Such events could result in the complete or partial closure of clinical trial sites, one or more manufacturing facilities which could impact our supply of our clinical product candidates. In addition, it could impact economies and financial markets, resulting in an economic downturn that could impact our ability to raise capital or slow down potential partnering relationships.

In addition. the COVID-19 outbreak could disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our office, or due to quarantines. The COVID-19 illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings for the management of our affairs.

The global outbreak of the virus continues to rapidly evolve. The extent to which the virus may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. We do not yet know the full extent of potential delays or impacts on our business, operations, or the global economy as a whole. While the spread of COVID-19 may eventually be contained or mitigated, there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur, or that the global economy will recover, either of which could seriously harm our business.

Difficulties enrolling patients in our clinical trials or delays in enrollment are expected to result in our clinical development activities being delayed or otherwise adversely affected.

Delays in patient enrollment may result in increased cost or may adversely affect timing or outcome of planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. In some cases, generating meaningful clinical data may require rigorous screening criteria which may result in unintended and higher than anticipated patient-related screen-fail rates, as has occurred with our current investigator-sponsored Phase 2b clinical study conducted by CSMC. This can lead to delays in completion of clinical trials as well as additional expense for recruitment of patients. In addition, the COVID-19 pandemic may result in fewer technicians being available to conduct clinical testing for patients currently enrolled in our clinical trial.

Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.

We recently have experienced delays in clinical testing of our product candidates due to COVID-19 and may in the future experience other delays. We do not know when the planned SYN-004 clinical trial will initiate or when the SYN-010 clinical trial will recommence enrollment. These delays may result in the need for trials to be redesigned and will impact whether they will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the COVID-19 pandemic, delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Manufacturing considerations for clinical development candidates may include an expected several month lead time following a decision to commence any clinical trial(s) and capacity considerations of our third-party contract manufacturers to provide clinical supply of our product candidates could cause delays in clinical trials. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing clinical trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether to offer their patients enrollment in clinical trials of our product candidates versus treating these patients with commercially available drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product development and timeliness and approval process and delay our ability to generate revenue.

RISKS RELATING TO OUR SECURITIES

We cannot assure you that our Common Stock will be liquid or that it will remain listed on the NYSE American. A failure to regain compliance with the NYSE American stockholders’ equity listing requirements or failure to continue to meet the other listing requirements could result in a de-listing of our Common Stock.

Our Common Stock is listed on the NYSE American. The NYSE American’s listing standards generally mandate that we meet certain requirements relating to stockholders’ equity, stock price, market capitalization, aggregate market value of publicly held shares and distribution requirements. We cannot assure you that we will be able to maintain the continued listing standards of the NYSE American. The NYSE American requires companies to meet certain continued listing criteria including a minimum stockholders’ equity of $6.0 million if an issuer has sustained losses from continuing operations and/or net losses in its five most recent years, as outlined in the NYSE American Company Guide. At June 30, 2020, we had a stockholders’ deficit of $6.8 million. The NYSE American Company Guide also states that the NYSE normally will not consider removing from listing securities of an issuer with total value of market capitalization of at least $50.0 million and 1,100,000 shares publicly held, a market value of publicly held shares of at least $15.0 million and 400 round lot shareholders. Although we have more than 1,100,000 shares publicly held and 400 round lot shareholders, our stock price is volatile and, during the first two quarters of 2018, the price of our Common Stock experienced a sustained decrease resulting in a period where our market capitalization fell below $50.0 million. Our market capitalization is currently below $50.0 million

On November 25, 2019, we announced that we received written communication from the NYSE American stating we were no longer in compliance with certain continued listing standards as set forth in the NYSE American Company Guide relating to stockholders’ equity as of September 30, 2019. Specifically, the Deficiency Letter stated that we were not in compliance with Section 1003(a)(iii) (requiring stockholders’ equity of $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years). The Deficiency Letter noted that the Company had stockholders’ equity of $4.9 million as of September 30, 2019 and had reported net losses in its five most recent fiscal years. On December 20, 2019, we submitted a plan of compliance to the NYSE American outlining our plan to regain compliance with certain continued listing standards as set forth in Part 10, Section 1003(iii) of the NYSE American Company Guide by November 25, 2020, the conclusion of the compliance plan period. On February 7, 2020, we received notice from the NYSE American that it had accepted our plan and granted a plan period through November 25, 2020 to regain compliance. On July 30, 2020 we received written communication from NYSE American stating that in addition to Section 1003(iii), the Company is also not in compliance with Section 1003(i) and Section 1003(ii) of the NYSE American Company Guide since it reported a stockholders’ deficit of ($4.0) million as of March 31, 2020 and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2019. As a result, the Company is now subject to the procedures and requirements set forth in Section 1009 of the Company Guide. The Company remains subject to the conditions set forth in the Exchange’s letter dated November 25, 2019 for the initial equity noncompliance. The NYSE Regulation staff will review our company periodically for compliance with the initiatives outlined in the plan. If we are not in compliance with the continued listing standards by November 25, 2020 or if we do not make progress consistent with the plan during the plan period, NYSE Regulation staff may initiate a delisting proceeding as appropriate.

There can be no assurance that we can regain compliance with the listing standards of the NYSE American, or that the NYSE American will continue to list our Common Stock if we regain compliance, or if we continue to fail to maintain the minimum stockholders’ equity. In addition, in the future we may not be able to maintain such minimum stockholders’ equity and/or issue additional equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders’ equity required by the NYSE American. If we are delisted from the NYSE American then our Common Stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. If our Common Stock is delisted from the NYSE American due to our failure to regain compliance with the listing standards by the end of the compliance period or for any other reason, and the market value of our shares of Common Stock held by non-affiliates remains below $15 million, we will likely no longer be eligible to sell Common Stock pursuant to the B. Riley FBR Sales Agreement or otherwise utilize our shelf registration statement. In addition, delisting of our Common Stock could depress our stock price, substantially limit liquidity of our Common Stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE American could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities. We cannot assure you that our Common Stock will be liquid or that it will remain listed on the NYSE American. A failure to regain compliance with the NYSE American stockholders’ equity requirements or failure to continue to meet the other listing requirements could result in a de-listing of our Common Stock.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

We did not sell any equity securities during the three and six months ended June 30, 2020 in transactions that were not registered under the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

Not applicable

ITEM 6. EXHIBITS

The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYNTHETIC BIOLOGICS, INC.

	By:	/s/ Steven A. Shallcross
		Steven A. Shallcross
		Chief Executive Officer, Chief Financial Officer
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

		Date: August 6, 2020

EXHIBIT INDEX

Exhibit Number		Exhibit Title

31.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*

32.1		Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101.INS		XBRL Instance Document*

101.SCH		XBRL Taxonomy Extension Schema*

101.CAL		XBRL Taxonomy Extension Calculation Linkbase*

101.DEF		XBRL Taxonomy Extension Definition Linkbase*

101.LAB		XBRL Taxonomy Extension Label Linkbase*

101.PRE		XBRL Taxonomy Extension Presentation Linkbase*

*Filed herewith.

EX-31.1 2 tm2020466d1_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Steven A. Shallcross, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Synthetic Biologics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 6, 2020	By:	/s/ Steven A. Shallcross
		Name: Steven A. Shallcross
		Chief Executive Officer, Chief Financial Officer
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

EX-32.1 3 tm2020466d1_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFCIER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the “Registrant”) hereby certifies, to such officer’s knowledge, that:

(1)	the accompanying Quarterly Report on Form 10-Q of the Registrant for the quarter ended June 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: August 6, 2020
	By:	/s/ Steven A. Shallcross
		Name: Steven A. Shallcross
		Chief Executive Officer, Chief Financial Officer
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

GRAPHIC 4 image_004.jpg GRAPHIC begin 644 image_004.jpg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end EX-101.INS 5 syn-20200630.xml XBRL INSTANCE DOCUMENT 0000894158 us-gaap:IPOMember 2020-06-30 0000894158 us-gaap:IPOMember 2019-06-30 0000894158 2017-12-26 0000894158 syn:FbrCapitalMarketsCoMember 2016-08-01 2016-08-05 0000894158 syn:ClassAMember 2018-10-15 2018-10-15 0000894158 us-gaap:OverAllotmentOptionMember 2018-10-11 2018-10-15 0000894158 us-gaap:CommonClassBMember 2018-10-11 2018-10-15 0000894158 us-gaap:CommonClassAMember 2018-10-11 2018-10-15 0000894158 syn:ClassBMember 2018-10-11 2018-10-15 0000894158 us-gaap:OverAllotmentOptionMember 2018-10-02 2018-10-10 0000894158 us-gaap:IPOMember 2016-11-02 2016-11-18 0000894158 us-gaap:RetainedEarningsMember 2020-06-30 0000894158 us-gaap:NoncontrollingInterestMember 2020-06-30 0000894158 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000894158 us-gaap:RetainedEarningsMember 2020-03-31 0000894158 us-gaap:NoncontrollingInterestMember 2020-03-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000894158 2020-03-31 0000894158 us-gaap:RetainedEarningsMember 2019-12-31 0000894158 us-gaap:NoncontrollingInterestMember 2019-12-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000894158 us-gaap:RetainedEarningsMember 2019-06-30 0000894158 us-gaap:NoncontrollingInterestMember 2019-06-30 0000894158 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000894158 us-gaap:RetainedEarningsMember 2019-03-31 0000894158 us-gaap:NoncontrollingInterestMember 2019-03-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000894158 2019-03-31 0000894158 us-gaap:RetainedEarningsMember 2018-12-31 0000894158 us-gaap:NoncontrollingInterestMember 2018-12-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000894158 us-gaap:CommonStockMember 2020-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2020-03-31 0000894158 us-gaap:CommonStockMember 2020-03-31 0000894158 us-gaap:CommonStockMember 2019-12-31 0000894158 us-gaap:SeriesBPreferredStockMember 2019-06-30 0000894158 us-gaap:CommonStockMember 2019-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2019-03-31 0000894158 us-gaap:CommonStockMember 2019-03-31 0000894158 us-gaap:SeriesBPreferredStockMember 2018-12-31 0000894158 us-gaap:CommonStockMember 2018-12-31 0000894158 us-gaap:CommonClassAMember 2018-10-15 0000894158 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0000894158 syn:StockPlan2010Member 2020-06-30 0000894158 syn:StockPlan2007Member 2020-06-30 0000894158 syn:StockPlan2010Member 2010-11-02 0000894158 syn:StockPlan2007Member 2007-03-20 0000894158 us-gaap:EmployeeStockOptionMember 2019-12-31 0000894158 us-gaap:EmployeeStockOptionMember 2018-12-31 0000894158 srt:MinimumMember syn:StockPlan2010Member 2019-09-01 2019-09-05 0000894158 srt:MaximumMember syn:StockPlan2010Member 2019-09-01 2019-09-05 0000894158 srt:MinimumMember syn:StockPlan2010Member 2018-09-01 2018-09-24 0000894158 srt:MaximumMember syn:StockPlan2010Member 2018-09-01 2018-09-24 0000894158 srt:MinimumMember syn:StockPlan2010Member 2017-09-01 2017-09-07 0000894158 srt:MaximumMember syn:StockPlan2010Member 2017-09-01 2017-09-07 0000894158 srt:MinimumMember syn:StockPlan2010Member 2016-08-01 2016-08-25 0000894158 srt:MaximumMember syn:StockPlan2010Member 2016-08-01 2016-08-25 0000894158 srt:MinimumMember syn:StockPlan2010Member 2015-05-01 2015-05-15 0000894158 srt:MaximumMember syn:StockPlan2010Member 2015-05-01 2015-05-15 0000894158 srt:MinimumMember syn:StockPlan2010Member 2013-10-01 2013-10-22 0000894158 srt:MaximumMember syn:StockPlan2010Member 2013-10-01 2013-10-22 0000894158 srt:MaximumMember syn:StockPlan2007Member 2007-03-01 2007-03-20 0000894158 syn:ClassAMember 2014-10-10 0000894158 us-gaap:EmployeeStockOptionMember 2020-06-30 0000894158 us-gaap:IPOMember 2014-10-10 0000894158 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0000894158 syn:CedarssinaiMedicalCenterMember 2020-04-01 2020-06-30 0000894158 syn:CedarssinaiMedicalCenterMember 2020-01-01 2020-06-30 0000894158 syn:CedarssinaiMedicalCenterMember 2019-04-01 2019-06-30 0000894158 syn:CedarssinaiMedicalCenterMember 2019-01-01 2019-06-30 0000894158 2018-09-01 2018-09-05 0000894158 us-gaap:LeaseholdImprovementsMember 2020-06-30 0000894158 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-06-30 0000894158 syn:ComputersAndOfficeEquipmentMember 2020-06-30 0000894158 us-gaap:LeaseholdImprovementsMember 2019-12-31 0000894158 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0000894158 syn:ComputersAndOfficeEquipmentMember 2019-12-31 0000894158 2018-10-11 2018-10-15 0000894158 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-09-08 2017-09-11 0000894158 2018-01-01 2018-12-31 0000894158 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-12-31 0000894158 us-gaap:SeriesBPreferredStockMember 2020-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2020-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2019-12-31 0000894158 us-gaap:SeriesAPreferredStockMember 2019-12-31 0000894158 us-gaap:SeriesAPreferredStockMember us-gaap:PrivatePlacementMember 2017-09-11 0000894158 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2020-04-01 2020-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-03-31 0000894158 us-gaap:SeriesAPreferredStockMember 2019-04-01 2019-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-03-31 0000894158 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-12-31 0000894158 syn:StockWarrantsMember 2014-10-01 2014-10-10 0000894158 us-gaap:SeriesBPreferredStockMember 2018-10-11 2018-10-15 0000894158 us-gaap:WarrantMember 2018-10-15 0000894158 us-gaap:SeriesBPreferredStockMember 2018-10-15 0000894158 us-gaap:IPOMember 2016-11-18 0000894158 2018-10-31 0000894158 2018-10-15 0000894158 us-gaap:SeriesBMember us-gaap:IPOMember 2016-11-18 0000894158 us-gaap:SeriesAMember us-gaap:IPOMember 2016-11-18 0000894158 us-gaap:MoneyMarketFundsMember 2020-06-30 0000894158 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000894158 2019-06-30 0000894158 2018-12-31 0000894158 us-gaap:WarrantMember 2020-04-01 2020-06-30 0000894158 us-gaap:StockOptionMember 2020-04-01 2020-06-30 0000894158 us-gaap:WarrantMember 2020-01-01 2020-06-30 0000894158 us-gaap:StockOptionMember 2020-01-01 2020-06-30 0000894158 us-gaap:WarrantMember 2019-01-01 2019-06-30 0000894158 us-gaap:StockOptionMember 2019-01-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000894158 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000894158 us-gaap:SeriesAPreferredStockMember 2017-09-08 2017-09-11 0000894158 syn:OctoberTwoThousandEighteenWarrantsMember syn:UnderwrittenPublicOfferingMember 2018-10-11 2018-10-15 0000894158 syn:ExercisePrice5005Member 2020-01-01 2020-06-30 0000894158 syn:ExercisePrice3.24Member 2020-01-01 2020-06-30 0000894158 syn:ExercisePrice1820Member 2020-01-01 2020-06-30 0000894158 syn:ExercisePrice138Member 2020-01-01 2020-06-30 0000894158 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000894158 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0000894158 syn:ExercisePrice5005Member 2020-06-30 0000894158 syn:ExercisePrice3.24Member 2020-06-30 0000894158 syn:ExercisePrice1820Member 2020-06-30 0000894158 syn:ExercisePrice138Member 2020-06-30 0000894158 us-gaap:WarrantMember 2017-12-26 0000894158 2019-01-01 2019-12-31 0000894158 us-gaap:CommonClassBMember 2018-10-15 0000894158 syn:ClassAMember 2018-10-15 0000894158 us-gaap:SeriesAPreferredStockMember 2017-09-11 0000894158 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-06-30 0000894158 2018-10-01 2018-10-31 0000894158 syn:CedarssinaiMedicalCenterMember 2020-06-30 0000894158 syn:CedarssinaiMedicalCenterMember 2018-09-05 0000894158 syn:SyntheticBiomicsIncMember syn:CedarssinaiMedicalCenterMember 2020-06-30 0000894158 syn:SyntheticBiomicsIncMember syn:CedarssinaiMedicalCenterMember 2018-09-05 0000894158 us-gaap:OverAllotmentOptionMember 2018-10-10 0000894158 us-gaap:OverAllotmentOptionMember 2018-10-15 0000894158 syn:StockWarrantsMember 2014-10-10 0000894158 us-gaap:SeriesBPreferredStockMember 2018-10-01 2018-10-31 0000894158 syn:StockWarrantsMember 2020-06-30 0000894158 syn:StockWarrantsMember 2019-06-30 0000894158 syn:CedarssinaiMedicalCenterMember 2018-09-01 2018-09-05 0000894158 2019-01-01 2019-06-30 0000894158 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000894158 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0000894158 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000894158 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000894158 2020-04-01 2020-06-30 0000894158 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000894158 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000894158 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000894158 2020-01-01 2020-03-31 0000894158 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000894158 us-gaap:NoncontrollingInterestMember 2019-04-01 2019-06-30 0000894158 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000894158 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000894158 2019-04-01 2019-06-30 0000894158 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000894158 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000894158 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000894158 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000894158 2019-01-01 2019-03-31 0000894158 us-gaap:SeriesBPreferredStockMember 2020-04-01 2020-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-03-31 0000894158 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-06-30 0000894158 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-03-31 0000894158 syn:FbrCapitalMarketsCoMember 2016-08-05 0000894158 syn:SYNBiomicsMember syn:CedarssinaiMedicalCenterMember 2018-09-05 0000894158 syn:SyntheticBiomicsIncMember 2018-09-05 0000894158 syn:SYNBiomicsMember 2020-06-30 0000894158 syn:SYNBiomicsMember 2019-06-30 0000894158 2020-06-30 0000894158 2019-12-31 0000894158 2020-08-03 0000894158 2020-01-01 2020-06-30 syn:D iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares false --12-31 Q2 2020 2020-06-30 10-Q 0000894158 19440346 Yes false Non-accelerated Filer Yes Synthetic Biologics, Inc. false true SYN 684000 704000 <div> <div> Accrued employee benefits (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued severance expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 399 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued bonus expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 396 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 858 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued vacation expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 132 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 77 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 927 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 935 </td> </tr> </table></div>   <div /></div> </div> <div> <div> Accrued expenses (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued clinical consulting services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 704 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 684 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued vendor payments </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 376 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 456 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued manufacturing costs </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 635 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,209 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,776 </td> </tr> </table></div>   <div /></div> </div> 635000 129000 456000 376000 2900000 2900000 2420000 2420000 0.030 0.03 0.03 0.03 0.03 0 1035000 1000 0 -398000 -638000 0 303000 1000 0 -117000 -187000 0 1072000 1000 0 -404000 -669000 0 1039000 1000 0 -392000 -648000 900869 -1036 262608 -302 933045 -1073 904349 -1040 515000 796000 23000 23000 285000 0 0 0.0999 -105000 -120000 56000 67000 0.50 1807826 1807826 7480000 7480000 7480000 50000 50000 50000 2022 0.0499 0.0999 1.20 515000 117000 796000 392000 18.90 1.15 1.15 1338 302 2113 1040 48000 471000 134000 91000 622000 94000 <div> <div> A summary of all warrant activity for the Company for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,915,851 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.85 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (200,852) </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61.25 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2020 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> </tr> </table></div>   <div /></div> </div> <div> <div> A summary of all outstanding and exercisable warrants as of June 30, 2020 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.02%;"> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td colspan="2" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercisable </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.38 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,999,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,999,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.28 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18.20 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 714 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 714 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.49 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50.05 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 714,286 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 714,286 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.39 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.24 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.17 years </td> </tr> </table></div>   <div /></div> </div> 0.42 714 17999999 714 18714999 714286 <div> <div> The assumptions used for the awards during the year ended December 31, 2019 were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.42 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 84 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk free interest rate </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.61 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected life of option </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.5 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   <div /></div> </div> 470000 0 0 0 200852 17000 -36000 0 53000 0 0 45000 0 0 45000 0 0 26000 0 0 26000 0 0 10000 0 0 10000 0 0 <div> <div> 6. Stock Warrants On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of Common Stock, and one five-year warrant to purchase one share of Common Stock at an exercise price of $1.38 per share (each a “Warrant” and collectively, the “Warrants”), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the “Class B Units”, and together with the Class A Units, the “Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants . In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the “Underwriters”), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock. The Warrants are immediately exercisable at a price of $1.38 per share of Common Stock (which is 120% of the public offering price of the Class A Units) and expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. On November 18, 2016, the Company completed a public offering of 714,286 shares of Common Stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of Common Stock. The stock and warrants were sold in combination, with two warrants for each share of Common Stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of Common Stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of Common Stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $50.05 and the per share exercise price of the Series B warrants is $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants may be exercised at any time on or after the date of issuance. The Series A warrants are exercisable until the four-year anniversary of the issuance date. The Series B warrants expired on December 31, 2017 and none were exercised prior to expiration. The warrants include a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Condensed Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and June 30, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price. On October 10, 2014, the Company raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the  Company's Common Stock and a warrant to purchase 0.50 shares of Common Stock. The warrants, exercisable for an aggregate of 200,852 shares of Common Stock, had an exercise price of $61.25 per share and a life of five years. The warrants vested immediately and expired on October 10, 2019. The warrants issued in conjunction with the registered direct offering in October 2014 included a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date, which was $7.4 million, and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and 2019, the fair value of the warrant liability was zero. The warrants were valued on the date of grant using the Black-Scholes option pricing model which approximates the value derived using Monte Carlo simulations. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company's current stock price. A summary of all warrant activity for the Company for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Number of </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2018 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,915,851 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.85 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (200,852) </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 61.25 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at December 31, 2019 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:72.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance at June 30, 2020 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.24 </td> </tr> </table></div>   On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, was paid a monthly fee, and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company's Common Stock on the date of issuance. The warrant is equity classified and the fair value of the warrant approximated $9,000 on the date of grant and was measured using the Black-Scholes option pricing model. This entire expense was recorded in the quarter ended March 31, 2018. A summary of all outstanding and exercisable warrants as of June 30, 2020 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.02%;"> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Warrants </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> </tr> <tr> <td colspan="2" valign="bottom" style="width:23.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercise Price </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Exercisable </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.38 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,999,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 17,999,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.28 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18.20 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 714 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 714 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2.49 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50.05 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 714,286 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 714,286 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.39 years </td> </tr> <tr> <td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.24 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 18,714,999 </td> <td valign="bottom" style="width:04.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 3.17 years </td> </tr> </table></div>   <div /></div> </div> 62000 36000 1.38 18.20 3.24 50.05 P5Y 2315000 1025000 858000 396000 935000 927000 1776000 1776000 1209000 1209000 77000 132000 887000 1003000 232580000 234860000 64000 64000 0 0 0 0 91000 91000 0 0 0 0 83000 83000 0 0 0 0 86000 86000 0 0 0 0 7875 106000 110000 19000 1000 50000 32000 9000 1000 79000 31000 53000 6000 40000 15000 27000 4000 6802608 843119 18915851 6802608 4804348 2472362 18714999 4804348 2472362 18714999 17235000 9582000 16426000 8956000 28918000 21712000 15045000 15045000 8059000 8100000 8059000 98000 114000 -7206000 -6986000 50.05 60.20 1.38 1.38 1.38 1428571 2428825 13672173 2428825 13672173 13672173 <div> <div> 11. Commitments and Contingencies Leases All of the Company’s existing leases as of June 30, 2020 are classified as operating leases. As of June 30, 2020, the Company has one material operating lease for facilities with a remaining term expiring in 2022. The existing lease has fair value renewal options, none of  which are considered certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the lease liability was 9.9%. The rates implicit within the Company’s leases are generally not determinable, therefore, the Company’s incremental borrowing rate is used to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. Because the Company currently has no outstanding debt, the incremental borrowing rate for each lease is primarily based on publicly-available information for companies within the same industry and with similar credit profiles. The rate is then adjusted for the impact of collateralization, the lease term and other specific terms included in the Company’s lease arrangements. The incremental borrowing rate is determined at lease commencement, or as of January 1, 2019 for operating leases in existence upon adoption of ASC 842. The incremental borrowing rate is subsequently reassessed upon a modification to the lease arrangement. ROU assets are subsequently assessed for impairment in accordance with the Company’s accounting policy for long-lived assets. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statement of operations, and for the three and six months ended June 30, 2020 approximated $50,000 and $101,000, respectively, and for three and six months ended June 30, 2019 approximated $50,000 and $101,000, respectively. For the three and six months ended June 30, 2020, operating cash flows used for operating leases approximated $77,000 and $154,000, respectively, and for three and six months ended June 30, 2019 approximated $75,000 and $149,000, respectively. The  right of use assets exchanged for operating lease obligations was $0. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000. A maturity analysis of our operating leases as of June 30, 2020 is as follows (amounts in thousands of dollars):   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Future undiscounted cash flow for the years ending December 31: </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 321 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 192 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 669 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Discount factor </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (67) </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 602 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Amount due within 12 months </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (268) </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability – long term </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 334 </td> </tr> </table></div>   Risks and Uncertainties On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. As the COVID-19 coronavirus continues to spread around the globe, the Company experienced disruptions that impact its business and clinical trials, including halting the enrollment of new patients in the ongoing Phase 2b investigator-sponsored clinical trial of SYN-010 and postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company’s business, the clinical development of SYN-010, SYN-004 (ribaxamase) and SYN-020, the business of the Company’s suppliers and other commercial partners, the Company’s corporate development objectives and the value of and market for the Company’s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces. <div /></div> </div> 3800000 0.001 0.001 200000000 200000000 16808758 18646152 16806430 18643824 17000 19000 825000 1317000 13672173 13672173 10198 30 20 122000 116000 <div> <div> 5. Stock-Based Compensation Stock Incentive Plans On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 71,429 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2020, there were 7,052 options issued and outstanding under the 2007 Stock Plan. On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 85,714 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 85,714 to 171,429. On May 15, 2015, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 171,429 to 228,572. On August 25, 2016, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 228,572 to 400,000. On September 7, 2017, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 400,000 to 500,000. On September 24, 2018, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 500,000 to 1,000,000. On September 5, 2019, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Common Stock reserved for issuance under the 2010 Stock Plan from 1,000,000 to 4,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and expire between five and ten years after the grant date. As of June 30, 2020, there were 2,465,310 options issued and outstanding under the 2010 Stock Plan. In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized as compensation expense over the stated vesting period. The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three and six months ended June 30, 2020 and 2019. The assumptions used for the awards during the year ended December 31, 2019 were as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Exercise price </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.42 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Expected dividends </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected volatility </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 84 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Risk free interest rate </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1.61 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> % </td> </tr> <tr> <td valign="bottom" style="width:84.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expected life of option </td> <td valign="bottom" style="width:02.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.5 </td> <td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> years </td> </tr> </table></div>   Expected dividends —The Company has never declared or paid dividends on its Common Stock and has no plans to do so in the foreseeable future. Expected volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Risk-free interest rate—The assumed risk free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option. Expected life of the option—The period of time that the options granted are expected to remain unexercised. Options granted during 2019 have a maximum term of seven years. The Company estimates the expected life of the option based on the weighted average life between the dates that options become fully vested and the maximum life of options granted. The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> immediate vesting;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> half vesting immediately and remaining over three years;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> in full on one-year anniversary of grant date;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> quarterly over three years;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> annually over three years;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> one-third immediate vesting and remaining annually over two years;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> one half immediate vesting and remaining over nine months;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> one quarter immediate vesting and remaining over three years;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> one quarter immediate vesting and remaining over 33 months; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> monthly over three years.</td></tr></table></div> A summary of stock option activity for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average Exercise </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance - December 31, 2018 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 938,982 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15.18 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.19 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,725,000 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.42 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (94,738) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 58.25 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (67,232) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.95 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance - December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,502,012 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.62 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.51 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153,353 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (29,650) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.55 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance - June 30, 2020 - outstanding </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,472,362 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.65 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.98 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 158,270 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance - June 30, 2020 - exercisable </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 628,408 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.89 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.16 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15,129 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Grant date fair value of options granted - six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average grant date fair value - six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Grant date fair value of options granted - year ended December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 470,000 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average grant date fair value - year ended December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.27 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> </table></div>   Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $40,000 and $79,000, respectively, and $50,000 and $106,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in  research and development expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $15,000 and $31,000, respectively, and $32,000 and $110,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2020 was $27,000 and $53,000, respectively, and $9,000 and $19,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and  six months ended June 30, 2020 was $4,000 and $6,000, respectively, and $1,000 for the three and six months ended June 30, 2019. As of June 30, 2020, total unrecognized stock-based compensation expense related to stock options was $498,000, which is expected to be expensed through July 2022. The FASB’s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June 30, 2020 and 2019. <div /></div> </div> 70.00 61000 0 0 0 61000 0 61000 0 0 0 61000 0 62000 0 0 0 62000 0 63000 0 0 0 63000 0 122000 125000 -0.48 -0.23 -0.38 -0.18 <div> <div> 7. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the three and six months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.1 million and $0.5 million, respectively, on converted shares and $0.1 million of Series A accrued dividends. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020 and 2019 were 4,804,348 and 6,802,608, respectively. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively and for the six months ended June 30, 2019 were 843,119 and 18,915,851, respectively, because their effect is anti-dilutive. <div /></div> </div> 935000 927000 498000 7400000 <div> <div> 3.  Fair Value of Financial Instruments ASC 820, Fair Value Measurement, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 2 inputs: Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</td></tr></table></div> In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy. The carrying amounts of the Company’s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments. Cash and cash equivalents include money market accounts of $114,000 as of June 30, 2020 and $98,000 as of December 31, 2019 that are measured using Level 1 inputs. The Company uses Monte Carlo simulations to estimate the fair value of its stock warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company’s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price. <div /></div> </div> 2199000 1044000 2679000 1286000 490000 -1290000 627000 -567000 -821000 -8000 706000 -484000 125000 80000 44000 6000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Future undiscounted cash flow for the years ending December 31: </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">      </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 156 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2021 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 321 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2022 </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 192 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 669 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Discount factor </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (67) </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 602 </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Amount due within 12 months </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (268) </td> </tr> <tr> <td valign="bottom" style="width:83.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Lease liability – long term </td> <td valign="bottom" style="width:02.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 334 </td> </tr> </table></div>   <div /></div> </div> 669000 156000 192000 321000 67000 5748000 3763000 17235000 9582000 5275000 3429000 -2878000 -2884000 <div> <div> 8. Non-controlling Interest The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”), and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Synthetic Biomics, Inc. (“SYN Biomics”). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company's equity interest in SYN Biomics is 83% and the non-controlling stockholder's interest is 17%. As of June 30, 2020 , the accumulated net loss attributable to the non-controlling interest is $2.9 million. In consideration of the support provided by CSMC for the Study, the Company will pay $441,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (“Synbiomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. During the three and six months ended June 30, 2019, research and development expense recorded related to this transaction approximated $119,000 and $174,000, respectively. The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company's common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics. <div /></div> </div> 0.17 0.17 0.17 0.83 0 0 0 0 -7206000 -6986000 -3512000 0 0 0 -3512000 0 -7043000 -3531000 -3531000 0 0 0 -3531000 0 -2964000 0 0 0 -2964000 0 -5831000 -2867000 -2867000 0 0 0 -2867000 0 -16000 0 0 -16000 0 0 -43000 -27000 -27000 0 0 -27000 0 0 -26000 0 0 -26000 0 0 -42000 -16000 -16000 0 0 -16000 0 0 -7680000 -3709000 -6752000 -3322000 125000 80000 44000 6000 7211000 3638000 5917000 2889000 -7211000 -3638000 -5917000 -2889000 101000 50000 101000 50000 602000 249000 268000 268000 473000 334000 334000 149000 75000 154000 77000 419000 352000 0.099 <div> <div> 1. Organization, Nature of Operations and Basis of Presentation Description of Business Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN‑004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN‑010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN‑020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2019 Form 10‑K. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results for the full year. The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods. Recent Accounting Pronouncements and Developments On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was enacted. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States’ economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company has assessed the impact of the CARES Act and based upon our initial assessment, we do not believe that it will have a significant effect on our financial position, results of operations or cash flows. The Company continues to evaluate its impact as new information becomes available. Impairment of Long-Lived Assets Long-lived assets include property, equipment and right-of-use assets. In accordance with Accounting Standards Codification (“ASC”) 360 - Property, Plant and Equipment (“ASC 360”), management reviews the Company’s recorded long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between fair value and the carrying value of the asset. The Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2020. <div /></div> </div> 1000 0 3000 0 399000 500000 100000 800000 400000 0.020 0.02 0.01 0.01 0.01 0.01 100000 122000 122000 515000 61000 61000 117000 100000 125000 125000 796000 63000 63000 392000 0.001 1000 0.001 1000 0.001 1000 6900000 9100000 10000000 10000000 10000000 10000000 120000 7638 120000 5525 120000 7638 120000 5525 4761000 3444000 1381000 1381000 897000 897000 25000 0 549000 241000 19100000 12000000 18600000 -7086000 -7086000 -3558000 -5873000 -5873000 -2883000 1254000 804000 11000 439000 1254000 804000 11000 439000 367000 367000 251000 251000 <div> <div> Property and equipment, net (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Computers and office equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 804 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 804 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 439 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 439 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Software </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,254 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,254 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,003) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (887) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 251 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 367 </td> </tr> </table></div>   <div /></div> </div> 441000 <div> <div> 10. Related Party Transactions On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) to: (i) issued to CSMC fifty thousand (50,000)  shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary Synthetic Biomics, Inc. (“SYN Biomics”) owned by the Company, such that after such issuance CSMC will own an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent  (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics. In December 2013, through the Company’s subsidiary, Synthetic Biomics, Inc., the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and  six months ended June 30, 2020 and 2019, the Company did not owe and did not pay CSMC for milestone payments related this license agreement.   <div /></div> </div> 5012000 174000 2594000 119000 3238000 92000 1603000 25000 -235537000 -242289000 538000 538000 0 0 100 14059616 1.47 35.00 <div> <div> Prepaid expenses and other current assets (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid clinical research organizations </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 471 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurances </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 241 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 549 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid manufacturing expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 94 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 622 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid consulting, subscriptions and other expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 91 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 134 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid conferences, travel </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other receivables </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 897 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,381 </td> </tr> </table></div>   <div /></div> </div> <div> <div> A summary of stock option activity for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Weighted Average </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Aggregate </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Average Exercise </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Remaining </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Intrinsic </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Options </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Price </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Contractual Life </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:09.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> Value </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance - December 31, 2018 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 938,982 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 15.18 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.19 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 1,725,000 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 0.42 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (94,738) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 58.25 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (67,232) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.95 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Balance - December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 2,502,012 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 3.62 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 6.51 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 153,353 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Granted </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercised </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Expired </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Forfeited </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (29,650) </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.55 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance - June 30, 2020 - outstanding </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2,472,362 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.65 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.98 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 158,270 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance - June 30, 2020 - exercisable </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 628,408 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12.89 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 5.16 years </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 15,129 </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Grant date fair value of options granted - six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average grant date fair value - six months ended June 30, 2020 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Grant date fair value of options granted - year ended December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 470,000 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:48.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Weighted average grant date fair value - year ended December 31, 2019 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 0.27 </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:16.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:07.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">    </td> </tr> </table></div>   <div /></div> </div> 155000 169000 200852 0 61.25 0 0 0 18915851 18714999 18714999 3.85 3.24 3.24 P3Y3M11D P2Y5M27D P3Y2M1D P4M21D 0.00 P4Y6M 0.84 0.0161 17999999 714 18714999 714286 15129 61.25 628408 12.89 P5Y1M28D 94738 0 5.95 0.55 67232 29650 0 0 0 0 7143 171429 85714 228572 171429 400000 228572 500000 400000 1000000 500000 1725000 4000000 1000000 0 0.27 0.00 0 153353 158270 71429 85714 938982 2502012 7052 2465310 2472362 15.18 3.62 3.65 P6Y2M9D P6Y6M4D P5Y11M23D 0.00 0.00 58.25 0.00 0.42 0.00 1.15 15482083 9161 16382952 8125 16645560 7823 16806430 7638 17739475 6565 18643824 5525 1821000 -3966000 14159000 230754000 15000 -2909000 -219461000 5760000 10651000 231817000 16000 -2872000 -223432000 5122000 7168000 232211000 17000 -2854000 -227141000 4935000 -1057000 -1057000 232580000 17000 -2878000 -235537000 4761000 -4000000 233735000 18000 -2878000 -238967000 4092000 -6850000 -6850000 234860000 19000 -2884000 -242289000 3444000 <div> <div> 9. Common and Preferred Stock Series B Preferred Stock On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units , with each Class A Unit offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units, with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October 2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series B Preferred Stock discount. In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October 10, 2018, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock. The Units were offered by the Company pursuant to a registration statement on Form S‑1 (File No. 333‑227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018. The conversion price of the Series B Preferred Stock and exercise price of the October 2018 Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances. During the three and six months ended June 30, 2020, 1,040 and 2,113 Series B shares, respectively, have been converted into common stock resulting in the recognition of $392,000 and $796,000, respectively, of unamortized discount from the conversion. During the three and six months ended June 30, 2019, 302 and 1,338 Series B shares, respectively, have been converted into common stock resulting in the recognition of $117,000 and $515,000, respectively, of unamortized discount from the conversion. As of June 30, 2020, 10,198 shares have been converted resulting in the recognition of $3.8 million of unamortized discount. This is recorded as a deemed dividend in accumulated deficit. The October 2018 Warrants are immediately exercisable at a price of $1.38 per share of common stock (which is 120% of the public offering price of the Class A Units) and will expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October 2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October 2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company may not effect, and the holder will not be entitled to, exercise any Warrants or conversion of the Series B Preferred Stock, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the exercise or conversion, as such percentage ownership is determined in accordance with the terms of the October 2018 Warrants or Series B Preferred Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to the Company. The holders of the Series B Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Upon a defined Fundamental Transaction, the holders of the Series B Preferred Stock are entitled to the same consideration as are holders of Common Stock. The Series B Preferred Stock ranks junior to existing Series A Preferred Stock but on parity with common stock. Liquidation preference is equal to an amount pari passu with the common stock on an as converted basis (i.e., there is no preference to common stock). Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2018, the Company recorded a discount of $9.1 million and immediately amortized the discount to record the deemed dividend. Series A Preferred Stock On September 11, 2017, the Company entered into a share purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) for an aggregate purchase price of $12 million, or $100 per share. The Series A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets upon any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $18.90 per share, subject to certain customary anti-dilution adjustments. Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only. On or at any time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock of $7,875, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred Stock, or (ii) the five year anniversary of the issuance date, the Company has the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value (as defined in the Certificate of Designations). The Series A Preferred Stock is classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company’s control. Since the effective conversion price of the Series A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively. During the three and six months ended June 30, 2019, the Company accrued dividends of $61,000 and $122,000, respectively. Once the dividend is declared, the Company will reclassify the declared amount from temporary equity to a dividends payable liability. When the redemption of the Series A Preferred Stock becomes probable, the temporary equity will be accreted to redemption value as a deemed dividend. B. Riley FBR Sales Agreement On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.), which enables the Company to offer and sell shares of the Company's common stock with an aggregate sales price of up to $40.0 million from time to time through B. Riley FBR, Inc. as the Company’s sales agent. Sales of common stock under the B. Riley FBR Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley FBR, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Company's common stock sold on the Company’s behalf. The Company has not sold any shares during 2020 and 2019 through the B. Riley FBR Sales Agreement. <div /></div> </div> 714286 120000 2428825 15723 2520000 15723 2428825 2520000 0 0 1000 1000 40000000 <div> <div> 12. Subsequent Events On June 30, 2020 the Company submitted an Investigational New Drug (IND) application with the FDA for SYN-020, an oral formulation of recombinant intestinal alkaline phosphatase (IAP). On July 30, 2020 the Company announced that it received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 single ascending dose study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. The Phase 1 clinical program is intended to support the clinical development of SYN-020 in multiple indications, including the treatment of radiation enteropathy secondary to pelvic cancer therapy. On January 7, 2020 the Company held a Type-C meeting with the FDA to discuss the clinical program requirements needed to evaluate safety, tolerability and potential absorption into the systemic circulation (if any) of SYN-004 (ribaxamase) in adult allogeneic HCT recipients. On July 30, 2020 the Company received written notification from the FDA informing it that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients is safe to proceed per the submitted clinical program protocol. <div /></div> </div> <div> <div> 2. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company continues to incur losses and, as of June 30, 2020, the Company had an accumulated deficit of approximately $242.3 million. Since inception, the Company has financed its activities principally from the proceeds from the issuance of equity securities. The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern. The Company does not have sufficient capital to fund its operations for the next twelve months following the issuance date of its Quarterly Report on Form 10-Q. In order to address its capital needs, including its planned clinical trials, the Company is actively pursuing additional equity or debt financing in the form of either a private placement or a public offering. The Company has been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. Such additional financing opportunities might not be available to the Company when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances, the Company’s operating results and prospects will be adversely affected. In January 2020, the World Health Organization declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple countries, including throughout the United States. As the COVID-19 coronavirus continues to spread around the globe, the Company has experienced disruptions that impact our business and clinical trials, including temporarily halting the enrollment of new patients in its SYN-010 Phase 2b clinical study and the postponement of clinical site initiation for its SYN-004 Phase 1b/2a clinical study. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, results of operations and growth prospects could be materially adversely affected. With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, initiation of the Company's Phase 1b/2a clinical study of SYN-004 to be conducted by Washington University in Allogeneic HCT Recipients has been postponed until Q1 2021, subject to COVID-19 global pandemic. Enrollment of new patients in the Company's Phase 2b clinical study of SYN-010 was temporarily halted during the first and second quarter of 2020 due to the COVID-19 pandemic and has since recommenced. However, the ability to continue to recruit new patients into this clinical trial remains at the discretion of CSMC and contingent upon the COVID-19 global pandemic. At June 30, 2020, the Company had cash and cash equivalents of approximately $8.1 million. As a result of the global COVID-19 pandemic, management has been able to extend its cash runway since its clinical development partners (Cedars-Sinai Medical Center (CSMC) and Washington University) continued to limit non-essential activities during the second quarter, which included the halting of enrollment in the ongoing Phase 2b clinical trial of SYN-010 and postponement of the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase). The Company anticipates its current cash will allow it to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts, including completing its funding requirements for its ongoing Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients.  The Company does not anticipate any additional expense related to the Phase 1b/2a SYN-004 (ribaxamase) clinical trial until the trial is cleared for commencement by Washington University.  Commencement of planned future Phase 3 clinical trials of SYN-004 and SYN-010 are subject to the Company’s successful pursuit of opportunities that will allow it to establish the clinical infrastructure and financial resources necessary to successfully initiate and complete its plan. The Company will be required to obtain additional funding in order to continue the development of its current product candidates beyond its Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004  in allogeneic HCT recipients within the anticipated time periods, if at all, and to continue to fund operations at the current cash expenditure levels. Currently, the Company does not have commitments from any third parties to provide it with capital.  If the Company fails to obtain additional funding for its clinical trials, whether through the sale of securities or a partner or collaborator, and otherwise when needed, it will not be able to fully execute its business plan as planned and will be forced to cease certain development activities until funding is received and its business will suffer, which would have a material adverse effect on its financial position, results of operations and cash flows.Potential sources of financing include strategic relationships, public or private sales of equity (including through the “at-the-market” Issuance Sales Agreement (the “FBR Sales Agreement”) that the Company entered into with FBR Capital Markets & Co. in August 2016) or debt and other sources. The Company cannot assure that it will meet the requirements for use of the FBR Sales Agreement or that additional funding will be available on favorable terms, or at all. Current cash is expected to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts. The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond its control. These factors include the following: <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the progress of its research activities;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the number and scope of its research programs;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the ability to recruit patients for clinical studies in a timely manner;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the progress of its preclinical and clinical development activities;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the progress of the development efforts of parties with whom the Company has entered into research and development agreements and amount of funding received from partners and collaborators;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> its ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> its ability to achieve our milestones under licensing arrangements;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the costs associated with manufacturing-related services to produce material for use in our clinical trials;</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; </td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the costs and timing of regulatory approvals; and</td></tr></table></div> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"></td><td valign="top" align="left" style="width: 17.00pt;"> · </td><td style="width:1pt;"></td><td align="left" valign="top"> the ability to commence or complete clinical trials due to the ongoing impact of the  COVID-19 global pandemic.</td></tr></table></div> The Company has based its estimates of funding requirements on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates. If the Company raises funds by selling additional shares of Common Stock or other securities convertible into Common Stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out its business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed. <div /></div> </div> <div> <div> 4. Selected Balance Sheet Information Prepaid expenses and other current assets (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid clinical research organizations </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 471 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 48 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid insurances </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 241 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 549 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid manufacturing expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 94 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 622 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Prepaid consulting, subscriptions and other expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 91 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 134 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Prepaid conferences, travel </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 25 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other receivables </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  3 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 897 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,381 </td> </tr> </table></div>   Amounts prepaid to clinical research organizations (CROs) are classified as current assets. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.   Property and equipment, net (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Computers and office equipment </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 804 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 804 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Leasehold improvements </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 439 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 439 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Software </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 11 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,254 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,254 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Less: accumulated depreciation and amortization </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (1,003) </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> (887) </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 251 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 367 </td> </tr> </table></div>   Accrued expenses (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued clinical consulting services </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 704 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 684 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued vendor payments </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 376 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 456 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued manufacturing costs </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 129 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 635 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Other accrued expenses </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  — </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">  1 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,209 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 1,776 </td> </tr> </table></div>   Accrued employee benefits (in thousands)   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> June 30,  </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> December 31,  </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2020 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">      </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> 2019 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued severance expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 399 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">  — </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Accrued bonus expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 396 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 858 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> Accrued vacation expense </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 132 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 77 </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:73.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 927 </td> <td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> 935 </td> </tr> </table></div>   <div /></div> </div> 12544000 12669000 15700000 9000 100000 100000 16063283 16465314 17748688 18405884 EX-101.SCH 6 syn-20200630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases (Details) link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Stock-Based Compensation - Schedule of assumptions used for awards (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Stock Warrants - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Stock Warrants - Summary of all warrant activity (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Stock warrants - Summary of all outstanding and exercisable warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Net Loss per Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Non-controlling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Common and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Selected Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Stock Warrants link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Non-controlling Interest link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Common and Preferred Stock link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Selected Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Stock Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 syn-20200630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 syn-20200630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 syn-20200630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information Document Type Document Period End Date Entity Registrant Name Trading Symbol Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Statement [Table] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series B Preferred Stock [Member] Series B Preferred Stock [Member] Statement [Line Items] Accrued employee benefits Statement Assets [Abstract] Assets Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value. Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Assets, Current Total Current Assets Property, Plant and Equipment, Net Total Property and equipment, net Operating Lease, Right-of-Use Asset Right of use asset Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer). Deposits and Other Assets Noncurrent Deposits and other assets Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Deficit Liabilities, Current [Abstract] Current Liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Total Accrued expenses Accrued Employee Benefits, Current Accrued employee benefits Operating Lease, Liability, Current Amount due within 12 months Lease liability Liabilities, Current Total Current Liabilities Operating Lease, Liability, Noncurrent Lease liability - long term Liabilities Total Liabilities Temporary Equity, Carrying Amount, Attributable to Parent Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Deficit: Preferred Stock, Value, Issued Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 5,525 issued and outstanding and 7,638 issued and outstanding Common Stock, Value, Issued Common Stock, $0.001 par value; 200,000,000 shares authorized, 18,646,152 and 16,808,758 issued and 18,643,824 and 16,806,430 outstanding Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit). Accumulated deficit Stockholders' Equity Attributable to Parent Total Synthetic Biologics, Inc. and Subsidiaries Deficit Stockholders' Equity Attributable to Noncontrolling Interest Non-controlling interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total Stockholders' Deficit Liabilities and Equity Total Liabilities and Stockholders' Deficit Series A Preferred Stock [Member] Series A Preferred Stock [Member] Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Issued Common stock, Shares Issued Common Stock, Shares, Outstanding Common stock, Shares Outstanding Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Condensed Consolidated Statements of Operations Operating Expenses [Abstract] Operating Costs and Expenses: General and Administrative Expense General and administrative Research and Development Expense Research and Development Expense Research and development Operating Expenses Total Operating Costs and Expenses Operating Income (Loss) Loss from Operations Nonoperating Income (Expense) [Abstract] Other Income : Investment Income, Interest Interest income Nonoperating Income (Expense) Total Other Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Loss Net Income (Loss) Attributable to Noncontrolling Interest Non-controlling interest Net Loss Attributable to Non-controlling Interest Net Income (Loss) Attributable to Parent Net loss Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries Preferred Stock Dividends, Income Statement Impact Preferred Stock Dividends, Income Statement Impact preferred stock accrued dividends Net Income (Loss) Available to Common Stockholders, Basic Net Loss Attributable to Common Stockholders Earnings Per Share, Basic and Diluted Net Loss Per Share - Basic and Dilutive Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of shares outstanding during the period - Basic and Dilutive Condensed Consolidated Statements of Stockholders Equity (Deficit) Shares, Outstanding Balance (in shares) Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation Dividends, Preferred Stock Series A Preferred Stock Dividends Represents the value of new stock of syn biomics stock issued. Stock Issued During Period Value Of Syn Biomics Stock Issuance of SYN Biomics Stock Represents conversion of preferred stock to common stock Conversion of Series B Preferred Stock to Common Stock Conversion of Series B Preferred Stock to Common Number of conversion of series B preferred stock to common stock issued. Conversion of Series B Preferred Stock to Common Stock Shares Conversion of Series B Preferred Stock to Common (in shares) Preferred Stock, Dividend Rate, Per-Dollar-Amount Preferred stock, par value The amount per share used to calculated conversion of preferred stock to common stock. Conversion of Preferred Stock To Common Stock Conversion of preferred stock to common stock Condensed Consolidated Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows From Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation Stock-based compensation Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors. Subsidiary Stock Issues To Vendor Subsidiary stock issued to vendor Depreciation, Depletion and Amortization Depreciation Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets An amount of increase decrease in lease liability. Increase decrease Right of use assets Right of use asset Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Employee Related Liabilities Accrued employee benefits An amount of Increase decrease right of use assets Increase decrease lease liability Lease liability Net Cash Provided by (Used in) Operating Activities Net Cash Used In Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows From Investing Activities: Net Cash Provided by (Used in) Investing Activities Net Cash From Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows From Financing Activities: Net Cash Provided by (Used in) Financing Activities Net Cash From Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Noncash Investing and Financing Items [Abstract] Noncash Financing Activities: Conversion of Stock, Amount Converted Conversion of Series B Preferred Stock Amount of Deemed Dividends With Beneficial Conversion Feature. Deemed dividends for beneficial conversion features Deemed dividends for accretion of Series B Preferred Stock discount Dividends, Preferred Stock, Paid-in-kind In-kind dividends paid in preferred stock Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right of use asset from operating lease Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Organization, Nature of Operations and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization, Nature of Operations and Basis of Presentation n/a. Going Concern Substantial Doubt about Going Concern [Text Block] Going Concern Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments n/a Selected Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Selected Balance Sheet Information Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Stock Warrants The entire disclosure related to Stock Purchase Warrants. Stock Purchase Warrants [Text Block] Stock Warrants Net Loss per Share Earnings Per Share [Text Block] Net Loss per Share Non-controlling Interest Noncontrolling Interest Disclosure [Text Block] Non-controlling Interest Common and Preferred Stock Stockholders' Equity Note Disclosure [Text Block] Common and Preferred Stock Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Subsequent Events Subsequent Events [Text Block] Subsequent Events Schedule of Other Current Assets [Table Text Block] Schedule of prepaid expenses and other current assets Property, Plant and Equipment [Table Text Block] Schedule of property, plant and equipment, net Tabular disclosure of accrued expenses. Accrued Expenses [Table Text Block] Schedule of accrued expenses Tabular disclosure of information related to accrued employee benefits. Accrued Employee Benefits [Table Text Block] Schedule of accrued employee benefits Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable. Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block] Schedule of assumptions used for awards Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Tabular disclosure of warrant activity. Schedule Of Warrant Activity [Table Text Block] Summary of all warrant activity Tabular disclosure relates to warrant outstanding and exercisable. Schedule Of Warrant Outstanding and Exercisable [Table Text Block] Summary of all outstanding and exercisable warrants Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of maturity analysis of operating leases Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Sum of the amount paid in advance for clinical research organization. Prepaid Clinical Research Organizations Expense Current Prepaid clinical research organizations Prepaid Insurance Prepaid insurances Amount of Prepaid Manufacturing Expense. Prepaid Manufacturing Expense Prepaid manufacturing expenses Sum of the amount paid in advance for consulting, subscriptions and other expenses. Prepaid Consulting Subscriptions And Other Expenses Prepaid consulting, subscriptions and other expenses Prepaid Expense, Current Prepaid conferences, travel Other Receivables, Net, Current Other receivables Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Computers And Office Equipment [Member] Computers and office equipment [Member] Leasehold Improvements [Member] Leasehold Improvements [Member] Computer Software Intangible Asset [Member] Software [Member] Property, Plant and Equipment [Line Items] Property and equipment, net Property, Plant and Equipment, Gross Property, Plant and Equipment, Gross, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization The carrying value of accrued clinical consulting services payable as on balance sheet date. Accrued Clinical Consulting Services Accrued clinical consulting services Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments. Accrued Vendor Payments Accrued vendor payments The manufacturing costs incurred in the production of goods for sale. Accrued manufacturing costs Accrued manufacturing costs Other Accrued Liabilities, Current Other accrued expenses Liability, Pension and Other Postretirement and Postemployment Benefits, Current Accrued severance expense Accrued Bonuses, Current Accrued bonus expense Accrued Vacation, Current Accrued vacation expense Employee-related Liabilities, Current Total Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award. Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividends Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk -free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected life of option Award Type [Axis] Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Equity Award [Domain] Employee Stock Option [Member] Stock Option [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Options, Ending Balance Options, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options, Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Beginning Balance Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Balance Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Life, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value Grant date fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Stock Plan2007 [Member] 2007 Stock Plan [Member] Stock Plan2010 [Member] 2010 Stock Plan [Member] Range [Axis] Range [Member] Range [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Allocated Share-based Compensation Expense Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Class of Treasury Stock [Table] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Warrant [Member] Warrant [Member] Stock Warrants [Member] Series A Warrants [Member] Sale of Stock [Axis] Sale Of Stock Name Of Transaction [Domain] Sale of Stock [Domain] I P O [Member] IPO [Member] Underwritten Public Offering [Member] Underwritten Public Offering [Member] Over Allotment Option [Member] Over-Allotment Option [Member] Auction Market Preferred Securities, Stock Series [Axis] Auction Market Preferred Securities Stock Series Title [Domain] Auction Market Preferred Securities, Stock Series, Title [Domain] Series A [Member] Series A [Member] Series B [Member] Series B [Member] Class of Warrant or Right [Axis] Class Of Warrant Or Right [Domain] Class of Warrant or Right [Domain] October Two Thousand Eighteen Warrants [Member] October 2018 Warrants [Member] Class A [Member] Class A [Member] Class B [Member] Class B [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock Proceeds from Issuance or Sale of Equity Proceeds from Issuance or Sale of Equity Warrants Not Settleable in Cash, Fair Value Disclosure Warrants Not Settleable in Cash, Fair Value Disclosure The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan. Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number Warrants Exercisable Stock Issued During Period, Shares, New Issues Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Number of Shares Issued in Transaction Warrants issued to purchase common stock. Issuance Of Warrants To Purchase Of Common Stock Issuance Of Warrants To Purchase Of Common Stock As of the balance sheet date, the number of warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan. Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number The value pertaining to fair value of warrant liability. Fair Value of Warrant Liability Fair Value of Warrant Liability Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Fair Value Adjustment of Warrants Fair Value Adjustment of Warrants Sale of Stock, Price Per Share Sale of Stock, Price Per Share Represents the warrant term. Warrant Term Warrant Term The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted. Preferred Stock Conversion Price Per Share Preferred Stock Conversion Price Per Share Stock Issued During Period, Value, Issued for Services Stock Issued During Period, Value, Issued for Services Conversion of Stock, Shares Converted Conversion of Stock, Shares Converted Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Warrants, Ending Balance Number of Warrants, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of Warrants, Granted Number of share warrants exercised during the period. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Number of Warrants, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of Warrants, Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Ending Balance Weighted Average Exercise Price, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Granted Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Exercise Price, Forfeited Exercise Price Range [Axis] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Exercise Price138 [Member] Exercise Price 1.38 [Member] Exercise Price1820 [Member] Exercise Price 18.20 [Member] Exercise Price5005 [Member] Exercise Price 50.05 [Member] It stands for exercise price 3.24. Exercise Price3.24 [Member] Exercise price 3.24 [Member] Exercise price of the warrants. Warrants Exercise Price Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Warrants Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Weighted Average Remaining Contractual Life (in years) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Stock Option [Member] Equity Option [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Preferred Stock, Accretion of Redemption Discount Accretion of preferred discount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Noncontrolling Interest [Table] Noncontrolling Interest [Line Items] Noncontrolling Interest Noncontrolling Interest, Ownership Percentage by Parent Equity interest by parent The number of common stock to be issued under stock purchase agreement. Number Of Common Stock To Be Issued Number Of Common Stock To Be Issued The additional number of common stock to be issued under stock purchase agreement. Additional Number Of Common Stock To Be Issued Additional Number Of Common Stock To Be Issued The additional number of common stock to be held by the related party under stock purchase agreement. Number Of Common Stock To Be Held By Related Party Number Of Common Stock To Be Held By Related Party Related Party Transaction, Expenses from Transactions with Related Party Related Party Transaction, Expenses from Transactions with Related Party Amount represents the fair value of shares issued. Fair Value Of Shares Issued Fair Value Of Shares Issued Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners The amount of accumulated net loss attributable to the non-controlling interest as of balance sheet date. Accumulated Net Gain (Loss) Attributable to Noncontrolling Interest Accumulated net loss attributable to the non-controlling interest Stockholders' Equity Common Class A [Member] Common Class A [Member] Common Class B [Member] Common Class B [Member] Legal Entity [Axis] Entity [Domain] Entity [Domain] Fbr Capital Markets Co [Member] Fbr Capital Markets Co [Member] Private Placement [Member] Private Placement [Member] Proceeds from Issuance of Convertible Preferred Stock Sale of Stock, Consideration Received Per Transaction Preferred Stock, Dividend Rate, Percentage Debt Instrument, Convertible, Threshold Trading Days Debt Instrument, Convertible, Threshold Consecutive Trading Days Dividends Payable, Amount Per Share Adjustments to Additional Paid in Capital, Stock Split Stock Issued During Period, Value, New Issues Represent that percentage of commission revenue from buying and selling securities on behalf of customers. Brokerage Commission percentage Shares Issued, Price Per Share Preferred Stock Redemption Discount Percentage of issue of public offering price Percentage of issue of the public offering The percentage of exceed aggregate number of common stock. Percentage Exceed Aggregate Number Of Common Stock The percentage of exceed aggregate number of common stock outstanding. Percentage Exceed Aggregate Number Of Common Stock Outstanding Other percentage of increase decrease in excess of preferred stock. Increase Decrease in Excess of Other Percentage The no of shares converted into common stock Preferred Stock Shares Converted The amount represents preferred shares, unamortized discount from the conversion. Preferred Shares, Unamortized Discount From Conversion Common Stock, Discount on Shares It represent additional of warrant to purchase of common stock Issue of warrants to purchase common stock Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three 2022 Lessee, Operating Lease, Liability, Payments, Due Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Discount factor Operating Lease, Liability Lease liability Adjustments for New Accounting Pronouncements [Axis] Type Of Adoption [Member] Type of Adoption [Domain] Accounting Standards Update201602 [Member] ASU 2016-02 Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Cost Operating Lease, Cost Operating Lease, Payments Operating Lease, Payments Maturity of Operating Lease year Operating Lease Expiration Year Operating Lease Expiration Year Common Stock [Member] Common Stock [Member] Additional Paid In Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Inputs Level1 [Member] Level 1 Cash and Cash Equivalents [Axis] Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money market accounts Grantee Status [Axis] Grantee Status [Domain] Grantee Status [Domain] Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee or employer-consultant relationships based on law of pertinent jurisdiction. Share Based Payment Arrangement Employee And Consultant [Member] Employees and consultants Share Based Payment Arrangement Employee [Member] Employees Share Based Payment Arrangement Nonemployee [Member] Consultants Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General And Administrative Expense [Member] General and Administrative Expense Research And Development Expense [Member] Research and Development Expense Related Party [Axis] Related Party [Domain] Related Party [Domain] na Cedarssinai Medical Center [Member] Cedarssinai Medical Center [Member] Ownership [Axis] Ownership [Domain] Ownership [Domain] S Y N Biomics S Y N Biomics [Member] SYN Biomics NA Synthetic Biomics Inc [Member] Synthetic Biomics Inc [Member] EX-101.PRE 10 syn-20200630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.2

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2020

Aug. 03, 2020

Document and Entity Information

Document Type 10-Q

Document Period End Date Jun. 30, 2020

Entity Registrant Name Synthetic Biologics, Inc.

Trading Symbol SYN

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 19,440,346

Entity Central Index Key 0000894158

Current Fiscal Year End Date --12-31

Document Fiscal Year Focus 2020

Document Fiscal Period Focus Q2

Amendment Flag false

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Current Assets

Cash and cash equivalents $ 8,059 $ 15,045

Prepaid expenses and other current assets 897 1,381

Total Current Assets 8,956 16,426

Property and equipment, net 251 367

Right of use asset 352 419

Deposits and other assets 23 23

Total Assets 9,582 17,235

Current Liabilities:

Accounts payable 1,025 2,315

Accrued expenses 1,209 1,776

Accrued employee benefits 927 935

Lease liability 268 249

Total Current Liabilities 3,429 5,275

Lease liability - long term 334 473

Total Liabilities 3,763 5,748

Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,669 12,544

Stockholders' Deficit:

Common Stock, $0.001 par value; 200,000,000 shares authorized, 18,646,152 and 16,808,758 issued and 18,643,824 and 16,806,430 outstanding 19 17

Additional paid-in capital 234,860 232,580

Accumulated deficit (242,289) (235,537)

Total Synthetic Biologics, Inc. and Subsidiaries Deficit (3,966) 1,821

Non-controlling interest (2,884) (2,878)

Total Stockholders' Deficit (6,850) (1,057)

Total Liabilities and Stockholders' Deficit 9,582 17,235

Series B Preferred Stock [Member]

Stockholders' Deficit:

Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 5,525 issued and outstanding and 7,638 issued and outstanding 3,444 4,761

Total Stockholders' Deficit $ 3,444 $ 4,761

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
No definition available.
+ Details

Name: syn_DepositsAndOtherAssetsNoncurrent

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedEmployeeBenefitsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(24))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(22))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_MinorityInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.
+ References
No definition available.
+ Details

Name: us-gaap_TemporaryEquityCarryingAmountAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 13 R3.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2020

Dec. 31, 2019

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, Shares Authorized 200,000,000 200,000,000

Common stock, Shares Issued 18,646,152 16,808,758

Common stock, Shares Outstanding 18,643,824 16,806,430

Series A Preferred Stock [Member]

Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001

Preferred Stock, Shares Authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 120,000 120,000

Preferred Stock, Shares Outstanding 120,000 120,000

Series B Preferred Stock [Member]

Preferred Stock, Par or Stated Value Per Share $ 1,000 $ 1,000

Preferred Stock, Shares Authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 5,525 7,638

Preferred Stock, Shares Outstanding 5,525 7,638

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 14 R4.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Operating Costs and Expenses:

General and administrative $ 1,286,000 $ 1,044,000 $ 2,679,000 $ 2,199,000

Research and development 1,603,000 2,594,000 3,238,000 5,012,000

Total Operating Costs and Expenses 2,889,000 3,638,000 5,917,000 7,211,000

Loss from Operations (2,889,000) (3,638,000) (5,917,000) (7,211,000)

Other Income :

Interest income 6,000 80,000 44,000 125,000

Total Other Income 6,000 80,000 44,000 125,000

Net Loss (2,883,000) (3,558,000) (5,873,000) (7,086,000)

Net Loss Attributable to Non-controlling Interest (16,000) (27,000) (42,000) (43,000)

Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries (2,867,000) (3,531,000) (5,831,000) (7,043,000)

Net Loss Attributable to Common Stockholders $ (3,322,000) $ (3,709,000) $ (6,752,000) $ (7,680,000)

Net Loss Per Share - Basic and Dilutive $ (0.18) $ (0.23) $ (0.38) $ (0.48)

Weighted average number of shares outstanding during the period - Basic and Dilutive 18,405,884 16,465,314 17,748,688 16,063,283

Series A Preferred Stock [Member]

Other Income :

Preferred Stock Dividends, Income Statement Impact $ (63,000) $ (61,000) $ (125,000) $ (122,000)

Series B Preferred Stock [Member]

Other Income :

Net Loss Attributable to Non-controlling Interest 0 0

Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries 0 0

Preferred Stock Dividends, Income Statement Impact $ (392,000) $ (117,000) $ (796,000) $ (515,000)

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 15 R5.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Noncontrolling Interest [Member]

Series B Preferred Stock [Member]

Total

Balance at Dec. 31, 2018 $ 15 $ 230,754 $ (219,461) $ (2,909) $ 5,760 $ 14,159

Balance (in shares) at Dec. 31, 2018 15,482,083 9,161

Stock-based compensation $ 0 64 0 0 $ 0 64

Series A Preferred Stock Dividends 0 0 (61) 0 0 (61)

Issuance of SYN Biomics Stock 0 (36) 0 53 0 17

Conversion of Series B Preferred Stock to Common $ 1 1,035 (398) 0 $ (638) 0

Conversion of Series B Preferred Stock to Common (in shares) 900,869 (1,036)

Net loss $ 0 0 (3,512) 0 $ 0 (3,512)

Non-controlling interest 0 0 0 (16) 0 (16)

Balance at Mar. 31, 2019 $ 16 231,817 (223,432) (2,872) $ 5,122 10,651

Balance (in shares) at Mar. 31, 2019 16,382,952 8,125

Balance at Dec. 31, 2018 $ 15 230,754 (219,461) (2,909) $ 5,760 14,159

Balance (in shares) at Dec. 31, 2018 15,482,083 9,161

Net loss (7,043)

Non-controlling interest (43)

Balance at Jun. 30, 2019 $ 17 232,211 (227,141) (2,854) $ 4,935 7,168

Balance (in shares) at Jun. 30, 2019 16,645,560 7,823

Balance at Mar. 31, 2019 $ 16 231,817 (223,432) (2,872) $ 5,122 10,651

Balance (in shares) at Mar. 31, 2019 16,382,952 8,125

Stock-based compensation $ 0 91 0 0 $ 0 91

Series A Preferred Stock Dividends 0 0 (61) 0 0 (61)

Issuance of SYN Biomics Stock 0 0 0 45 0 45

Conversion of Series B Preferred Stock to Common $ 1 303 (117) 0 $ (187) 0

Conversion of Series B Preferred Stock to Common (in shares) 262,608 (302)

Net loss $ 0 0 (3,531) 0 $ 0 (3,531)

Non-controlling interest 0 0 0 (27) 0 (27)

Balance at Jun. 30, 2019 $ 17 232,211 (227,141) (2,854) $ 4,935 7,168

Balance (in shares) at Jun. 30, 2019 16,645,560 7,823

Balance at Dec. 31, 2019 $ 17 232,580 (235,537) (2,878) $ 4,761 (1,057)

Balance (in shares) at Dec. 31, 2019 16,806,430 7,638

Stock-based compensation $ 0 83 0 0 $ 0 83

Series A Preferred Stock Dividends 0 0 (62) 0 0 (62)

Issuance of SYN Biomics Stock 0 0 0 26 0 26

Conversion of Series B Preferred Stock to Common $ 1 1,072 (404) 0 $ (669) 0

Conversion of Series B Preferred Stock to Common (in shares) 933,045 (1,073)

Net loss $ 0 0 (2,964) 0 $ 0 (2,964)

Non-controlling interest 0 0 0 (26) 0 (26)

Balance at Mar. 31, 2020 $ 18 233,735 (238,967) (2,878) $ 4,092 (4,000)

Balance (in shares) at Mar. 31, 2020 17,739,475 6,565

Balance at Dec. 31, 2019 $ 17 232,580 (235,537) (2,878) $ 4,761 (1,057)

Balance (in shares) at Dec. 31, 2019 16,806,430 7,638

Net loss (5,831)

Non-controlling interest (42)

Balance at Jun. 30, 2020 $ 19 234,860 (242,289) (2,884) $ 3,444 (6,850)

Balance (in shares) at Jun. 30, 2020 18,643,824 5,525

Balance at Mar. 31, 2020 $ 18 233,735 (238,967) (2,878) $ 4,092 (4,000)

Balance (in shares) at Mar. 31, 2020 17,739,475 6,565

Stock-based compensation $ 0 86 0 0 $ 0 86

Series A Preferred Stock Dividends 0 0 (63) 0 0 (63)

Issuance of SYN Biomics Stock 0 0 0 10 0 10

Conversion of Series B Preferred Stock to Common $ 1 1,039 (392) 0 $ (648) 0

Conversion of Series B Preferred Stock to Common (in shares) 904,349 (1,040)

Net loss $ 0 0 (2,867) 0 $ 0 (2,867)

Non-controlling interest 0 0 0 (16) 0 (16)

Balance at Jun. 30, 2020 $ 19 $ 234,860 $ (242,289) $ (2,884) $ 3,444 $ (6,850)

Balance (in shares) at Jun. 30, 2020 18,643,824 5,525

X

- Definition
Represents conversion of preferred stock to common stock
+ References
No definition available.
+ Details

Name: syn_ConversionOfSeriesBPreferredStockToCommonStock

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of conversion of series B preferred stock to common stock issued.
+ References
No definition available.
+ Details

Name: syn_ConversionOfSeriesBPreferredStockToCommonStockShares

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Represents the value of new stock of syn biomics stock issued.
+ References
No definition available.
+ Details

Name: syn_StockIssuedDuringPeriodValueOfSynBiomicsStock

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_DividendsPreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Stockholders Equity (Parenthetical) - $ / shares
3 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2019

Mar. 31, 2019

Series A Preferred Stock [Member]

Preferred stock, par value $ 0.01 $ 0.01 $ 0.01 $ 0.01

Series B Preferred Stock [Member]

Conversion of preferred stock to common stock $ 0.03 $ 0.03 $ 0.03 $ 0.03

X

- Definition
The amount per share used to calculated conversion of preferred stock to common stock.
+ References
No definition available.
+ Details

Name: syn_ConversionOfPreferredStockToCommonStock

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount per share used to calculated dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePerDollarAmount

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.20.2

Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended

Jun. 30, 2020

Jun. 30, 2019

Cash Flows From Operating Activities:

Net loss $ (5,873,000) $ (7,086,000)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation 169,000 155,000

Subsidiary stock issued to vendor 36,000 62,000

Depreciation 116,000 122,000

Changes in operating assets and liabilities:

Prepaid expenses and other current assets 484,000 (706,000)

Right of use asset 67,000 56,000

Accounts payable (1,290,000) 490,000

Accrued expenses (567,000) 627,000

Accrued employee benefits (8,000) (821,000)

Lease liability (120,000) (105,000)

Net Cash Used In Operating Activities (6,986,000) (7,206,000)

Cash Flows From Investing Activities:

Net Cash From Investing Activities 0 0

Cash Flows From Financing Activities:

Net Cash From Financing Activities 0 0

Net decrease in cash and cash equivalents (6,986,000) (7,206,000)

Cash and cash equivalents at beginning of period 15,045,000 28,918,000

Cash and cash equivalents at end of period 8,059,000 21,712,000

Noncash Financing Activities:

Deemed dividends for accretion of Series B Preferred Stock discount 796,000 515,000

In-kind dividends paid in preferred stock 125,000 122,000

Right of use asset from operating lease 0 538,000

Series B Preferred Stock [Member]

Noncash Financing Activities:

Conversion of Series B Preferred Stock $ 1,317,000 $ 825,000

X

- Definition
Amount of Deemed Dividends With Beneficial Conversion Feature.
+ References
No definition available.
+ Details

Name: syn_DeemedDividendsWithBeneficialConversionFeature

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
An amount of Increase decrease right of use assets
+ References
No definition available.
+ Details

Name: syn_IncreaseDecreaseLeaseLiability

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
An amount of increase decrease in lease liability.
+ References
No definition available.
+ Details

Name: syn_IncreaseDecreaseRightOfUseAssets

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.
+ References
No definition available.
+ Details

Name: syn_SubsidiaryStockIssuesToVendor

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_ConversionOfStockAmountConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 405
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details

Name: us-gaap_DividendsPreferredStockPaidinkind

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.20.2

Organization, Nature of Operations and Basis of Presentation
6 Months Ended

Jun. 30, 2020

Organization, Nature of Operations and Basis of Presentation

Organization, Nature of Operations and Basis of Presentation

1. Organization, Nature of Operations and Basis of Presentation

Description of Business

Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN‑004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN‑010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN‑020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2019 Form 10‑K. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results for the full year.

The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.

Recent Accounting Pronouncements and Developments

On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was enacted. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States’ economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company has assessed the impact of the CARES Act and based upon our initial assessment, we do not believe that it will have a significant effect on our financial position, results of operations or cash flows. The Company continues to evaluate its impact as new information becomes available.

Impairment of Long-Lived Assets

Long-lived assets include property, equipment and right-of-use assets. In accordance with Accounting Standards Codification (“ASC”) 360 - Property, Plant and Equipment (“ASC 360”), management reviews the Company’s recorded long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between fair value and the carrying value of the asset. The Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2020.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.20.2

Going Concern
6 Months Ended

Jun. 30, 2020

Going Concern

Going Concern

2. Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company continues to incur losses and, as of June 30, 2020, the Company had an accumulated deficit of approximately $242.3 million. Since inception, the Company has financed its activities principally from the proceeds from the issuance of equity securities.

The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

The Company does not have sufficient capital to fund its operations for the next twelve months following the issuance date of its Quarterly Report on Form 10-Q. In order to address its capital needs, including its planned clinical trials, the Company is actively pursuing additional equity or debt financing in the form of either a private placement or a public offering. The Company has been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings. Such additional financing opportunities might not be available to the Company when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances, the Company’s operating results and prospects will be adversely affected.

In January 2020, the World Health Organization declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple countries, including throughout the United States. As the COVID-19 coronavirus continues to spread around the globe, the Company has experienced disruptions that impact our business and clinical trials, including temporarily halting the enrollment of new patients in its SYN-010 Phase 2b clinical study and the postponement of clinical site initiation for its SYN-004 Phase 1b/2a clinical study. While the Company is experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, the Company’s business, financial condition, results of operations and growth prospects could be materially adversely affected. With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, initiation of the Company's Phase 1b/2a clinical study of SYN-004 to be conducted by Washington University in Allogeneic HCT Recipients has been postponed until Q1 2021, subject to COVID-19 global pandemic. Enrollment of new patients in the Company's Phase 2b clinical study of SYN-010 was temporarily halted during the first and second quarter of 2020 due to the COVID-19 pandemic and has since recommenced. However, the ability to continue to recruit new patients into this clinical trial remains at the discretion of CSMC and contingent upon the COVID-19 global pandemic.

At June 30, 2020, the Company had cash and cash equivalents of approximately $8.1 million. As a result of the global COVID-19 pandemic, management has been able to extend its cash runway since its clinical development partners (Cedars-Sinai Medical Center (CSMC) and Washington University) continued to limit non-essential activities during the second quarter, which included the halting of enrollment in the ongoing Phase 2b clinical trial of SYN-010 and postponement of the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase). The Company anticipates its current cash will allow it to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts, including completing its funding requirements for its ongoing Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients.

The Company does not anticipate any additional expense related to the Phase 1b/2a SYN-004 (ribaxamase) clinical trial until the trial is cleared for commencement by Washington University. Commencement of planned future Phase 3 clinical trials of SYN-004 and SYN-010 are subject to the Company’s successful pursuit of opportunities that will allow it to establish the clinical infrastructure and financial resources necessary to successfully initiate and complete its plan. The Company will be required to obtain additional funding in order to continue the development of its current product candidates beyond its Phase 2b investigator-sponsored clinical study of SYN-010 and its planned Phase 1b/2a clinical study of SYN-004 in allogeneic HCT recipients within the anticipated time periods, if at all, and to continue to fund operations at the current cash expenditure levels. Currently, the Company does not have commitments from any third parties to provide it with capital. If the Company fails to obtain additional funding for its clinical trials, whether through the sale of securities or a partner or collaborator, and otherwise when needed, it will not be able to fully execute its business plan as planned and will be forced to cease certain development activities until funding is received and its business will suffer, which would have a material adverse effect on its financial position, results of operations and cash flows.Potential sources of financing include strategic relationships, public or private sales of equity (including through the “at-the-market” Issuance Sales Agreement (the “FBR Sales Agreement”) that the Company entered into with FBR Capital Markets & Co. in August 2016) or debt and other sources. The Company cannot assure that it will meet the requirements for use of the FBR Sales Agreement or that additional funding will be available on favorable terms, or at all. Current cash is expected to cover overhead costs, manufacturing costs for clinical supply, commercial scale up costs and limited research efforts.

The actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond its control. These factors include the following:

·

the progress of its research activities;

·

the number and scope of its research programs;

·

the ability to recruit patients for clinical studies in a timely manner;

·

the progress of its preclinical and clinical development activities;

·

the progress of the development efforts of parties with whom the Company has entered into research and development agreements and amount of funding received from partners and collaborators;

·

its ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;

·

its ability to achieve our milestones under licensing arrangements;

·

the costs associated with manufacturing-related services to produce material for use in our clinical trials;

·

the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;

·

the costs and timing of regulatory approvals; and

·

the ability to commence or complete clinical trials due to the ongoing impact of the COVID-19 global pandemic.

The Company has based its estimates of funding requirements on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or in greater amounts than it currently anticipates.

If the Company raises funds by selling additional shares of Common Stock or other securities convertible into Common Stock, the ownership interest of the existing stockholders will be diluted. If the Company is not able to obtain financing when needed, it may be unable to carry out its business plan. As a result, the Company may have to significantly limit its operations and its business, financial condition and results of operations would be materially harmed.

X

- Definition
n/a.
+ References
No definition available.
+ Details

Name: syn_GoingConcernAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.2

Fair Value of Financial Instruments
6 Months Ended

Jun. 30, 2020

Fair Value of Financial Instruments

Fair Value of Financial Instruments

3. Fair Value of Financial Instruments

ASC 820, Fair Value Measurement, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

·

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

·

Level 2 inputs: Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and

·

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.

The carrying amounts of the Company’s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.

Cash and cash equivalents include money market accounts of $114,000 as of June 30, 2020 and $98,000 as of December 31, 2019 that are measured using Level 1 inputs.

The Company uses Monte Carlo simulations to estimate the fair value of its stock warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company’s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information
6 Months Ended

Jun. 30, 2020

Selected Balance Sheet Information

Selected Balance Sheet Information

4. Selected Balance Sheet Information

Prepaid expenses and other current assets (in thousands)

June 30,

December 31,



2020



2019

Prepaid clinical research organizations

$

471

$

48

Prepaid insurances

241

549

Prepaid manufacturing expenses

94

622

Prepaid consulting, subscriptions and other expenses

91

134

Prepaid conferences, travel

—

25

Other receivables

—

3

Total

$

897

$

1,381

Amounts prepaid to clinical research organizations (CROs) are classified as current assets. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.

Property and equipment, net (in thousands)



June 30,

December 31,

2020



2019

Computers and office equipment

$

804

$

804

Leasehold improvements

439

439

Software

11

11

1,254

1,254

Less: accumulated depreciation and amortization

(1,003)

(887)

Total

$

251

$

367

Accrued expenses (in thousands)



June 30,

December 31,

2020



2019

Accrued clinical consulting services

$

704

$

684

Accrued vendor payments

376

456

Accrued manufacturing costs

129

635

Other accrued expenses

—

1

Total

$

1,209

$

1,776

Accrued employee benefits (in thousands)



June 30,

December 31,

2020



2019

Accrued severance expense

$

399

$

—

Accrued bonus expense

396

858

Accrued vacation expense

132

77

$

927

$

935

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: syn_BalanceSheetInformationAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-URI http://asc.fasb.org/topic&trid=2122208
+ Details

Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation
6 Months Ended

Jun. 30, 2020

Stock-Based Compensation

Stock-Based Compensation

5. Stock-Based Compensation

Stock Incentive Plans

On March 20, 2007, the Company’s Board of Directors approved the 2007 Stock Incentive Plan (the “2007 Stock Plan”) for the issuance of up to 71,429 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2020, there were 7,052 options issued and outstanding under the 2007 Stock Plan.

On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (“2010 Stock Plan”) for the issuance of up to 85,714 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. On October 22, 2013, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 85,714 to 171,429. On May 15, 2015, the stockholders approved and adopted an amendment to the Company’s 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the Plan from 171,429 to 228,572. On August 25, 2016, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 228,572 to 400,000. On September 7, 2017, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 400,000 to 500,000. On September 24, 2018, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Company’s Common Stock reserved for issuance under the 2010 Stock Plan from 500,000 to 1,000,000. On September 5, 2019, the stockholders approved and adopted an amendment to the 2010 Stock Plan to increase the number of shares of the Common Stock reserved for issuance under the 2010 Stock Plan from 1,000,000 to 4,000,000. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company’s Common Stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and expire between five and ten years after the grant date. As of June 30, 2020, there were 2,465,310 options issued and outstanding under the 2010 Stock Plan.

In the event of an employee’s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized as compensation expense over the stated vesting period.

The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three and six months ended June 30, 2020 and 2019. The assumptions used for the awards during the year ended December 31, 2019 were as follows:

Exercise price



$

0.42

Expected dividends

0
%

Expected volatility

84

%

Risk free interest rate

1.61

%

Expected life of option

4.5
years

Expected dividends —The Company has never declared or paid dividends on its Common Stock and has no plans to do so in the foreseeable future.

Expected volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.

Risk-free interest rate—The assumed risk free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.

Expected life of the option—The period of time that the options granted are expected to remain unexercised. Options granted during 2019 have a maximum term of seven years. The Company estimates the expected life of the option based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.

The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:

·

immediate vesting;

·

half vesting immediately and remaining over three years;

·

in full on one-year anniversary of grant date;

·

quarterly over three years;

·

annually over three years;

·

one-third immediate vesting and remaining annually over two years;

·

one half immediate vesting and remaining over nine months;

·

one quarter immediate vesting and remaining over three years;

·

one quarter immediate vesting and remaining over 33 months; and

·

monthly over three years.

A summary of stock option activity for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:





Weighted



Weighted Average



Aggregate

Average Exercise

Remaining

Intrinsic

Options

Price

Contractual Life

Value

Balance - December 31, 2018

938,982

$

15.18

6.19 years

$

—

Granted

1,725,000

0.42





Exercised

—

—

Expired

(94,738)

58.25





Forfeited

(67,232)

5.95





Balance - December 31, 2019

2,502,012

$

3.62

6.51 years

$

153,353

Granted

—

—





Exercised

—

—

Expired

—

—





Forfeited

(29,650)

0.55





Balance - June 30, 2020 - outstanding

2,472,362

$

3.65

5.98 years

$

158,270

Balance - June 30, 2020 - exercisable

628,408

$

12.89

5.16 years

$

15,129

Grant date fair value of options granted - six months ended June 30, 2020

$

—





Weighted average grant date fair value - six months ended June 30, 2020

$

—





Grant date fair value of options granted - year ended December 31, 2019

$

470,000





Weighted average grant date fair value - year ended December 31, 2019

$

0.27





Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $40,000 and $79,000, respectively, and $50,000 and $106,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in research and development expenses relating to stock options issued to employees for the three and six months ended June 30, 2020 was $15,000 and $31,000, respectively, and $32,000 and $110,000 for the three and six months ended June 30, 2019, respectively.

Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2020 was $27,000 and $53,000, respectively, and $9,000 and $19,000 for the three and six months ended June 30, 2019, respectively. Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and six months ended June 30, 2020 was $4,000 and $6,000, respectively, and $1,000 for the three and six months ended June 30, 2019.

As of June 30, 2020, total unrecognized stock-based compensation expense related to stock options was $498,000, which is expected to be expensed through July 2022.

The FASB’s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June 30, 2020 and 2019.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.2

Stock Warrants
6 Months Ended

Jun. 30, 2020

Stock Warrants

Stock Warrants

6. Stock Warrants

On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of Common Stock, and one five-year warrant to purchase one share of Common Stock at an exercise price of $1.38 per share (each a “Warrant” and collectively, the “Warrants”), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the “Class B Units”, and together with the Class A Units, the “Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants . In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the “Underwriters”), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.

The Warrants are immediately exercisable at a price of $1.38 per share of Common Stock (which is 120% of the public offering price of the Class A Units) and expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations.

On November 18, 2016, the Company completed a public offering of 714,286 shares of Common Stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of Common Stock. The stock and warrants were sold in combination, with two warrants for each share of Common Stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of Common Stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of Common Stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $50.05 and the per share exercise price of the Series B warrants is $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants may be exercised at any time on or after the date of issuance. The Series A warrants are exercisable until the four-year anniversary of the issuance date. The Series B warrants expired on December 31, 2017 and none were exercised prior to expiration. The warrants include a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Condensed Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and June 30, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company’s current stock price.

On October 10, 2014, the Company raised net proceeds of $19.1 million through the sale of 14,059,616 units at a price of $1.47 per unit to certain institutional investors in a registered direct offering. Each unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.50 shares of Common Stock. The warrants, exercisable for an aggregate of 200,852 shares of Common Stock, had an exercise price of $61.25 per share and a life of five years. The warrants vested immediately and expired on October 10, 2019.

The warrants issued in conjunction with the registered direct offering in October 2014 included a provision that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder at a premium. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date, which was $7.4 million, and changes in estimated fair value are being recorded as non-cash income or expense in the Company’s Consolidated Statements of Operations at each subsequent period. At June 30, 2020 and 2019, the fair value of the warrant liability was zero. The warrants were valued on the date of grant using the Black-Scholes option pricing model which approximates the value derived using Monte Carlo simulations. In 2020 and 2019, the Monte Carlo simulations were not used as the value of the warrants were deemed to be minimal based on the historical fair value of the warrants and the Company's current stock price.

A summary of all warrant activity for the Company for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:



Number of



Weighted Average

Warrants

Exercise Price

Balance at December 31, 2018

18,915,851

$

3.85

Granted

—

—

Exercised

—

—

Forfeited

(200,852)

61.25

Balance at December 31, 2019

18,714,999

3.24

Granted

—

—

Exercised

—

—

Forfeited

—

—

Balance at June 30, 2020

18,714,999

$

3.24

On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, was paid a monthly fee, and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company's Common Stock on the date of issuance. The warrant is equity classified and the fair value of the warrant approximated $9,000 on the date of grant and was measured using the Black-Scholes option pricing model. This entire expense was recorded in the quarter ended March 31, 2018.

A summary of all outstanding and exercisable warrants as of June 30, 2020 is as follows:







Weighted Average

Warrants

Warrants

Remaining

Exercise Price

Outstanding

Exercisable

Contractual Life

$

1.38

17,999,999

17,999,999

3.28 years

18.20

714

714

2.49 years

50.05

714,286

714,286

0.39 years

$

3.24

18,714,999

18,714,999

3.17 years

X

- Definition
The entire disclosure related to Stock Purchase Warrants.
+ References
No definition available.
+ Details

Name: syn_StockPurchaseWarrantsTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: syn_StockWarrantsAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.20.2

Net Loss per Share
6 Months Ended

Jun. 30, 2020

Net Loss per Share

Net Loss per Share

7. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the three and six months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.1 million and $0.5 million, respectively, on converted shares and $0.1 million of Series A accrued dividends. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020 and 2019 were 4,804,348 and 6,802,608, respectively. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively and for the six months ended June 30, 2019 were 843,119 and 18,915,851, respectively, because their effect is anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.20.2

Non-controlling Interest
6 Months Ended

Jun. 30, 2020

Non-controlling Interest

Non-controlling Interest

8. Non-controlling Interest

The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”), and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Synthetic Biomics, Inc. (“SYN Biomics”). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company's equity interest in SYN Biomics is 83% and the non-controlling stockholder's interest is 17%. As of June 30, 2020 , the accumulated net loss attributable to the non-controlling interest is $2.9 million.

In consideration of the support provided by CSMC for the Study, the Company will pay $441,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (“Synbiomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. During the three and six months ended June 30, 2019, research and development expense recorded related to this transaction approximated $119,000 and $174,000, respectively.

The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company's common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.

X

- Definition
The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_MinorityInterestDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncontrollingInterestAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.20.2

Common and Preferred Stock
6 Months Ended

Jun. 30, 2020

Common and Preferred Stock

Common and Preferred Stock

9. Common and Preferred Stock

Series B Preferred Stock

On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units , with each Class A Unit offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units, with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October 2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series B Preferred Stock discount.

In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October 10, 2018, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.

The Units were offered by the Company pursuant to a registration statement on Form S‑1 (File No. 333‑227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018.

The conversion price of the Series B Preferred Stock and exercise price of the October 2018 Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.

During the three and six months ended June 30, 2020, 1,040 and 2,113 Series B shares, respectively, have been converted into common stock resulting in the recognition of $392,000 and $796,000, respectively, of unamortized discount from the conversion. During the three and six months ended June 30, 2019, 302 and 1,338 Series B shares, respectively, have been converted into common stock resulting in the recognition of $117,000 and $515,000, respectively, of unamortized discount from the conversion. As of June 30, 2020, 10,198 shares have been converted resulting in the recognition of $3.8 million of unamortized discount. This is recorded as a deemed dividend in accumulated deficit.

The October 2018 Warrants are immediately exercisable at a price of $1.38 per share of common stock (which is 120% of the public offering price of the Class A Units) and will expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October 2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October 2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.

The Company may not effect, and the holder will not be entitled to, exercise any Warrants or conversion of the Series B Preferred Stock, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the exercise or conversion, as such percentage ownership is determined in accordance with the terms of the October 2018 Warrants or Series B Preferred Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to the Company. The holders of the Series B Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Upon a defined Fundamental Transaction, the holders of the Series B Preferred Stock are entitled to the same consideration as are holders of Common Stock. The Series B Preferred Stock ranks junior to existing Series A Preferred Stock but on parity with common stock. Liquidation preference is equal to an amount pari passu with the common stock on an as converted basis (i.e., there is no preference to common stock).

Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2018, the Company recorded a discount of $9.1 million and immediately amortized the discount to record the deemed dividend.

Series A Preferred Stock

On September 11, 2017, the Company entered into a share purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) for an aggregate purchase price of $12 million, or $100 per share.

The Series A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets upon any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $18.90 per share, subject to certain customary anti-dilution adjustments.

Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.

On or at any time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock of $7,875, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred Stock, or (ii) the five year anniversary of the issuance date, the Company has the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value (as defined in the Certificate of Designations).

The Series A Preferred Stock is classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company’s control. Since the effective conversion price of the Series A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively. During the three and six months ended June 30, 2019, the Company accrued dividends of $61,000 and $122,000, respectively. Once the dividend is declared, the Company will reclassify the declared amount from temporary equity to a dividends payable liability. When the redemption of the Series A Preferred Stock becomes probable, the temporary equity will be accreted to redemption value as a deemed dividend.

B. Riley FBR Sales Agreement

On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.), which enables the Company to offer and sell shares of the Company's common stock with an aggregate sales price of up to $40.0 million from time to time through B. Riley FBR, Inc. as the Company’s sales agent. Sales of common stock under the B. Riley FBR Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley FBR, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Company's common stock sold on the Company’s behalf. The Company has not sold any shares during 2020 and 2019 through the B. Riley FBR Sales Agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.20.2

Related Party Transactions
6 Months Ended

Jun. 30, 2020

Related Party Transactions

Related Party Transactions

10. Related Party Transactions

On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).

In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) to: (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary Synthetic Biomics, Inc. (“SYN Biomics”) owned by the Company, such that after such issuance CSMC will own an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock.

The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.

In December 2013, through the Company’s subsidiary, Synthetic Biomics, Inc., the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2020 and 2019, the Company did not owe and did not pay CSMC for milestone payments related this license agreement.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.20.2

Commitments and Contingencies
6 Months Ended

Jun. 30, 2020

Commitments and Contingencies

Commitments and Contingencies

11. Commitments and Contingencies

Leases

All of the Company’s existing leases as of June 30, 2020 are classified as operating leases. As of June 30, 2020, the Company has one material operating lease for facilities with a remaining term expiring in 2022. The existing lease has fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. The discount rate used in the calculation of the lease liability was 9.9%. The rates implicit within the Company’s leases are generally not determinable, therefore, the Company’s incremental borrowing rate is used to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. Because the Company currently has no outstanding debt, the incremental borrowing rate for each lease is primarily based on publicly-available information for companies within the same industry and with similar credit profiles. The rate is then adjusted for the impact of collateralization, the lease term and other specific terms included in the Company’s lease arrangements. The incremental borrowing rate is determined at lease commencement, or as of January 1, 2019 for operating leases in existence upon adoption of ASC 842. The incremental borrowing rate is subsequently reassessed upon a modification to the lease arrangement. ROU assets are subsequently assessed for impairment in accordance with the Company’s accounting policy for long-lived assets. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statement of operations, and for the three and six months ended June 30, 2020 approximated $50,000 and $101,000, respectively, and for three and six months ended June 30, 2019 approximated $50,000 and $101,000, respectively. For the three and six months ended June 30, 2020, operating cash flows used for operating leases approximated $77,000 and $154,000, respectively, and for three and six months ended June 30, 2019 approximated $75,000 and $149,000, respectively. The right of use assets exchanged for operating lease obligations was $0. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.

A maturity analysis of our operating leases as of June 30, 2020 is as follows (amounts in thousands of dollars):

Future undiscounted cash flow for the years ending December 31:





2020

$

156

2021

321

2022

192

Total

$

669

Discount factor

$

(67)

Lease liability

$

602

Amount due within 12 months

$

(268)

Lease liability – long term

$

334

Risks and Uncertainties

On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

As the COVID-19 coronavirus continues to spread around the globe, the Company experienced disruptions that impact its business and clinical trials, including halting the enrollment of new patients in the ongoing Phase 2b investigator-sponsored clinical trial of SYN-010 and postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company’s business, the clinical development of SYN-010, SYN-004 (ribaxamase) and SYN-020, the business of the Company’s suppliers and other commercial partners, the Company’s corporate development objectives and the value of and market for the Company’s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company’s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.20.2

Subsequent Events
6 Months Ended

Jun. 30, 2020

Subsequent Events

Subsequent Events

12. Subsequent Events

On June 30, 2020 the Company submitted an Investigational New Drug (IND) application with the FDA for SYN-020, an oral formulation of recombinant intestinal alkaline phosphatase (IAP). On July 30, 2020 the Company announced that it received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 single ascending dose study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. The Phase 1 clinical program is intended to support the clinical development of SYN-020 in multiple indications, including the treatment of radiation enteropathy secondary to pelvic cancer therapy.

On January 7, 2020 the Company held a Type-C meeting with the FDA to discuss the clinical program requirements needed to evaluate safety, tolerability and potential absorption into the systemic circulation (if any) of SYN-004 (ribaxamase) in adult allogeneic HCT recipients. On July 30, 2020 the Company received written notification from the FDA informing it that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients is safe to proceed per the submitted clinical program protocol.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information (Tables)
6 Months Ended

Jun. 30, 2020

Selected Balance Sheet Information

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets (in thousands)

June 30,

December 31,



2020



2019

Prepaid clinical research organizations

$

471

$

48

Prepaid insurances

241

549

Prepaid manufacturing expenses

94

622

Prepaid consulting, subscriptions and other expenses

91

134

Prepaid conferences, travel

—

25

Other receivables

—

3

Total

$

897

$

1,381

Schedule of property, plant and equipment, net

Property and equipment, net (in thousands)



June 30,

December 31,

2020



2019

Computers and office equipment

$

804

$

804

Leasehold improvements

439

439

Software

11

11

1,254

1,254

Less: accumulated depreciation and amortization

(1,003)

(887)

Total

$

251

$

367

Schedule of accrued expenses

Accrued expenses (in thousands)



June 30,

December 31,

2020



2019

Accrued clinical consulting services

$

704

$

684

Accrued vendor payments

376

456

Accrued manufacturing costs

129

635

Other accrued expenses

—

1

Total

$

1,209

$

1,776

Schedule of accrued employee benefits

Accrued employee benefits (in thousands)



June 30,

December 31,

2020



2019

Accrued severance expense

$

399

$

—

Accrued bonus expense

396

858

Accrued vacation expense

132

77

$

927

$

935

X

- Definition
Tabular disclosure of information related to accrued employee benefits.
+ References
No definition available.
+ Details

Name: syn_AccruedEmployeeBenefitsTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of accrued expenses.
+ References
No definition available.
+ Details

Name: syn_AccruedExpensesTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: syn_BalanceSheetInformationAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amounts of other current assets.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2020

Stock-Based Compensation

Schedule of assumptions used for awards

The assumptions used for the awards during the year ended December 31, 2019 were as follows:

Exercise price



$

0.42

Expected dividends

0
%

Expected volatility

84

%

Risk free interest rate

1.61

%

Expected life of option

4.5
years

Summary of stock option activity

A summary of stock option activity for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:





Weighted



Weighted Average



Aggregate

Average Exercise

Remaining

Intrinsic

Options

Price

Contractual Life

Value

Balance - December 31, 2018

938,982

$

15.18

6.19 years

$

—

Granted

1,725,000

0.42





Exercised

—

—

Expired

(94,738)

58.25





Forfeited

(67,232)

5.95





Balance - December 31, 2019

2,502,012

$

3.62

6.51 years

$

153,353

Granted

—

—





Exercised

—

—

Expired

—

—





Forfeited

(29,650)

0.55





Balance - June 30, 2020 - outstanding

2,472,362

$

3.65

5.98 years

$

158,270

Balance - June 30, 2020 - exercisable

628,408

$

12.89

5.16 years

$

15,129

Grant date fair value of options granted - six months ended June 30, 2020

$

—





Weighted average grant date fair value - six months ended June 30, 2020

$

—





Grant date fair value of options granted - year ended December 31, 2019

$

470,000





Weighted average grant date fair value - year ended December 31, 2019

$

0.27





X

- Definition
Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.20.2

Stock Warrants (Tables)
6 Months Ended

Jun. 30, 2020

Stock Warrants

Summary of all warrant activity

A summary of all warrant activity for the Company for the six months ended June 30, 2020 and the year ended December 31, 2019 is as follows:



Number of



Weighted Average

Warrants

Exercise Price

Balance at December 31, 2018

18,915,851

$

3.85

Granted

—

—

Exercised

—

—

Forfeited

(200,852)

61.25

Balance at December 31, 2019

18,714,999

3.24

Granted

—

—

Exercised

—

—

Forfeited

—

—

Balance at June 30, 2020

18,714,999

$

3.24

Summary of all outstanding and exercisable warrants

A summary of all outstanding and exercisable warrants as of June 30, 2020 is as follows:







Weighted Average

Warrants

Warrants

Remaining

Exercise Price

Outstanding

Exercisable

Contractual Life

$

1.38

17,999,999

17,999,999

3.28 years

18.20

714

714

2.49 years

50.05

714,286

714,286

0.39 years

$

3.24

18,714,999

18,714,999

3.17 years

X

- Definition
Tabular disclosure of warrant activity.
+ References
No definition available.
+ Details

Name: syn_ScheduleOfWarrantActivityTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure relates to warrant outstanding and exercisable.
+ References
No definition available.
+ Details

Name: syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock

Namespace Prefix: syn_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: syn_StockWarrantsAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.20.2

Commitments and Contingencies (Tables)
6 Months Ended

Jun. 30, 2020

Commitments and Contingencies

Schedule of maturity analysis of operating leases

Future undiscounted cash flow for the years ending December 31:





2020

$

156

2021

321

2022

192

Total

$

669

Discount factor

$

(67)

Lease liability

$

602

Amount due within 12 months

$

(268)

Lease liability – long term

$

334

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.20.2

Going Concern (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Jun. 30, 2019

Dec. 31, 2018

Going Concern

Accumulated deficit $ (242,289) $ (235,537)

Cash and Cash Equivalents, at Carrying Value $ 8,059 $ 15,045 $ 21,712 $ 28,918

X

- Definition
n/a.
+ References
No definition available.
+ Details

Name: syn_GoingConcernAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.20.2

Fair Value of Financial Instruments (Details) - Money market accounts - USD ($)

Jun. 30, 2020

Dec. 31, 2019

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis

Cash and cash equivalents $ 114,000

Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis

Cash and cash equivalents $ 98,000

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Selected Balance Sheet Information

Prepaid clinical research organizations $ 471 $ 48

Prepaid insurances 241 549

Prepaid manufacturing expenses 94 622

Prepaid consulting, subscriptions and other expenses 91 134

Prepaid conferences, travel 0 25

Other receivables 0 3

Total $ 897 $ 1,381

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: syn_BalanceSheetInformationAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the amount paid in advance for clinical research organization.
+ References
No definition available.
+ Details

Name: syn_PrepaidClinicalResearchOrganizationsExpenseCurrent

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the amount paid in advance for consulting, subscriptions and other expenses.
+ References
No definition available.
+ Details

Name: syn_PrepaidConsultingSubscriptionsAndOtherExpenses

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of Prepaid Manufacturing Expense.
+ References
No definition available.
+ Details

Name: syn_PrepaidManufacturingExpense

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidInsurance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Property and equipment, net

Property, Plant and Equipment, Gross, Total $ 1,254 $ 1,254

Less: accumulated depreciation and amortization (1,003) (887)

Total 251 367

Computers and office equipment [Member]

Property and equipment, net

Property, Plant and Equipment, Gross, Total 804 804

Leasehold Improvements [Member]

Property and equipment, net

Property, Plant and Equipment, Gross, Total 439 439

Software [Member]

Property and equipment, net

Property, Plant and Equipment, Gross, Total $ 11 $ 11

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information - Schedule of accrued expenses (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Selected Balance Sheet Information

Accrued clinical consulting services $ 704 $ 684

Accrued vendor payments 376 456

Accrued manufacturing costs 129 635

Other accrued expenses 0 1

Total $ 1,209 $ 1,776

X

- Definition
The carrying value of accrued clinical consulting services payable as on balance sheet date.
+ References
No definition available.
+ Details

Name: syn_AccruedClinicalConsultingServices

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The manufacturing costs incurred in the production of goods for sale.
+ References
No definition available.
+ Details

Name: syn_AccruedManufacturingCosts

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.
+ References
No definition available.
+ Details

Name: syn_AccruedVendorPayments

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: syn_BalanceSheetInformationAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.20.2

Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Selected Balance Sheet Information

Accrued severance expense $ 399

Accrued bonus expense 396 $ 858

Accrued vacation expense 132 77

Total $ 927 $ 935

X

- Definition
n/a
+ References
No definition available.
+ Details

Name: syn_BalanceSheetInformationAbstract

Namespace Prefix: syn_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedBonusesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 710
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765
+ Details

Name: us-gaap_AccruedVacationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 712
-SubTopic 10
-Section 25
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919
+ Details

Name: us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation - Schedule of assumptions used for awards (Details)
12 Months Ended

Dec. 31, 2019

$ / shares

Stock-Based Compensation

Exercise price $ 0.42

Expected dividends 0.00%

Expected volatility 84.00%

Risk -free interest rate 1.61%

Expected life of option 4 years 6 months

X

- Definition
Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation - Summary of stock option activity (Details) - Stock Option [Member] - USD ($)
6 Months Ended 12 Months Ended

Jun. 30, 2020

Dec. 31, 2019

Dec. 31, 2018

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options, Beginning Balance 2,502,012 938,982

Options, Granted 0 1,725,000

Options, Exercised 0 0

Options, Expired 0 (94,738)

Options, Forfeited (29,650) (67,232)

Options, Ending Balance 2,472,362 2,502,012 938,982

Options, Exercisable 628,408

Weighted Average Exercise Price, Beginning Balance $ 3.62 $ 15.18

Weighted Average Exercise Price, Granted 0.00 0.42

Weighted Average Exercise Price, Exercised 0.00 0.00

Weighted Average Exercise Price, Expired 0.00 58.25

Weighted Average Exercise Price, Forfeited 0.55 5.95

Weighted Average Exercise Price, Ending Balance 3.65 $ 3.62 $ 15.18

Weighted Average Exercise Price, Exercisable $ 12.89

Weighted Average Remaining Contractual Life, Balance Outstanding 5 years 11 months 23 days 6 years 6 months 4 days 6 years 2 months 9 days

Weighted Average Remaining Contractual Life, Exercisable 5 years 1 month 28 days

Aggregate Intrinsic Value, Ending Balance $ 158,270 $ 153,353 $ 0

Aggregate Intrinsic Value, Exercisable 15,129

Grant date fair value of options granted $ 0 $ 470,000

Weighted average grant date fair value $ 0.00 $ 0.27

X

- Definition
Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price of options that were either forfeited or expired.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)-(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.20.2

Stock-Based Compensation - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Sep. 05, 2019

Sep. 07, 2017

May 15, 2015

Sep. 24, 2018

Aug. 25, 2016

Oct. 22, 2013

Mar. 20, 2007

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Nov. 02, 2010

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 0 0 0 0

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options $ 498,000 $ 498,000

Employees | General and Administrative Expense

Share-based Compensation Arrangement by Share-based Payment Award

Allocated Share-based Compensation Expense 40,000 $ 50,000 79,000 $ 106,000

Employees | Research and Development Expense

Share-based Compensation Arrangement by Share-based Payment Award

Allocated Share-based Compensation Expense 15,000 32,000 31,000 110,000

Consultants | General and Administrative Expense

Share-based Compensation Arrangement by Share-based Payment Award

Allocated Share-based Compensation Expense 27,000 9,000 53,000 19,000

Consultants | Research and Development Expense

Share-based Compensation Arrangement by Share-based Payment Award

Allocated Share-based Compensation Expense $ 4,000 $ 1,000 $ 6,000 $ 1,000

2007 Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 71,429 7,052 7,052

2007 Stock Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 7,143

2010 Stock Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2,465,310 2,465,310 85,714

2010 Stock Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 4,000,000 500,000 228,572 1,000,000 400,000 171,429

2010 Stock Plan [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1,000,000 400,000 171,429 500,000 228,572 85,714

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net number of share options (or share units) granted during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockPlan2007Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockPlan2010Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.20.2

Stock Warrants - Additional Information (Details) - USD ($)
1 Months Ended 6 Months Ended

Oct. 15, 2018

Oct. 15, 2018

Oct. 10, 2018

Oct. 10, 2014

Nov. 18, 2016

Jun. 30, 2020

Dec. 31, 2019

Jun. 30, 2019

Oct. 31, 2018

Dec. 26, 2017

Equity, Class of Treasury Stock

Proceeds from Issuance or Sale of Equity $ 18,600,000

Warrants Not Settleable in Cash, Fair Value Disclosure $ 9,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 13,672,173 13,672,173

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.38 $ 1.38 $ 1.38

Class A [Member]

Equity, Class of Treasury Stock

Stock Issued During Period, Shares, New Issues 2,520,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 61.25

Preferred Stock Conversion Price Per Share $ 1.15 $ 1.15

Class B [Member]

Equity, Class of Treasury Stock

Stock Issued During Period, Shares, New Issues 15,723

Series B Preferred Stock [Member]

Equity, Class of Treasury Stock

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 13,672,173 13,672,173

Stock Issued During Period, Value, Issued for Services $ 1,000

Preferred Stock, Par or Stated Value Per Share $ 1,000 $ 1,000 $ 1,000 $ 1,000

Conversion of Stock, Shares Converted 13,672,173 10,198

IPO [Member]

Equity, Class of Treasury Stock

Warrants Not Settleable in Cash, Fair Value Disclosure $ 15,700,000 $ 100,000 $ 100,000

Stock Issued During Period, Shares, New Issues 714,286

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,428,571

Sale of Stock, Price Per Share $ 1.47 $ 35.00

IPO [Member] | Series A [Member]

Equity, Class of Treasury Stock

Class of Warrant or Right, Exercise Price of Warrants or Rights 50.05

IPO [Member] | Series B [Member]

Equity, Class of Treasury Stock

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 60.20

Over-Allotment Option [Member]

Equity, Class of Treasury Stock

Stock Issued During Period, Shares, New Issues 2,428,825 2,428,825

Issuance Of Warrants To Purchase Of Common Stock 1,807,826 1,807,826

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,428,825 2,428,825 2,428,825

Underwritten Public Offering [Member] | October 2018 Warrants [Member]

Equity, Class of Treasury Stock

Warrant Term 5 years

Series A Warrants [Member]

Equity, Class of Treasury Stock

Proceeds from Issuance of Common Stock $ 19,100,000

Sale of Stock, Number of Shares Issued in Transaction 14,059,616

Issuance Of Warrants To Purchase Of Common Stock 0.50

Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number 200,852

Fair Value of Warrant Liability $ 0 $ 0

Fair Value Adjustment of Warrants $ 7,400,000

Warrant [Member]

Equity, Class of Treasury Stock

Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number 714

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 13,672,173 13,672,173

X

- Definition
The value pertaining to fair value of warrant liability.
+ References
No definition available.
+ Details

Name: syn_FairValueOfWarrantLiability

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Warrants issued to purchase common stock.
+ References
No definition available.
+ Details

Name: syn_IssuanceOfWarrantsToPurchaseOfCommonStock

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.
+ References
No definition available.
+ Details

Name: syn_PreferredStockConversionPricePerShare

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the number of warrants into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the warrant term.
+ References
No definition available.
+ Details

Name: syn_WarrantTerm

Namespace Prefix: syn_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EquityClassOfTreasuryStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value portion of warrants not settleable in cash classified as equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=syn_ClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=syn_ClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=syn_OctoberTwoThousandEighteenWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=syn_StockWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.20.2

Stock Warrants - Summary of all warrant activity (Details) - $ / shares
6 Months Ended 12 Months Ended

Jun. 30, 2020

Dec. 31, 2019

Stock-Based Compensation

Number of Warrants, Beginning Balance 18,714,999 18,915,851

Number of Warrants, Granted 0

Number of Warrants, Exercised 0

Number of Warrants, Forfeited 0 (200,852)

Number of Warrants, Ending Balance 18,714,999 18,714,999

Weighted Average Exercise Price, Beginning Balance $ 3.24 $ 3.85

Weighted Average Exercise Price, Granted 0

Weighted Average Exercise Price, Exercised 0

Weighted Average Exercise Price, Forfeited 0 61.25

Weighted Average Exercise Price, Ending Balance $ 3.24 $ 3.24

X

- Definition
Number of share warrants exercised during the period.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2

Stock warrants - Summary of all outstanding and exercisable warrants (Details)
6 Months Ended

Jun. 30, 2020

$ / shares

shares

Exercise Price 1.38 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price | $ / shares $ 1.38

Warrants Outstanding 17,999,999

Warrants Exercisable 17,999,999

Weighted Average Remaining Contractual Life (in years) 3 years 3 months 11 days

Exercise Price 18.20 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price | $ / shares $ 18.20

Warrants Outstanding 714

Warrants Exercisable 714

Weighted Average Remaining Contractual Life (in years) 2 years 5 months 27 days

Exercise Price 50.05 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price | $ / shares $ 50.05

Warrants Outstanding 714,286

Warrants Exercisable 714,286

Weighted Average Remaining Contractual Life (in years) 4 months 21 days

Exercise price 3.24 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise Price | $ / shares $ 3.24

Warrants Outstanding 18,714,999

Warrants Exercisable 18,714,999

Weighted Average Remaining Contractual Life (in years) 3 years 2 months 1 day

X

- Definition
The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.
+ References
No definition available.
+ Details

Name: syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price of the warrants.
+ References
No definition available.
+ Details

Name: syn_WarrantsExercisePrice

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice138Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice5005Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice3.24Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R36.htm IDEA: XBRL DOCUMENT v3.20.2

Net Loss per Share - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2020

Mar. 31, 2020

Jun. 30, 2019

Mar. 31, 2019

Jun. 30, 2020

Jun. 30, 2019

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Net Loss Attributable to Non-controlling Interest $ (16,000) $ (26,000) $ (27,000) $ (16,000) $ (42,000) $ (43,000)

Series A Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

preferred stock accrued dividends 63,000 61,000 125,000 122,000

Series B Preferred Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Net Loss Attributable to Non-controlling Interest 0 $ 0 0 $ 0

Accretion of preferred discount 400,000 100,000 800,000 500,000

preferred stock accrued dividends $ 392,000 $ 117,000 $ 796,000 $ 515,000

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 4,804,348 6,802,608 4,804,348 6,802,608

Equity Option [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 2,472,362 2,472,362 843,119

Warrant [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 18,714,999 18,714,999 18,915,851

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of accretion of the preferred stock redemption discount during the period.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockAccretionOfRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.20.2

Non-controlling Interest (Details) - USD ($)
3 Months Ended 6 Months Ended

Sep. 05, 2018

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Noncontrolling Interest

Related Party Transaction, Expenses from Transactions with Related Party $ 441,000

Research and Development Expense $ 1,603,000 $ 2,594,000 $ 3,238,000 $ 5,012,000

SYN Biomics

Noncontrolling Interest

Equity interest by parent 83.00% 83.00%

Accumulated net loss attributable to the non-controlling interest $ 2,900,000 2,900,000 $ 2,900,000 2,900,000

Cedarssinai Medical Center [Member]

Noncontrolling Interest

Number Of Common Stock To Be Issued 50,000 50,000 50,000

Research and Development Expense $ 25,000 $ 119,000 $ 92,000 $ 174,000

Fair Value Of Shares Issued $ 285,000

Cedarssinai Medical Center [Member] | SYN Biomics

Noncontrolling Interest

Additional Number Of Common Stock To Be Issued 2,420,000

Number Of Common Stock To Be Held By Related Party 7,480,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00%

X

- Definition
The amount of accumulated net loss attributable to the non-controlling interest as of balance sheet date.
+ References
No definition available.
+ Details

Name: syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The additional number of common stock to be issued under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_AdditionalNumberOfCommonStockToBeIssued

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount represents the fair value of shares issued.
+ References
No definition available.
+ Details

Name: syn_FairValueOfSharesIssued

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The additional number of common stock to be held by the related party under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_NumberOfCommonStockToBeHeldByRelatedParty

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of common stock to be issued under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_NumberOfCommonStockToBeIssued

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByParent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: srt_OwnershipAxis=syn_SYNBiomicsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.2

Common and Preferred Stock (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended

Oct. 15, 2018

USD ($)

$ / shares

shares

Oct. 10, 2018

shares

Sep. 11, 2017

USD ($)

D

$ / shares

shares

Aug. 05, 2016

USD ($)

Oct. 31, 2018

$ / shares

Jun. 30, 2020

USD ($)

$ / shares

shares

Jun. 30, 2019

USD ($)

shares

Jun. 30, 2020

USD ($)

$ / shares

shares

Jun. 30, 2019

USD ($)

shares

Dec. 31, 2019

$ / shares

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 13,672,173

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 1.38 $ 1.38

Preferred Stock Redemption Discount $ 9,100,000

Percentage of issue of the public offering 120.00%

Common Stock, Discount on Shares $ 3,800,000 $ 3,800,000

Proceeds from Issuance or Sale of Equity $ 18,600,000

Over-Allotment Option [Member]

Stock Issued During Period, Shares, New Issues | shares 2,428,825 2,428,825

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 2,428,825 2,428,825

Issue of warrants to purchase common stock | shares 1,807,826

Warrant [Member]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 13,672,173

Fbr Capital Markets Co [Member]

Stock Issued During Period, Value, New Issues $ 40,000,000

Brokerage Commission percentage 3.00%

Series A Preferred Stock [Member]

Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.001 $ 0.001 $ 0.001

Preferred Stock, Dividend Rate, Percentage 2.00% 2.00%

Preferred Stock Conversion Price Per Share | $ / shares $ 18.90

Debt Instrument, Convertible, Threshold Trading Days | D 20

Debt Instrument, Convertible, Threshold Consecutive Trading Days | D 30

Dividends Payable, Amount Per Share | $ / shares $ 70.00

Adjustments to Additional Paid in Capital, Stock Split $ 7,875

preferred stock accrued dividends $ 63,000 $ 61,000 $ 125,000 $ 122,000

Preferred Stock Redemption Discount $ 6,900,000

Series A Preferred Stock [Member] | Private Placement [Member]

Stock Issued During Period, Shares, New Issues | shares 120,000

Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.001

Proceeds from Issuance of Convertible Preferred Stock $ 12,000,000

Sale of Stock, Consideration Received Per Transaction $ 100

Series B Preferred Stock [Member]

Preferred Stock, Par or Stated Value Per Share | $ / shares $ 1,000 $ 1,000 $ 1,000 $ 1,000

preferred stock accrued dividends $ 392,000 $ 117,000 $ 796,000 $ 515,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 13,672,173

Stock Issued During Period, Value, Issued for Services $ 1,000

Percentage Exceed Aggregate Number Of Common Stock 4.99%

Percentage Exceed Aggregate Number Of Common Stock Outstanding 9.99%

Increase Decrease in Excess of Other Percentage 9.99%

Preferred Stock Shares Converted | shares 1,040 302 2,113 1,338

Preferred Shares, Unamortized Discount From Conversion $ 392,000 $ 117,000 $ 796,000 $ 515,000

Conversion of Stock, Shares Converted | shares 13,672,173 10,198

Common Class A [Member]

Stock Issued During Period, Shares, New Issues | shares 2,520,000

Shares Issued, Price Per Share | $ / shares $ 1.15

Common Class B [Member]

Stock Issued During Period, Shares, New Issues | shares 15,723

Preferred Stock Conversion Price Per Share | $ / shares $ 1.15

X

- Definition
Represent that percentage of commission revenue from buying and selling securities on behalf of customers.
+ References
No definition available.
+ Details

Name: syn_BrokerageCommissionPercentage

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Other percentage of increase decrease in excess of preferred stock.
+ References
No definition available.
+ Details

Name: syn_IncreaseDecreaseInExcessOfOtherPercentage

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
It represent additional of warrant to purchase of common stock
+ References
No definition available.
+ Details

Name: syn_IssueOfWarrantsToPurchaseCommonStock

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The percentage of exceed aggregate number of common stock.
+ References
No definition available.
+ Details

Name: syn_PercentageExceedAggregateNumberOfCommonStock

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The percentage of exceed aggregate number of common stock outstanding.
+ References
No definition available.
+ Details

Name: syn_PercentageExceedAggregateNumberOfCommonStockOutstanding

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of issue of public offering price
+ References
No definition available.
+ Details

Name: syn_PercentageOfIssueOfThePublicOffering

Namespace Prefix: syn_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount represents preferred shares, unamortized discount from the conversion.
+ References
No definition available.
+ Details

Name: syn_PreferredSharesUnamortizedDiscountFromConversion

Namespace Prefix: syn_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.
+ References
No definition available.
+ Details

Name: syn_PreferredStockConversionPricePerShare

Namespace Prefix: syn_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The no of shares converted into common stock
+ References
No definition available.
+ Details

Name: syn_PreferredStockSharesConverted

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.4-07)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187103-122770
+ Details

Name: us-gaap_CommonStockDiscountOnShares

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_ConversionOfStockSharesConverted1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
The per share amount of a dividend declared, but not paid, as of the financial reporting date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DividendsPayableAmountPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The percentage rate used to calculate dividend payments on preferred stock.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendRatePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.
+ References
No definition available.
+ Details

Name: us-gaap_PreferredStockDividendsIncomeStatementImpact

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=27010884&loc=d3e42851-122695
+ Details

Name: us-gaap_PreferredStockRedemptionDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedPerTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R39.htm IDEA: XBRL DOCUMENT v3.20.2

Related Party Transactions (Details) - USD ($)
$ / shares in Units, $ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Oct. 31, 2018

Oct. 15, 2018

Sep. 05, 2018

Related Party Transaction

Common Stock, Shares, Issued 18,646,152 16,808,758

Common Stock, Value, Issued $ 19 $ 17

Common Stock, Par or Stated Value Per Share $ (0.001) $ (0.001)

Class of Warrant or Right, Number of Securities Called by Warrants or Rights 13,672,173

Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.38 $ 1.38

Synthetic Biomics Inc [Member]

Related Party Transaction

Additional Number Of Common Stock To Be Issued 2,420,000

Cedarssinai Medical Center [Member]

Related Party Transaction

Number Of Common Stock To Be Issued 50,000 50,000

Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]

Related Party Transaction

Number Of Common Stock To Be Held By Related Party 7,480,000 7,480,000

Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00% 17.00%

X

- Definition
The additional number of common stock to be issued under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_AdditionalNumberOfCommonStockToBeIssued

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The additional number of common stock to be held by the related party under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_NumberOfCommonStockToBeHeldByRelatedParty

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of common stock to be issued under stock purchase agreement.
+ References
No definition available.
+ Details

Name: syn_NumberOfCommonStockToBeIssued

Namespace Prefix: syn_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_OwnershipAxis=syn_SyntheticBiomicsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R40.htm IDEA: XBRL DOCUMENT v3.20.2

Commitments and Contingencies - Maturity analysis of operating leases (Details) - USD ($)
$ in Thousands

Jun. 30, 2020

Dec. 31, 2019

Commitments and Contingencies

2020 $ 156

2021 321

2022 192

Total 669

Discount factor (67)

Lease liability 602

Amount due within 12 months (268) $ (249)

Lease liability - long term $ 334 $ 473

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2

Commitments and Contingencies - Additional Information (Details) - USD ($)
3 Months Ended 6 Months Ended

Jan. 01, 2019

Jun. 30, 2020

Jun. 30, 2019

Jun. 30, 2020

Jun. 30, 2019

Operating Lease, Weighted Average Discount Rate, Percent 9.90% 9.90%

Operating Lease, Cost $ 50,000 $ 50,000 $ 101,000 $ 101,000

Operating Lease, Payments $ 77,000 $ 75,000 154,000 149,000

Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 0 $ 538,000

Operating Lease Expiration Year 2022

ASU 2016-02

Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 538,000

X

- Definition
Maturity of Operating Lease year
+ References
No definition available.
+ Details

Name: syn_OperatingLeaseExpirationYear

Namespace Prefix: syn_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeasePayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Weighted average discount rate for operating lease calculated at point in time.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(4)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of increase in right-of-use asset obtained in exchange for operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 193 298 1 false 44 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders Equity (Deficit) Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical) Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders Equity (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation Sheet http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation Organization, Nature of Operations and Basis of Presentation Notes 8 false false R9.htm 10201 - Disclosure - Going Concern Sheet http://www.syntheticbiologics.com/role/DisclosureGoingConcern Going Concern Notes 9 false false R10.htm 10301 - Disclosure - Fair Value of Financial Instruments Sheet http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 10401 - Disclosure - Selected Balance Sheet Information Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation Selected Balance Sheet Information Notes 11 false false R12.htm 10501 - Disclosure - Stock-Based Compensation Sheet http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 10601 - Disclosure - Stock Warrants Sheet http://www.syntheticbiologics.com/role/DisclosureStockWarrants Stock Warrants Notes 13 false false R14.htm 10701 - Disclosure - Net Loss per Share Sheet http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare Net Loss per Share Notes 14 false false R15.htm 10801 - Disclosure - Non-controlling Interest Sheet http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest Non-controlling Interest Notes 15 false false R16.htm 10901 - Disclosure - Common and Preferred Stock Sheet http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock Common and Preferred Stock Notes 16 false false R17.htm 11001 - Disclosure - Related Party Transactions Sheet http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 17 false false R18.htm 11101 - Disclosure - Commitments and Contingencies Sheet http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 11201 - Disclosure - Subsequent Events Sheet http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 30403 - Disclosure - Selected Balance Sheet Information (Tables) Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables Selected Balance Sheet Information (Tables) Tables http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation 20 false false R21.htm 30503 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation 21 false false R22.htm 30603 - Disclosure - Stock Warrants (Tables) Sheet http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables Stock Warrants (Tables) Tables http://www.syntheticbiologics.com/role/DisclosureStockWarrants 22 false false R23.htm 31103 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies 23 false false R24.htm 40201 - Disclosure - Going Concern (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureGoingConcernDetails Going Concern (Details) Details http://www.syntheticbiologics.com/role/DisclosureGoingConcern 24 false false R25.htm 40301 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments 25 false false R26.htm 40401 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) Details 26 false false R27.htm 40402 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) Details 27 false false R28.htm 40403 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails Selected Balance Sheet Information - Schedule of accrued expenses (Details) Details 28 false false R29.htm 40404 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) Details 29 false false R30.htm 40501 - Disclosure - Stock-Based Compensation - Schedule of assumptions used for awards (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForAwardsDetails Stock-Based Compensation - Schedule of assumptions used for awards (Details) Details 30 false false R31.htm 40502 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of stock option activity (Details) Details 31 false false R32.htm 40503 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 32 false false R33.htm 40601 - Disclosure - Stock Warrants - Additional Information (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockWarrantsAdditionalInformationDetails Stock Warrants - Additional Information (Details) Details 33 false false R34.htm 40602 - Disclosure - Stock Warrants - Summary of all warrant activity (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails Stock Warrants - Summary of all warrant activity (Details) Details 34 false false R35.htm 40603 - Disclosure - Stock warrants - Summary of all outstanding and exercisable warrants (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails Stock warrants - Summary of all outstanding and exercisable warrants (Details) Details 35 false false R36.htm 40701 - Disclosure - Net Loss per Share - Additional Information (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails Net Loss per Share - Additional Information (Details) Details 36 false false R37.htm 40801 - Disclosure - Non-controlling Interest (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails Non-controlling Interest (Details) Details http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest 37 false false R38.htm 40901 - Disclosure - Common and Preferred Stock (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails Common and Preferred Stock (Details) Details http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock 38 false false R39.htm 41001 - Disclosure - Related Party Transactions (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions 39 false false R40.htm 41101 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesDetails Commitments and Contingencies - Maturity analysis of operating leases (Details) Details 40 false false R41.htm 41102 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 41 false false All Reports Book All Reports syn-20200630.xml syn-20200630.xsd syn-20200630_cal.xml syn-20200630_def.xml syn-20200630_lab.xml syn-20200630_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true ZIP 58 0001104659-20-091503-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-091503-xbrl.zip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�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end

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 03, 2020
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Entity Registrant Name	Synthetic Biologics, Inc.
Trading Symbol	SYN
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,440,346
Entity Central Index Key	0000894158
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 8,059	$ 15,045
Prepaid expenses and other current assets	897	1,381
Total Current Assets	8,956	16,426
Property and equipment, net	251	367
Right of use asset	352	419
Deposits and other assets	23	23
Total Assets	9,582	17,235
Current Liabilities:
Accounts payable	1,025	2,315
Accrued expenses	1,209	1,776
Accrued employee benefits	927	935
Lease liability	268	249
Total Current Liabilities	3,429	5,275
Lease liability - long term	334	473
Total Liabilities	3,763	5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,669	12,544
Stockholders' Deficit:
Common Stock, $0.001 par value; 200,000,000 shares authorized, 18,646,152 and 16,808,758 issued and 18,643,824 and 16,806,430 outstanding	19	17
Additional paid-in capital	234,860	232,580
Accumulated deficit	(242,289)	(235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit	(3,966)	1,821
Non-controlling interest	(2,884)	(2,878)
Total Stockholders' Deficit	(6,850)	(1,057)
Total Liabilities and Stockholders' Deficit	9,582	17,235
Series B Preferred Stock [Member]
Stockholders' Deficit:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 5,525 issued and outstanding and 7,638 issued and outstanding	3,444	4,761
Total Stockholders' Deficit	$ 3,444	$ 4,761

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, Shares Authorized	200,000,000	200,000,000
Common stock, Shares Issued	18,646,152	16,808,758
Common stock, Shares Outstanding	18,643,824	16,806,430
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	120,000	120,000
Preferred Stock, Shares Outstanding	120,000	120,000
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	5,525	7,638
Preferred Stock, Shares Outstanding	5,525	7,638

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Costs and Expenses:
General and administrative	$ 1,286,000	$ 1,044,000	$ 2,679,000	$ 2,199,000
Research and development	1,603,000	2,594,000	3,238,000	5,012,000
Total Operating Costs and Expenses	2,889,000	3,638,000	5,917,000	7,211,000
Loss from Operations	(2,889,000)	(3,638,000)	(5,917,000)	(7,211,000)
Other Income :
Interest income	6,000	80,000	44,000	125,000
Total Other Income	6,000	80,000	44,000	125,000
Net Loss	(2,883,000)	(3,558,000)	(5,873,000)	(7,086,000)
Net Loss Attributable to Non-controlling Interest	(16,000)	(27,000)	(42,000)	(43,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,867,000)	(3,531,000)	(5,831,000)	(7,043,000)
Net Loss Attributable to Common Stockholders	$ (3,322,000)	$ (3,709,000)	$ (6,752,000)	$ (7,680,000)
Net Loss Per Share - Basic and Dilutive	$ (0.18)	$ (0.23)	$ (0.38)	$ (0.48)
Weighted average number of shares outstanding during the period - Basic and Dilutive	18,405,884	16,465,314	17,748,688	16,063,283
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (63,000)	$ (61,000)	$ (125,000)	$ (122,000)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (392,000)	$ (117,000)	$ (796,000)	$ (515,000)

Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2018	$ 15	$ 230,754	$ (219,461)	$ (2,909)	$ 5,760	$ 14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Stock-based compensation	$ 0	64	0	0	$ 0	64
Series A Preferred Stock Dividends	0	0	(61)	0	0	(61)
Issuance of SYN Biomics Stock	0	(36)	0	53	0	17
Conversion of Series B Preferred Stock to Common	$ 1	1,035	(398)	0	$ (638)	0
Conversion of Series B Preferred Stock to Common (in shares)	900,869				(1,036)
Net loss	$ 0	0	(3,512)	0	$ 0	(3,512)
Non-controlling interest	0	0	0	(16)	0	(16)
Balance at Mar. 31, 2019	$ 16	231,817	(223,432)	(2,872)	$ 5,122	10,651
Balance (in shares) at Mar. 31, 2019	16,382,952				8,125
Balance at Dec. 31, 2018	$ 15	230,754	(219,461)	(2,909)	$ 5,760	14,159
Balance (in shares) at Dec. 31, 2018	15,482,083				9,161
Net loss						(7,043)
Non-controlling interest						(43)
Balance at Jun. 30, 2019	$ 17	232,211	(227,141)	(2,854)	$ 4,935	7,168
Balance (in shares) at Jun. 30, 2019	16,645,560				7,823
Balance at Mar. 31, 2019	$ 16	231,817	(223,432)	(2,872)	$ 5,122	10,651
Balance (in shares) at Mar. 31, 2019	16,382,952				8,125
Stock-based compensation	$ 0	91	0	0	$ 0	91
Series A Preferred Stock Dividends	0	0	(61)	0	0	(61)
Issuance of SYN Biomics Stock	0	0	0	45	0	45
Conversion of Series B Preferred Stock to Common	$ 1	303	(117)	0	$ (187)	0
Conversion of Series B Preferred Stock to Common (in shares)	262,608				(302)
Net loss	$ 0	0	(3,531)	0	$ 0	(3,531)
Non-controlling interest	0	0	0	(27)	0	(27)
Balance at Jun. 30, 2019	$ 17	232,211	(227,141)	(2,854)	$ 4,935	7,168
Balance (in shares) at Jun. 30, 2019	16,645,560				7,823
Balance at Dec. 31, 2019	$ 17	232,580	(235,537)	(2,878)	$ 4,761	(1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Stock-based compensation	$ 0	83	0	0	$ 0	83
Series A Preferred Stock Dividends	0	0	(62)	0	0	(62)
Issuance of SYN Biomics Stock	0	0	0	26	0	26
Conversion of Series B Preferred Stock to Common	$ 1	1,072	(404)	0	$ (669)	0
Conversion of Series B Preferred Stock to Common (in shares)	933,045				(1,073)
Net loss	$ 0	0	(2,964)	0	$ 0	(2,964)
Non-controlling interest	0	0	0	(26)	0	(26)
Balance at Mar. 31, 2020	$ 18	233,735	(238,967)	(2,878)	$ 4,092	(4,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Balance at Dec. 31, 2019	$ 17	232,580	(235,537)	(2,878)	$ 4,761	(1,057)
Balance (in shares) at Dec. 31, 2019	16,806,430				7,638
Net loss						(5,831)
Non-controlling interest						(42)
Balance at Jun. 30, 2020	$ 19	234,860	(242,289)	(2,884)	$ 3,444	(6,850)
Balance (in shares) at Jun. 30, 2020	18,643,824				5,525
Balance at Mar. 31, 2020	$ 18	233,735	(238,967)	(2,878)	$ 4,092	(4,000)
Balance (in shares) at Mar. 31, 2020	17,739,475				6,565
Stock-based compensation	$ 0	86	0	0	$ 0	86
Series A Preferred Stock Dividends	0	0	(63)	0	0	(63)
Issuance of SYN Biomics Stock	0	0	0	10	0	10
Conversion of Series B Preferred Stock to Common	$ 1	1,039	(392)	0	$ (648)	0
Conversion of Series B Preferred Stock to Common (in shares)	904,349				(1,040)
Net loss	$ 0	0	(2,867)	0	$ 0	(2,867)
Non-controlling interest	0	0	0	(16)	0	(16)
Balance at Jun. 30, 2020	$ 19	$ 234,860	$ (242,289)	$ (2,884)	$ 3,444	$ (6,850)
Balance (in shares) at Jun. 30, 2020	18,643,824				5,525

Condensed Consolidated Statements of Stockholders Equity (Parenthetical) - $ / shares	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Series B Preferred Stock [Member]
Conversion of preferred stock to common stock	$ 0.03	$ 0.03	$ 0.03	$ 0.03

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (5,873,000)	$ (7,086,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	169,000	155,000
Subsidiary stock issued to vendor	36,000	62,000
Depreciation	116,000	122,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	484,000	(706,000)
Right of use asset	67,000	56,000
Accounts payable	(1,290,000)	490,000
Accrued expenses	(567,000)	627,000
Accrued employee benefits	(8,000)	(821,000)
Lease liability	(120,000)	(105,000)
Net Cash Used In Operating Activities	(6,986,000)	(7,206,000)
Cash Flows From Investing Activities:
Net Cash From Investing Activities	0	0
Cash Flows From Financing Activities:
Net Cash From Financing Activities	0	0
Net decrease in cash and cash equivalents	(6,986,000)	(7,206,000)
Cash and cash equivalents at beginning of period	15,045,000	28,918,000
Cash and cash equivalents at end of period	8,059,000	21,712,000
Noncash Financing Activities:
Deemed dividends for accretion of Series B Preferred Stock discount	796,000	515,000
In-kind dividends paid in preferred stock	125,000	122,000
Right of use asset from operating lease	0	538,000
Series B Preferred Stock [Member]
Noncash Financing Activities:
Conversion of Series B Preferred Stock	$ 1,317,000	$ 825,000

Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2020
Organization, Nature of Operations and Basis of Presentation
Organization, Nature of Operations and Basis of Presentation	1. Organization, Nature of Operations and Basis of Presentation Description of Business Synthetic Biologics, Inc. (the “Company” or “Synthetic Biologics”) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN‑004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN‑010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also advancing SYN‑020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases. Basis of Presentation The accompanying condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (“U.S. GAAP”) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company’s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2019 Form 10‑K. The interim results for the three and six months ended June 30, 2020 are not necessarily indicative of results for the full year. The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods. Recent Accounting Pronouncements and Developments On January 30, 2020, the World Health Organization (WHO) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the COVID-19 outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (CARES Act) was enacted. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States’ economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. The Company has assessed the impact of the CARES Act and based upon our initial assessment, we do not believe that it will have a significant effect on our financial position, results of operations or cash flows. The Company continues to evaluate its impact as new information becomes available. Impairment of Long-Lived Assets Long-lived assets include property, equipment and right-of-use assets. In accordance with Accounting Standards Codification (“ASC”) 360 - Property, Plant and Equipment (“ASC 360”), management reviews the Company’s recorded long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset’s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between fair value and the carrying value of the asset. The Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2020.

Net Loss per Share	6 Months Ended
Net Loss per Share	Jun. 30, 2020
Net Loss per Share
Net Loss per Share	7. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the three and six months ended June 30, 2019 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.1 million and $0.5 million, respectively, on converted shares and $0.1 million of Series A accrued dividends. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020 and 2019 were 4,804,348 and 6,802,608, respectively. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively and for the six months ended June 30, 2019 were 843,119 and 18,915,851, respectively, because their effect is anti-dilutive.

Non-controlling Interest	6 Months Ended
Non-controlling Interest	Jun. 30, 2020
Non-controlling Interest
Non-controlling Interest	8. Non-controlling Interest The Company’s non-controlling interest is accounted for under ASC 810, Consolidation (“ASC 810”), and represents the minority shareholder’s ownership interest related to the Company’s subsidiary, Synthetic Biomics, Inc. (“SYN Biomics”). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company's equity interest in SYN Biomics is 83% and the non-controlling stockholder's interest is 17%. As of June 30, 2020 , the accumulated net loss attributable to the non-controlling interest is $2.9 million. In consideration of the support provided by CSMC for the Study, the Company will pay $441,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (“Synbiomics”) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. During the three and six months ended June 30, 2019, research and development expense recorded related to this transaction approximated $119,000 and $174,000, respectively. The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company's common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.

Common and Preferred Stock	6 Months Ended
Common and Preferred Stock	Jun. 30, 2020
Common and Preferred Stock
Common and Preferred Stock	9. Common and Preferred Stock Series B Preferred Stock On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units , with each Class A Unit offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units, with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October 2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series B Preferred Stock discount. In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October 10, 2018, the Company granted the Underwriters a 45 day option (the “Over-allotment Option”) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock. The Units were offered by the Company pursuant to a registration statement on Form S‑1 (File No. 333‑227400), as amended, filed with the SEC, which was declared effective by the SEC on October 10, 2018. The conversion price of the Series B Preferred Stock and exercise price of the October 2018 Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances. During the three and six months ended June 30, 2020, 1,040 and 2,113 Series B shares, respectively, have been converted into common stock resulting in the recognition of $392,000 and $796,000, respectively, of unamortized discount from the conversion. During the three and six months ended June 30, 2019, 302 and 1,338 Series B shares, respectively, have been converted into common stock resulting in the recognition of $117,000 and $515,000, respectively, of unamortized discount from the conversion. As of June 30, 2020, 10,198 shares have been converted resulting in the recognition of $3.8 million of unamortized discount. This is recorded as a deemed dividend in accumulated deficit. The October 2018 Warrants are immediately exercisable at a price of $1.38 per share of common stock (which is 120% of the public offering price of the Class A Units) and will expire on October 15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October 2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October 2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company may not effect, and the holder will not be entitled to, exercise any Warrants or conversion of the Series B Preferred Stock, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of the Company’s securities beneficially owned by the holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99%) of the combined voting power of all of the Company’s securities then outstanding immediately after giving effect to the exercise or conversion, as such percentage ownership is determined in accordance with the terms of the October 2018 Warrants or Series B Preferred Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to the Company. The holders of the Series B Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock. Upon a defined Fundamental Transaction, the holders of the Series B Preferred Stock are entitled to the same consideration as are holders of Common Stock. The Series B Preferred Stock ranks junior to existing Series A Preferred Stock but on parity with common stock. Liquidation preference is equal to an amount pari passu with the common stock on an as converted basis (i.e., there is no preference to common stock). Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2018, the Company recorded a discount of $9.1 million and immediately amortized the discount to record the deemed dividend. Series A Preferred Stock On September 11, 2017, the Company entered into a share purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series A Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) for an aggregate purchase price of $12 million, or $100 per share. The Series A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets upon any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $18.90 per share, subject to certain customary anti-dilution adjustments. Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only. On or at any time after (i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6 months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share of Series A Preferred Stock of $7,875, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Convertible Preferred Stock, or (ii) the five year anniversary of the issuance date, the Company has the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series A Convertible Preferred Stock then held, the outstanding Series A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value (as defined in the Certificate of Designations). The Series A Preferred Stock is classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company’s control. Since the effective conversion price of the Series A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (“BCF”) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a “deemed dividend” and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively. During the three and six months ended June 30, 2019, the Company accrued dividends of $61,000 and $122,000, respectively. Once the dividend is declared, the Company will reclassify the declared amount from temporary equity to a dividends payable liability. When the redemption of the Series A Preferred Stock becomes probable, the temporary equity will be accreted to redemption value as a deemed dividend. B. Riley FBR Sales Agreement On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets & Co. (now known as B. Riley FBR, Inc.), which enables the Company to offer and sell shares of the Company's common stock with an aggregate sales price of up to $40.0 million from time to time through B. Riley FBR, Inc. as the Company’s sales agent. Sales of common stock under the B. Riley FBR Sales Agreement are made in sales deemed to be “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley FBR, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Company's common stock sold on the Company’s behalf. The Company has not sold any shares during 2020 and 2019 through the B. Riley FBR Sales Agreement.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 30, 2020
Related Party Transactions
Related Party Transactions	10. Related Party Transactions On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN‑010 to be co-funded by the Company and CSMC (the “Study”). The Study will provide further evaluation of the efficacy and safety of SYN‑010, the Company’s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN‑010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) to: (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary Synthetic Biomics, Inc. (“SYN Biomics”) owned by the Company, such that after such issuance CSMC will own an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics’ common stock. The Agreement also provides CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company’s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics. In December 2013, through the Company’s subsidiary, Synthetic Biomics, Inc., the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2020 and 2019, the Company did not owe and did not pay CSMC for milestone payments related this license agreement.

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2020
Subsequent Events
Subsequent Events	12. Subsequent Events On June 30, 2020 the Company submitted an Investigational New Drug (IND) application with the FDA for SYN-020, an oral formulation of recombinant intestinal alkaline phosphatase (IAP). On July 30, 2020 the Company announced that it received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) to conduct a Phase 1 single ascending dose study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. The Phase 1 clinical program is intended to support the clinical development of SYN-020 in multiple indications, including the treatment of radiation enteropathy secondary to pelvic cancer therapy. On January 7, 2020 the Company held a Type-C meeting with the FDA to discuss the clinical program requirements needed to evaluate safety, tolerability and potential absorption into the systemic circulation (if any) of SYN-004 (ribaxamase) in adult allogeneic HCT recipients. On July 30, 2020 the Company received written notification from the FDA informing it that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients is safe to proceed per the submitted clinical program protocol.

Going Concern (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Going Concern
Accumulated deficit	$ (242,289)	$ (235,537)
Cash and Cash Equivalents, at Carrying Value	$ 8,059	$ 15,045	$ 21,712	$ 28,918

Fair Value of Financial Instruments (Details) - Money market accounts - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash and cash equivalents	$ 114,000
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash and cash equivalents		$ 98,000

Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Selected Balance Sheet Information
Prepaid clinical research organizations	$ 471	$ 48
Prepaid insurances	241	549
Prepaid manufacturing expenses	94	622
Prepaid consulting, subscriptions and other expenses	91	134
Prepaid conferences, travel	0	25
Other receivables	0	3
Total	$ 897	$ 1,381

Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and equipment, net
Property, Plant and Equipment, Gross, Total	$ 1,254	$ 1,254
Less: accumulated depreciation and amortization	(1,003)	(887)
Total	251	367
Computers and office equipment [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total	804	804
Leasehold Improvements [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total	439	439
Software [Member]
Property and equipment, net
Property, Plant and Equipment, Gross, Total	$ 11	$ 11

Selected Balance Sheet Information - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Selected Balance Sheet Information
Accrued clinical consulting services	$ 704	$ 684
Accrued vendor payments	376	456
Accrued manufacturing costs	129	635
Other accrued expenses	0	1
Total	$ 1,209	$ 1,776

Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Selected Balance Sheet Information
Accrued severance expense	$ 399
Accrued bonus expense	396	$ 858
Accrued vacation expense	132	77
Total	$ 927	$ 935

Stock-Based Compensation - Schedule of assumptions used for awards (Details)	12 Months Ended
	Dec. 31, 2019 $ / shares
Stock-Based Compensation
Exercise price	$ 0.42
Expected dividends	0.00%
Expected volatility	84.00%
Risk -free interest rate	1.61%
Expected life of option	4 years 6 months

Stock-Based Compensation - Additional Information (Details) - USD ($)				1 Months Ended				3 Months Ended		6 Months Ended
	Sep. 05, 2019	Sep. 07, 2017	May 15, 2015	Sep. 24, 2018	Aug. 25, 2016	Oct. 22, 2013	Mar. 20, 2007	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Nov. 02, 2010
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures								0	0	0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options								$ 498,000		$ 498,000
Employees \| General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense								40,000	$ 50,000	79,000	$ 106,000
Employees \| Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense								15,000	32,000	31,000	110,000
Consultants \| General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense								27,000	9,000	53,000	19,000
Consultants \| Research and Development Expense
Share-based Compensation Arrangement by Share-based Payment Award
Allocated Share-based Compensation Expense								$ 4,000	$ 1,000	$ 6,000	$ 1,000
2007 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number							71,429	7,052		7,052
2007 Stock Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							7,143
2010 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number								2,465,310		2,465,310		85,714
2010 Stock Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	4,000,000	500,000	228,572	1,000,000	400,000	171,429
2010 Stock Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,000,000	400,000	171,429	500,000	228,572	85,714

Stock Warrants - Additional Information (Details) - USD ($)					1 Months Ended	6 Months Ended
	Oct. 15, 2018	Oct. 15, 2018	Oct. 10, 2018	Oct. 10, 2014	Nov. 18, 2016	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Oct. 31, 2018	Dec. 26, 2017
Equity, Class of Treasury Stock
Proceeds from Issuance or Sale of Equity		$ 18,600,000
Warrants Not Settleable in Cash, Fair Value Disclosure										$ 9,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	13,672,173	13,672,173
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.38	$ 1.38							$ 1.38
Class A [Member]
Equity, Class of Treasury Stock
Stock Issued During Period, Shares, New Issues	2,520,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				61.25
Preferred Stock Conversion Price Per Share	$ 1.15	$ 1.15
Class B [Member]
Equity, Class of Treasury Stock
Stock Issued During Period, Shares, New Issues		15,723
Series B Preferred Stock [Member]
Equity, Class of Treasury Stock
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	13,672,173	13,672,173
Stock Issued During Period, Value, Issued for Services		$ 1,000
Preferred Stock, Par or Stated Value Per Share	$ 1,000	$ 1,000				$ 1,000	$ 1,000
Conversion of Stock, Shares Converted		13,672,173				10,198
IPO [Member]
Equity, Class of Treasury Stock
Warrants Not Settleable in Cash, Fair Value Disclosure					$ 15,700,000	$ 100,000		$ 100,000
Stock Issued During Period, Shares, New Issues					714,286
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,428,571
Sale of Stock, Price Per Share				$ 1.47	$ 35.00
IPO [Member] \| Series A [Member]
Equity, Class of Treasury Stock
Class of Warrant or Right, Exercise Price of Warrants or Rights					50.05
IPO [Member] \| Series B [Member]
Equity, Class of Treasury Stock
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 60.20
Over-Allotment Option [Member]
Equity, Class of Treasury Stock
Stock Issued During Period, Shares, New Issues		2,428,825	2,428,825
Issuance Of Warrants To Purchase Of Common Stock	1,807,826	1,807,826
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,428,825	2,428,825	2,428,825
Underwritten Public Offering [Member] \| October 2018 Warrants [Member]
Equity, Class of Treasury Stock
Warrant Term		5 years
Series A Warrants [Member]
Equity, Class of Treasury Stock
Proceeds from Issuance of Common Stock				$ 19,100,000
Sale of Stock, Number of Shares Issued in Transaction				14,059,616
Issuance Of Warrants To Purchase Of Common Stock				0.50
Share Based Compensation Arrangement By Share Based Payment Award Warrants Vested and Expected To Vest Outstanding Number				200,852
Fair Value of Warrant Liability						$ 0		$ 0
Fair Value Adjustment of Warrants				$ 7,400,000
Warrant [Member]
Equity, Class of Treasury Stock
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number										714
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	13,672,173	13,672,173

Stock warrants - Summary of all outstanding and exercisable warrants (Details)	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Exercise Price 1.38 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 1.38
Warrants Outstanding	17,999,999
Warrants Exercisable	17,999,999
Weighted Average Remaining Contractual Life (in years)	3 years 3 months 11 days
Exercise Price 18.20 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 18.20
Warrants Outstanding	714
Warrants Exercisable	714
Weighted Average Remaining Contractual Life (in years)	2 years 5 months 27 days
Exercise Price 50.05 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 50.05
Warrants Outstanding	714,286
Warrants Exercisable	714,286
Weighted Average Remaining Contractual Life (in years)	4 months 21 days
Exercise price 3.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price \| $ / shares	$ 3.24
Warrants Outstanding	18,714,999
Warrants Exercisable	18,714,999
Weighted Average Remaining Contractual Life (in years)	3 years 2 months 1 day

Non-controlling Interest (Details) - USD ($)		3 Months Ended		6 Months Ended
Non-controlling Interest (Details) - USD ($)	Sep. 05, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Noncontrolling Interest
Related Party Transaction, Expenses from Transactions with Related Party	$ 441,000
Research and Development Expense		$ 1,603,000	$ 2,594,000	$ 3,238,000	$ 5,012,000
SYN Biomics
Noncontrolling Interest
Equity interest by parent		83.00%		83.00%
Accumulated net loss attributable to the non-controlling interest		$ 2,900,000	2,900,000	$ 2,900,000	2,900,000
Cedarssinai Medical Center [Member]
Noncontrolling Interest
Number Of Common Stock To Be Issued	50,000	50,000		50,000
Research and Development Expense		$ 25,000	$ 119,000	$ 92,000	$ 174,000
Fair Value Of Shares Issued	$ 285,000
Cedarssinai Medical Center [Member] \| SYN Biomics
Noncontrolling Interest
Additional Number Of Common Stock To Be Issued	2,420,000
Number Of Common Stock To Be Held By Related Party	7,480,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	17.00%

Common and Preferred Stock (Details)					1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Common and Preferred Stock (Details)	Oct. 15, 2018 USD ($) $ / shares shares	Oct. 10, 2018 shares	Sep. 11, 2017 USD ($) D $ / shares shares	Aug. 05, 2016 USD ($)	Oct. 31, 2018 $ / shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) shares	Jun. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2019 USD ($) shares	Dec. 31, 2019 $ / shares	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	13,672,173
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.38				$ 1.38
Preferred Stock Redemption Discount											$ 9,100,000
Percentage of issue of the public offering					120.00%
Common Stock, Discount on Shares						$ 3,800,000		$ 3,800,000
Proceeds from Issuance or Sale of Equity	$ 18,600,000
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues \| shares	2,428,825	2,428,825
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	2,428,825	2,428,825
Issue of warrants to purchase common stock \| shares		1,807,826
Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	13,672,173
Fbr Capital Markets Co [Member]
Stock Issued During Period, Value, New Issues				$ 40,000,000
Brokerage Commission percentage				3.00%
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share \| $ / shares						$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Dividend Rate, Percentage			2.00%							2.00%
Preferred Stock Conversion Price Per Share \| $ / shares			$ 18.90
Debt Instrument, Convertible, Threshold Trading Days \| D			20
Debt Instrument, Convertible, Threshold Consecutive Trading Days \| D			30
Dividends Payable, Amount Per Share \| $ / shares			$ 70.00
Adjustments to Additional Paid in Capital, Stock Split			$ 7,875
preferred stock accrued dividends						$ 63,000	$ 61,000	$ 125,000	$ 122,000
Preferred Stock Redemption Discount												$ 6,900,000
Series A Preferred Stock [Member] \| Private Placement [Member]
Stock Issued During Period, Shares, New Issues \| shares			120,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001
Proceeds from Issuance of Convertible Preferred Stock			$ 12,000,000
Sale of Stock, Consideration Received Per Transaction			$ 100
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share \| $ / shares	$ 1,000					$ 1,000		$ 1,000		$ 1,000
preferred stock accrued dividends						$ 392,000	$ 117,000	$ 796,000	$ 515,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	13,672,173
Stock Issued During Period, Value, Issued for Services	$ 1,000
Percentage Exceed Aggregate Number Of Common Stock					4.99%
Percentage Exceed Aggregate Number Of Common Stock Outstanding					9.99%
Increase Decrease in Excess of Other Percentage					9.99%
Preferred Stock Shares Converted \| shares						1,040	302	2,113	1,338
Preferred Shares, Unamortized Discount From Conversion						$ 392,000	$ 117,000	$ 796,000	$ 515,000
Conversion of Stock, Shares Converted \| shares	13,672,173							10,198
Common Class A [Member]
Stock Issued During Period, Shares, New Issues \| shares	2,520,000
Shares Issued, Price Per Share \| $ / shares	$ 1.15
Common Class B [Member]
Stock Issued During Period, Shares, New Issues \| shares	15,723
Preferred Stock Conversion Price Per Share \| $ / shares	$ 1.15

Related Party Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Oct. 31, 2018	Oct. 15, 2018	Sep. 05, 2018
Related Party Transaction
Common Stock, Shares, Issued	18,646,152	16,808,758
Common Stock, Value, Issued	$ 19	$ 17
Common Stock, Par or Stated Value Per Share	$ (0.001)	$ (0.001)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				13,672,173
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.38	$ 1.38
Synthetic Biomics Inc [Member]
Related Party Transaction
Additional Number Of Common Stock To Be Issued					2,420,000
Cedarssinai Medical Center [Member]
Related Party Transaction
Number Of Common Stock To Be Issued	50,000				50,000
Cedarssinai Medical Center [Member] \| Synthetic Biomics Inc [Member]
Related Party Transaction
Number Of Common Stock To Be Held By Related Party	7,480,000				7,480,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	17.00%				17.00%

Commitments and Contingencies - Maturity analysis of operating leases (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Commitments and Contingencies
2020	$ 156
2021	321
2022	192
Total	669
Discount factor	(67)
Lease liability	602
Amount due within 12 months	(268)	$ (249)
Lease liability - long term	$ 334	$ 473

Commitments and Contingencies - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 01, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Lease, Weighted Average Discount Rate, Percent		9.90%		9.90%
Operating Lease, Cost		$ 50,000	$ 50,000	$ 101,000	$ 101,000
Operating Lease, Payments		$ 77,000	$ 75,000	154,000	149,000
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability				$ 0	$ 538,000
Operating Lease Expiration Year				2022
ASU 2016-02
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 538,000

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

Smaller Reporting Company

Emerging growth company